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Abstract 
Creatine supplementation is an ergogenic aid that is often used to enhance resistance 
training. Electrolytes can help to increase the absorption of creatine. This study examined effects 
of two differently formulated creatine supplements, creatine monohydrate (CM) or creatine-
magnesium chelate (CE), compared to placebo on fatigue, work, and power during knee 
extensions. Subjects (n=23; 21.9±1.8 years) maintained their regular resistance training program 
and had not supplemented with creatine in the previous 6 months. Supplementation was 4 g 
creatine daily for CM and CE, plus 400 mg magnesium in CE. Maximum torque and fatigue of 
knee extensions at 180 ° sec-1 were determined using an isokinetic dynamometer for 2 sets of 30 
repetitions each, with 2 minutes rest between sets. Fatigue was calculated by the ratio between 
the first 1/3 and the last 1/3 of work for each set.  Body composition was determined via a three-
site skin-folds using standard calipers. Statistical analyses were performed using mixed 
ANOVA. Fatigue results demonstrated no significant differences (p>0.05). For work and average 
power, there were no significant interaction effects (p>0.05) in either set 1 or 2. There was a 
significant time effect for work (1987.49±617.65 J, CM: 1978.55±723.21 J, CE: 2485.57±677.58 
J; p = 0.001; ηp2=0.371) and average power (165.4±70.33 W, CM: 160.59±56.28 W, CE: 
186±66.71 W; p = 0.003; ηp2=0.407) in set 1; with no significant differences in set 2 (p>0.05). 
There were no significant effects of time or group for body composition (p>0.05). There were no 
significant differences in these variables for the second set in any group. Supplementation with a 
creatine-electrolyte formula may help increase total work and average power in resistance-
trained individuals.   
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Chapter I 
The Problem and Its Scope 
Introduction 
 An individual who exerts a maximal effort utilizes primarily their anaerobic systems, 
both the phosphagen system and glycolysis. At the onset of physical activity, the body draws 
from its pool of phosphocreatine to provide this immediate energy and resynthesize adenosine 
triphosphate (ATP) from adenosine diphosphate (ADP). The primary objective in creatine 
supplementation is suggested to help increase the amount of phosphocreatine available in the 
muscle fiber (Lanhers, Pereira, Naughton, Trousselard, Lesage, & Dutheil, 2015).   
From recreational fitness enthusiasts to elite level athletes, the use of creatine 
supplementation has grown in popularity over the last several years. Creatine supplementation 
experienced a rapid increase in use following the 1992 Summer Olympic Games in Barcelona, 
Spain when gold medal winners Linford Christie and Sally Gunnel attributed part of their 
success to creatine supplementation. Many professional athletes including Olympic athletes, 
National League Football players, and professional baseball players have used creatine 
supplements (Rawson & Clarkson, 2000). Even as early as 2001, many middle and high school 
athletes were using creatine supplementation, and the proportion of collegiate athletes 
approached 28%. Reasons for creatine supplementation included: increased strength, endurance, 
lean body mass, and improved appearance (Metzl, Small, Levine, & Gershel, 2001). Among 
nutritional supplements to help increase performance activities related to strength, creatine 
supplementation is often suggested as an effective ergogenic aid. Despite the increasing amount 
of research on creatine use, many previous studies examining an athlete’s performance in 
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relation to creatine supplementation have had mixed results with some results showing 
improved performance and other results showing no change (Lanhers et al., 2015).    
  A key component of sports performance is the ability of muscle to resist fatigue. Many 
of the previous studies have not examined how a creatine-electrolyte multi-ingredient 
supplement affects muscle performance (Lanhers et al., 2015). Fatigue can be measured utilizing 
the fatigue index (FI). The FI is the decline in peak muscle force output expressed as a 
percentage of initial values of peak muscle force output (Thorstensson & Karlson, 1976).  
Isokinetic assessment is a common method of measuring fatigue. The method utilizing isokinetic 
measurement involves performing multiple muscle contractions at a preset velocity (Corin, 
Strutton, & McGregor, 2005). Examining the effects of a multi-ingredient creatine-electrolyte 
supplementation on muscle and how it may relate to decreasing fatigue allowing for continued 
maximal exertion will enable sports enthusiasts of all levels to better understand the putative 
benefits. More research is needed in this manner on the specificity of a particular exercise 
protocol.   
Purpose of the Study 
 The purpose of this study was to determine if a creatine-electrolyte performance 
supplement increases performance during resistance training following a six-week 
supplementation phase compared to creatine monohydrate alone or placebo groups.  This study 
attempted to determine if peak muscle force remained near initial peak force during repeated 
isokinetic knee extensions in subjects already resistance-trained by following a supplementation 
regimen using a creatine-electrolyte performance supplement. 
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Hypothesis 
 The null hypothesis stated that there would be no significant changes in muscle fatigue 
when comparing three resistance-trained sample groups after 6 weeks of intervention, with one 
group consuming a placebo (carbohydrate solution), a second group consuming the common 
monohydrate form of creatine, and the third group consuming the creatine-electrolyte 
supplement. The null hypothesis also stated that there would be no differences in peak isometric 
torque, peak isokinetic torque at both 60 and 180 deg/sec, total work, and mean power.  
Significance of the Study 
 Creatine supplementation continues to be researched examining the potential benefits for 
athletes of all ages and individuals with muscle atrophying diseases (Cooper, Naclerio, Allgrove, 
& Jimenez, 2013; D'Antona et al., 2014; Smith, Agharkar, & Gonzales, 2014).   More 
importantly, there is limited research on the use of creatine in conjunction with an electrolyte and 
or other nutrient supplements combined.  The use of an electrolyte-creatine supplement may 
elicit muscle fatigue reduction in resistance-trained individuals by potentially increasing the 
effects of creatine.   
Limitations of the Study 
1. Despite randomization in both groups, the pre-test may have had an influence on how 
participants did on the posttest due to a learning effect. Regardless of having 
controlled selection by randomization into placebo and experimental groups, the 
results obtained in this study may only pertain to the specific population sampled in 
this study.  
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2. Groups may have experienced participants dropping out, resulting in experimental 
mortality. 
3. Subjects in this study were already on a resistance-training regimen.  The strength and 
fatigue levels in this study may limit the application of results to a more diverse 
sample. 
4. It is possible the subject’s training will have resulted in the decreased amount of 
fatigue, not the supplement.  However, subjects were asked to maintain their current 
training regimen. 
5. Both groups were already resistance trained and over the course of the study may 
have gotten stronger because of their training.  The findings may have been 
influenced by improvements due to training.  The placebo group may have helped to 
control for this factor. 
6. Although daily supplement doses were given for consumption, participants may have 
not taken all the doses given to them. 
7. Hydration levels could have affected the total body water measurements.  Participants 
were instructed on the proper procedures to maintain hydration. 
Definition of Terms 
Anaerobic- Physical effort that does not involve the use of oxygen and activity that relies on 
phosphocreatine stores, sometimes known as the phosphagen system (Lanhers et al., 
2015). 
Concentric- A dynamic muscle contraction involving muscle shortening or also known as 
positive work (Knuttgen & Kraemer, 1987). 
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Creatine- A molecular compound that can be synthesized in the liver, kidney and pancreas by 
either certain amino acids or it can be consumed by eating meats and fish (Polyviou et al., 
2015). 
Creatine monohydrate- A common supplement used by athletes attempting to achieve greater 
gains in strength, mass, and physical performance (Rawson & Persky, 2007).   
Eccentric- A dynamic muscle action involving muscle lengthening or also known as negative 
work (Knuttgen & Kraemer, 1987) 
Electrolytes- Any fluid or mineral carrying an electric charge. Sodium, potassium, magnesium, 
chloride, and calcium are examples of minerals with an electric charge (National 
Institutes of Health, 2013).   
Fatigue- The intense use of muscle over a period of time leading to a decline in performance 
(reduction in force) with a return to maximal force generation after a period of rest 
(Allen, Lamb, & Westerblad, 2008). 
Isokinetic- Muscle activity in which a certain anatomical body part moves at a constant velocity 
that is controlled by an ergometer and can be either be done by either of the dynamic 
muscle contractions (Knuttgen & Kraemer, 1987). 
Isokinetic testing- An assessment method often using a dynamometer in which participants apply 
force during a predetermined velocity that can measure eccentric and concentric peak 
torque, total work, and average power of muscle action (Li, Wu, Maffulli, Chan, & Chan, 
1996). 
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Maximal voluntary contraction- The intentional maximal force output by the recruitment of as 
many muscle fibers as possible (Knuttgen &Kraemer, 1987). 
Phosphocreatine- Free form creatine in the body combined with a phosphate molecule 
(McBreairty et al., 2015). 
Power- The product of force times distance divided by a time component or more simply stated 
as force times velocity that is measured in watts (W) (Knuttgen & Kraemer, 1987). 
Torque- The product of force and the perpendicular distance from the axis of rotation to the line 
in which the force is being applied (Rothstein, Lamb, & Mayhew, 1987). 
Wingate test- A 30 second test measuring peak anaerobic power and capacity measured using a 
cycling ergometer (Smith & Hill, 1991). 
Work- Force times distance measured in joules (J) (Knuttgen & Kraemer, 1987). 
Work:rest ratio- A method helping to standardize a rest interval as in such example a work:rest 
ratio of 1:2 would be indicative of a work bout lasting 30 seconds with a 60-second rest 
interval (Blazquez, Warren, O'Hanlon, & Silvestri, 2013). 
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Chapter II 
Review of the Literature 
Introduction 
 The purpose of this study was to analyze the effects of using an electrolyte enriched 
creatine supplement compared to creatine monohydrate or placebo over a six-week interval on 
muscle fatigue. There is a robust amount of research on creatine supplementation.  There are 
various forms of creatine individuals can consume (Cooper, Naclerio, Allgrove, & Jimenez, 
2012). However, most of the research has focused on examining the outcomes of using creatine 
monohydrate.  Increases in strength, muscle hypertrophy along with an increase in lean body 
mass have been associated with creatine supplementation. Creatine benefits appear to decline 
with longer duration exercise (Cooper et al., 2012). Research has also examined the use of 
creatine in clinical settings with some studies showing improvements in patients with various 
muscular disorders (Alves et al., 2013; Hass, Collins, & Juncos, 2007; Tarnopolsky & Martin, 
1999). If athletes are to gain any advantage with creatine use, more research should be conducted 
regarding the effects of creatine and other nutrients combined on muscle fatigability. 
 For this review, previous research is organized into three major sections. The first section 
discusses creatine in the body and natural food sources containing creatine. The second section 
gives an overview on creatine supplementation including: possible health risks related to creatine 
supplements, the bioavailability of creatine supplements, dosage protocols used in existing 
research, effects on strength and torque, and effect on anaerobic and aerobic performance. The 
third section provides an overview on muscle fatigue, common methods to measure fatigue, and 
creatine’s effect on muscle fatigue. The physiological processes leading to muscle fatigue are 
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examined along with how creatine supplementation may help delay the onset of muscle fatigue 
thus decrease the loss of force production, particularly during resistance training.   
Review of the Pertinent Literature 
 Creatine.  At around the year 1847, a new organic compound was discovered in the meat 
from various animals. This discovery was made by a French scientist who had observed that 
creatine levels were significantly elevated in wild foxes in comparison to non-active animals and 
concluded that creatine is involved with muscle physiology (Balsom, Söderlund, & Ekblom, 
1994). Creatine in the body plays an important role in the physiology involving the synthesizing 
of adenosine triphosphate (ATP), which is the body’s energy currency (Balsom et al., 1994; 
McBreairty, Robinson, Furlong, Brunton, & Bertolo, 2015; Polyviou et al., 2015; Raluca-Ioana 
& Rahel, 2003). Natural creatine is synthesized within the liver, pancreas, and kidneys (Balsom 
et al., 1994).   
 Glycine, arginine, and S-adenosyl-methionine are the three amino acids that help in the 
synthesizing of creatine (Snow & Murphy, 2001). The physiological process of creatine 
formation primarily happens in the liver and pancreas (Snow & Murphy, 2001). Once creatine 
has been synthesized, 95 % is transferred by blood to skeletal muscle.  The heart muscle, brain, 
and testis is where the remaining five percent of the creatine resides (Balsom et al., 1994; Snow 
& Murphy, 2001). Creatine can also be consumed be eating a variety of meats and fish (Polyviou 
et al., 2015). Plant sources contain minimal amounts of creatine; therefore, people on meat-
restricted diets rely primarily on the creatine made within the body (Balsom et al., 1994).   
 At the cellular level, creatine helps to synthesize ATP by combining with phosphate to 
form creatine phosphate or also known as phosphocreatine (PCr). This molecule combines with 
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adenosine diphosphate (ADP) and is catalyzed by creatine kinase (CK) to resynthesize ATP 
(McBreairty et al., 2015). Inside the cells, creatine either can exist on its own or can be combined 
with phosphate making up the total amount of available creatine for high-energy demands of the 
brain and skeletal muscles. The body has enough stored creatine within the skeletal muscle to 
perform about 10 seconds of maximal muscle contraction. The short-term buffering system 
provided by PCr and CK pathway is efficient due to higher diffusion capability of PCr compared 
to ATP. This buffering system increases the efficiency of energy transfer to various cellular 
locations (Adhihetty & Beal, 2008). When an individual first exerts maximal force, the 
predominant form of ATP synthesis comes from the catabolism of phosphocreatine. However, 
the ability to resynthesize ATP from phosphocreatine rapidly declines within the first few 
seconds of exercise, much faster than the rate of glycolysis (Volek et al., 1997).  
The physiological enhancements of the PCr system, which provides essentially half the 
energy needed for physical activity involving durations of 10 seconds or less, is one of the 
original reasons why athletes have used creatine supplementation (Adhihetty & Beal, 2008). The 
levels of PCr that are found in skeletal muscle are up to 400% greater than the amounts of stored 
ATP and up to 500% greater than free creatine (Ellington, 1989). During significant energy 
demands of the muscle, an increase in inorganic phosphate (Pi) occurs at the same time PCr 
stores are being depleted. During these physiological reactions, the ATP and free ADP ratio 
remains the same (Ellington, 1989). The mechanisms for keeping the ATP and free ADP ratio 
consistent is due to the temporary buffering system provided the PCr/creatine phosphokinase 
(CPK) system (Ellington, 1989). The PCr shuttle is involved in the exchange of creatine between 
the cytosol and mitochondria (Engelhardt, Neumann, Berbalk, & Reuter, 1998). The adequate 
concentration of ATP and PCr along with the decreased metabolism of creatine to creatinine is 
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due to the PCr shuttle. Once creatine is metabolized into creatinine, it exits the muscle fiber 
where it is transferred to the kidney and excreted from the body (Engelhard et al., 1989).  
 At maximal efforts lasting one to two minutes, the supply of ATP is primarily from the 
anaerobic energy systems (Sahlin, 2014). At the same time, hydrogen ions (H+) and inorganic 
phosphates (Pi) rapidly accumulate in the muscle making muscle contraction more difficult to 
maintain (Sahlin, 2014). A major limitation to anaerobic capacity is the amount of phosphate 
storage in the muscle along with the level of protons that can be made. During maximal exercise, 
PCr stores can easily be depleted providing approximately 70 mmol per kg dry muscle of ATP 
(Sahlin, 2014). The two energy systems involved during anaerobic activity are the phosphagen 
and anaerobic glycolysis metabolic pathways. The amount of ATP supplied by either of these 
metabolic pathways is determined by the intensity and duration of physical activity (Sahlin, 
2014). Approximately, for the first three seconds of maximal intensity, the supply of ATP is 
primarily from PCr stores. As maximal effort continues the rate of PCr utilization declines as 
glycolysis begins to supply the needed ATP (Gaitanos, Williams, Boobis, & Brooks, 1993; 
Sahlin, 2014).    
 Creatine supplementation. Over the years, creatine has been used as a supplement in 
healthy individuals attempting to enhance performance as well as individuals suffering from 
neuromuscular disorders. There are numerous studies showing creatine supplementation may 
possibly be beneficial in sports performance (Cribb, Williams, & Hayes, 2007; Kirksey, Stone, 
M. H., Warren, Johnson, & Stone, M. E., 1999; Mujika, Padilla, Ibanez, Izquierdo, & 
Gorostiaga, 2000; Skare, Skadberg, & Wisnes, 2001; Stone et al., 1999). The studies available on 
the effects of creatine on muscle in relationship to maintaining muscle force production 
(indicating a reduction in fatigue) seem to be limited. A systematic review by Lanhers et al. 
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(2015) set out to compare 60 studies on the lower limb during creatine supplementation. Some of 
the key findings from the review by Lanhers et al. (2015) were that the quadriceps experienced 
the greatest gains in strength of all lower limb muscles. The review had calculated an average 
increase of people squatting 8% more weight and leg pressing 3% more weight (Lanhers. Et al., 
2015). Creatine supplementation is more beneficial for an untrained individual versus a trained 
individual with only a 14% increase in performance for a trained athletic person compared to a 
31% increase in performance in individuals who have not been training. However, there must be 
some scrutiny to these findings as the definition of trained versus untrained can vary from study 
to study. Many studies have focused on younger athletes, particularly males (Lanhers et al., 
2015).    
Creatine supplementation dosage.  Creatine supplementation typically involves two 
phases: a loading phase and maintenance phase (Buford et al., 2007). Loading phases often last 
between 5-7 days with an average consumption of 20 g/day. The typical maintenance dosage 
following the lading phase is between three to five grams a day (Buford et al., 2007). However, 
various studies have utilized an acute dosage protocol consisting of 20 g/day for 5-7 days 
(Mujika et al., 2000; Zuniga et al., 2012). Other dosage protocols of longer duration without a 
loading phase exist (Cooper, Naclerio, Allgrove, & Jimenez, 2012).  
 A study examining the effects of creatine use during a simulated cycling road race 
protocol had subjects consume 3 g/day with a placebo or creatine for 28 days. No loading phase 
was included in this investigation (Hickner, Dyck, Sklar, Hatley, & Byrd, 2010).  Prior to 
supplementation the finishing sprint times at the end of a two hour simulated race were 64.4 ± 
13.5 seconds for the creatine group and 69.0 ± 24.8 seconds for the placebo group.   
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  Both the creatine and supplement groups were able to increase their duration of their 
final sprint time by about 25 seconds. Both the creatine and placebo group had around a 33% 
increase in power output during the final sprint. Prior to supplementation, the power output was 
23,459 ± 6,430 joules for the creatine group and 19,509 ± 2,696 joules for the placebo group.  
After 28 days of supplementation, the power output for the creatine group was 30,811 ± 10,198 
joules and 26,599 ± 3,772 joules for the placebo group. Two other variables that creatine did not 
have an effect on were hemoglobin and hematocrit levels. At pre and post-testing, hemoglobin 
and hematocrit were 10% higher than the placebo group. There were significant changes in 
plasma volume for the creatine group at 90 minutes of cycling. Plasma volume from pre to post-
testing was +14.0 ± 6.3% for the creatine group and -10.4 ± 4.4% for the placebo group. It was 
concluded that 28 days of creatine supplementation did not have any beneficial effects on the 
final power output or duration of a finishing sprint after two hours of simulated racing. 
An investigation on creatine’s effect on strength gains in recreational bodybuilders 
involved subjects consuming 5 g/day of creatine. Participants were randomly assigned to a pre-
workout or post-workout consumption group in which the subjects consumed their creatine 
dosage either before or after their workout. The testing protocol lasted four weeks, with training 
sessions on five out of the seven days each week. On non-training days, subjects were allowed to 
consume their creatine dose anytime during the day (Antonio & Ciccone, 2013). After utilizing a 
magnitude-based inference, it was suggested that using creatine post-workout might be more 
beneficial than pre-workout consumption in regards to strength and lean body mass increases.  
During the post-test, the average increase in 1-RM bench press was 7.6 ± 6.2 kg for the post-
workout supplement group compared to 6.6 ± 8.2 kg for the pre-workout supplement group.  
This observation was a potential benefit for using creatine post-workout.  Lean body mass 
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increased by 2.0 ± 1.2 kg and 0.9 ± 1.8 kg for the creatine and placebo groups, respectively.  
This finding suggested possible benefits in consuming creatine post-workout compared to pre-
workout.   
After twelve weeks of creatine monohydrate supplementation involving a dosage of six 
grams daily, a 57.92% increase in myofibrillar protein was observed (Willoughby & Rosene, 
2001). There was no loading phase utilized in the study. The subjects were individuals who were 
not currently on any structured training program. The training protocol consisted of only lower-
extremity exercises, mainly the knee extensor muscles. Workouts were done on Monday, 
Wednesday, and Friday and included three sets of 6-8 repetitions at 85-90% 1-RM. The exercises 
utilized were bilateral leg press, knee extension, and knee curls. Subjects were split into three 
groups at random: a control group (placebo plus no resistance training) (CON), a resistance 
training group plus creatine supplementation (CRT), and a resistance training group consuming a 
placebo (PLC). There were significant changes in strength for the CRT group compared to both 
the CON and PLC group (p<0.05). To account for variations in absolute muscle strength and 
body mass between groups at the initiation of the study, relative strength was the variable used 
instead of absolute strength. The relative strength value was utilized due to its accounting of the 
differences in body mass between different subjects. For the placebo group, baseline 
measurements were 2.71 ± 0.41 kg/kg body weight and 2.61 ± 0.49 kg/kg body weight at the end 
the study. For the PLC group, baseline measurements were 3.18 ± 0.23 kg/kg body weight and 
4.10 ± 0.46 kg/kg body weight at post-testing. For the CRT group baseline measurements were 
3.23 ± 0.75 kg/kg body weight and 4.98 ± 0.26 kg/kg body weight during post-testing. Both the 
PLC and CRT groups had increased thigh volume compared to the CON group. However, there 
was significant increase, p < 0.05, in thigh volume in the CRT group compared to the PLC 
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group. Baseline values for thigh volume were 8.38 ± 2.09 m3 and 8.93 ± 0.81 m3 for the PLC and 
CRT group respectively. At 12 weeks, thigh volume was 9.29 ± 2.25 m3 and 10.55 ± 0.54 m3 for 
the PLC and CRT groups respectively. The increases in myofibrillar protein was 57.92%, 
11.62%, and 2.75% for the CRT, PLC, and CON groups, respectively. It was concluded that 
myosin heavy chain synthesis may result from engaging in a vigorous resistance-training 
program while on creatine supplementation (Willoughby & Rosene, 2001).   
Pearson, Hamby, Russel, & Harris (1999) did not utilize a loading phase in their study 
examining the long-term effects of creatine use on strength and power in collegiate football 
players. During a prior pilot, Pearson et al. (1999) had suggested eliminating the loading phase of 
20 g/day of creatine monohydrate for five days did not result in limitations to post-
supplementation performance. Participants placed into the treatment group consumed five grams 
of creatine monohydrate daily during the 10-week resistance-training program. After 10 weeks 
of supplementation, there were observed increases in strength during squats, bench press, and 
increased power while doing power cleans. Bench press strength in the creatine group when from 
baseline measurements of 149.12 ± 12.64 kg to 154.22 ± 12.54 kg following supplementation.  
The placebo group had baseline measurements 130.24 ± 26.73 kg and 128.63 ± 22.09 kg after 
the study. Squat strength for the creatine group had baseline measurements of 241 ± 12.64 kg 
and 268.59 ± 56.18 kg at the end of the study. The placebo group had baseline measurements of 
221.88 ± 67.95 kg and post study measurements of 232.47 ± 73.43 kg. The increase in power 
during power cleans went from baseline measurements of 123.32 ± 21.65 kg to 130.97 ± 20.57 
kg in the creatine group. For the placebo group baseline measurements in power clean were 
111.58 ± 15.42 kg, and measurements following the study were 109.32 ± 29.32 kg. The creatine 
group also experienced significant increase in body mass, which was suggested to be positive in 
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nature since there were no changes in body fat after 10 weeks of supplementation compared to 
baseline measures. Baseline body weight for the creatine group was 106.25 ± 15.61 kg and 
following 10 weeks of supplementation was 107.67 ± 14.22 kg. Body fat percentage using seven 
measurement sites was 15.37 ± 5.51 % at baseline and 16.24 ± 6.02 % after 10 weeks (Pearson et 
al., 1999).   
Studies have observed elevated creatine and PCr content in those who use creatine 
supplementation (Greenhaff, Bodin, Soderlund, & Hultman, 1994; Harris, Söderlund, & 
Hultman, 1992; Hultman, Soderlund, Timmons, Cederblad, & Greenhaff, 1996).  Greenhaff et al. 
(1994) had subjects consume 20 g/day creatine for 5 days. Prior to supplementation, the mean 
body weight for the sample group was 80.0 ± 4.7 kg and after five days, supplementation was 
81.6 ± 4.8 kg. The total muscle creatine content level at baseline following 120 seconds of 
intensive isometric contraction electrically induced was 122.1 ± 3.4 mmol/kg dry matter. After 
five days of creatine supplementation using the same testing protocol, at 120 seconds total 
muscle creatine content was 143.0 ± 2.2 mmol/kg dry matter (Greenhaff et al., 1994).   
Harris et al. (1992) had three different dosage protocols: 20 g/day for 4-5 days, 30 g/day 
for 4-5 days, or 30 g/day on alternating days for 21 days. The average baseline total muscle 
creatine content for all subjects in the study was 126.8 ± 11.7 mmol/ kg dry matter. Following 
supplementation, total muscle creatine content for all subjects was > 140 mmol/kg dry matter 
with observations of > 150 mmol/kg dry matter in six of the subjects. The average total muscle 
creatine content following supplementation for all subjects was 148.6 ± 5.0 mmol/kg dry matter.  
Hultman et al. (1996) had six subjects consume 20 g/day of creatine for six days (group 
1), and another group with nine subjects consuming 20 g/day creatine for six days and then 2 
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g/day for the following 28 days (group 2). There was not a significant difference between groups 
for baseline total muscle creatine level. Total muscle creatine content at baseline was 123.4 ± 3.0 
mmol/kg dry matter and 119.5 ± 2.5 mmol/kg dry matter for groups 1 and 2, respectively. Total 
creatine levels for both groups after six days of supplementation increased by about 23 mmol/ kg 
dry matter. After 35 days, the total creatine content had decreased to near baseline levels in 
group 1. For group 2, total creatine content in the muscle had remained nearly the same as after 
the six-day loading phase. For both groups, the majority of the increase in total creatine content 
was from free creatine. The increase in free creatine for both groups during the first six days was 
approximately 16 mmol/dg dry matter (p < 0.05).   
Increases in muscles storage resulting from supplementation of creatine can depend on 
the amount of creatine that has been stored in muscles prior to supplementing. Individuals 
consuming a vegetarian diet with little to no fish or meats are more likely to see bigger increases, 
20-40%, in muscle creatine stores compared to those who eat more meat and fish. Individuals 
with higher creatine content prior to supplementation may only increase creatine content by 10-
20% with supplementation (Buford et al., 2007). Harris et al. (1992) had made observations that 
indicated the increases in total muscle creatine content was not dependent on duration or the 
amount of the dose, but rather on initial total muscle creatine content. This led to the conclusion 
that there may be an upper limit to the total creatine content a muscle can store. This upper limit 
was identified to be around 155 mmol/kg dry matter (Harris et al., 1992). A supplementation 
dosage of 20 g per day for a period of two to six days has indicated a nearly 20% increase in the 
amount of PCr concentration in the muscle (Greenhaff et al., 1994; Harris et al., 1992). A greater 
concentration of PCr in the muscle results in the increased re-phosphorylation of ATP.  With the 
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production of ATP via the mechanisms using PCr, it allows the individual to have improvements 
in repeated exercises involving short and intense intervals (van Loon et al., 2003). 
Van Loon et al. investigated the effects creatine had on muscle creatine content, body 
composition, and muscle and whole body oxidative capacity in individuals who had not been on 
any regular training schedule. The dosage protocol used in this investigation was a five-day 
loading phase involving consumption of 20 g/day creatine followed by a 37-day maintenance 
dosage at 2 g/day. Total muscle creatine content in the supplement group on day six were 158.0 
± 4.4 mmol/kg of dry muscle and on day 42 were 136.6 ± 5.6 mmol/kg of dry muscle. For the 
placebo group, total creatine muscle content at six days was 128.1 ± 3.9 mmol/kg of dry muscle 
and at 42 days was 122.7 ± 9.4 mmol/kg of dry muscle. During the study, participants gained 
about 1.2 kg in weight during the five day 20 g/day loading phase. Body mass for the creatine 
group was 66.5 ± 1.7 kg at baseline, 67.6 ± 1.6 kg at six days, and 67.5 ± 1.5 kg at 42 days. For 
the placebo group, body mass was 70.9 ± 3.1 kg at baseline, 71.1 ± 2.9 kg at six days, and 70.7 ± 
3.1 kg at 42 days. A sudden increase in body mass during the loading phase is related to the 
increased water retention in the cells because of the increased osmolarity of the cells (van Loon 
et al., 2003).   
Health risks using creatine supplementation. For the most part, previous research has 
indicated that creatine supplementation remains adequately safe for human consumption. Other 
researchers have suggested the potential for renal dysfunction as a result of elevated creatinine 
levels due to creatine supplementation (Adhihetty & Beal, 2008). The effects of 
thermoregulation along with hydration while using creatine have also been examined. 
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 Lopez et al. (2009) conducted a systematic review with meta-analysis on 10 different 
original research articles on thermal regulation and hydration status. Studies included in these 
meta-analyses were original research in which all subjects were physically active, consumed 
greater than 2 g/day creatine, and dosage protocols that were at least 5 days long. Creatine 
dosages used among the ten studies were between 20-25 g/day. The length of creatine 
supplementation was between five and twenty-eight days. There were no studies in this 
systematic analysis that involved creatine usage over 28 days. There were no differences in body 
temperature in relationship to exercising in the heat between the placebo and creatine groups in 
six out of the ten studies examined. Three studies had observed rectal temperatures that were 
lower after creatine supplementation compared to the placebo group. One study observed lower 
rectal temperatures 40 minutes into exercise compared to the placebo group. It was stated these 
observations of lower rectal temperature were not significant in comparison to the placebo group. 
The systematic analysis led to the conclusion than an appropriate dosage of creatine 
supplementation does not hinder the body’s thermoregulatory system.  
Wright, Grandjean, and Pascoe (2007) utilized a dosage protocol consuming 20 g/day 
placebo in a flavored drink for six days during the first week of the study. During the second 
week, the 20 g/day placebo was replaced with creatine monohydrate. The testing protocol was 
done at the end of each week to compare the results between a placebo and creatine. Ten subjects 
warmed-up by cycling 30 minutes at 100 W followed by passive recovery. The testing protocol 
involved six 10-second all out sprints with one-minute recovery between sprints in a 35° C with 
60% humidity environment. There were significant decreases in plasma volume (%PV) during 
the tests. No significant differences between placebo and creatine were observed in relationship 
to %PV. For creatine, the %PV was -11.16 ± 6.66% versus -11.76 ± 7.67% for the placebo. 
19 
 
There were also no significant changes in average core temperature during the tests. Core 
temperature during testing following the placebo phase was 38.04 ± 0.56° C and 38.07 ± 0.47° C 
following the creatine supplementation phase. It was concluded from these results that 
supplemental use of creatine did not have any impairment on thermoregulatory function or 
hydration during 30 minutes of low intensity cycling or during a protocol using short sprints 
during hot or humid conditions (Wright et al., 2007). 
       The study by Wright et al. was one of the 10 studies included in the meta-analysis by 
Lopez et al. (2009) that had observed no significant differences in body temperature. Based on 
these findings, Lopez et al. (2009) concluded creatine supplementation causes no ill effects 
regarding heat injury during shorter exercise sessions. Some of the side effects of creatine 
supplementation that have been reported include: renal dysfunction, gastrointestinal discomfort, 
cardiovascular complications, and muscle damage (Terjung et al., 2000).   
There have been two cases involving renal toxicity levels resulting from creatine 
supplementation (Pline & Smith, 2005). The first case involved a 25-year-old man who had 
segmental glomerulosclerosis along with relapsing steroid-responsive nephrotic syndrome 
(Pritchard & Kalra, 1998). The man had suffered from this condition for eight years. Cyclosporin 
was used to help with his reduce his nephrotic relapses. Upon initiating creatine loading dose of 
15 g/day for seven days and then going on a maintenance dose of 2 g/day thereafter for seven 
weeks, he presented during a clinical exam serum creatinine levels of 180 μmol/L and 54 
mL/min of creatinine clearance. While on creatine supplementation, his renal function was 
declining. His creatinine levels prior to supplementation were 103 μmol/L and a creatinine 
excretion rate of 93 mL/min. One month after he was advised to stop creatine supplementation, 
his plasma creatinine was at 128 μmol/L and an excretion rate of 115 mL/min (Pritchard & 
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Kalra, 1998). The second case involved a 20-year-old man who had consumed 20 g/day pure 
creatine monohydrate for four weeks (Koshy, Griswold, & Schneeberger, 1999). Upon 
admission to the hospital after cessation of creatine supplementation, his serum creatinine 
concentration was 203 μmol/L. Focal interstitial nephritis, tubular injury, effacement of 
glomerular foot processes, and focal thickening of the basement membrane were discovered 
during clinical examinations (Kosky et al., 1999). In both of these cases, creatine levels had 
return to baseline following creatine supplementation cessation (Pline & Smith, 2005).  
Renal function complications related to creatine use in young healthy adults is minimal. 
As long as the recommended dosages of creatine use were followed, creatinine levels would 
slightly be elevated but with no progression towards renal dysfunction (Pline & Smith, 2005). 
However, patients consuming any amount of creatine should be monitored for any possible 
complications in renal function (Pline & Smith, 2005).  
There were no reported renal or liver complications in another study lasting three months 
on cardiac patients using supplemental creatine (Cornelissen et al., 2010). Cardiac patients were 
subjects in an examination of creatine supplementation’s effects while engaged in an endurance 
and resistance training program lasting three months. Skeletal muscle performance along with 
cardiorespiratory function were examined. The patients consumed five grams of creatine three 
times daily for one week. After the loading phase, patients consumed five grams of creatine for 
three months. The patients exercised three times per week with an average duration of 90 
minutes. The muscles tested for muscle strength and endurance were the knee extensors. Peak 
torque was measured by having patients perform three maximal knee extensions at a constant 
velocity of 60°/s from 90º to 180º. Muscle endurance was tested by performing two sets of 30 
isokinetic knee extensions with 30 seconds rest between intervals. The equation to determine 
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muscle endurance was: [(mean peak torque of the final five repetitions/mean torque of the first 
five repetitions) * 100]. There was not any significant difference in muscle endurance between 
the creatine or placebo groups. For the first set of 30 isokinetic knee extensions during baseline 
testing, the percentage of strength during the final five repetitions compared to the first five 
repetitions was 73.9 ± 7.3% and 71.0 ± 8.1% for the placebo and creatine group, respectively. 
Baseline measures for the second set of 30 repetitions were 62.9 ± 7.9% and 62.9 ± 6.7% for the 
placebo and creatine group, respectively. Post-test values for the first set of 30 repetitions were 
75.5 ± 8.6% and 74.3 ± 7.3% for the placebo and creatine group, respectively. Post-test values 
for the second set were 69.6 ± 8.3% and 68.8 ± 7.2% for the placebo and creatine group, 
respectively. Peak isokinetic torque at baseline was 127.7 ± 31.4 Nm and 141.6 ± 32.1 Nm for 
the placebo and creatine group respectively. Post-test data indicated peak torque values of 147.3 
± 35.0 Nm and 161.0 ± 36.4 Nm for the placebo and creatine group, respectively. The average 
torque during the second set of knee extensions at baseline was 85.4 ± 19.3 Nm and 93.8 ± 23.0 
Nm for the placebo and creatine group, respectively. Post-test average torque values for the 
second set of knee extensions were 98.9 ± 23.2 Nm and 103.7 ± 25.0 Nm for the placebo and 
creatine group, respectively.   
VO2 peak at baseline was 21.7 ± 3.8 ml/kg/min and 21.9 ± 6.4 ml/kg/min for the placebo 
and creatine groups, respectively. Post-test data revealed peak VO2
 values of 26.3 ± 5.3 
ml/kg/min and 26.0 ± 7.6 ml/kg/min for the placebo and creatine groups respectively. The 
findings from the study indicated that creatine dosages benefiting younger healthy individuals 
did not have any significant effect on patients with coronary artery disease or chronic heart 
failure (Cornelissen et al., 2010).  
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Schilling et al. (2001) examined creatine use over a time period of 0.8 to 4.0 years in 26 
athletes who were active in strength and power training. Participants in this study consumed 
creatine for four weeks and then went off the supplement for one to four weeks before resuming 
supplementation. Average dosage during the loading phase was 13.7 g ± 10.0 g/day. Average 
maintenance dosage was 9.7 ± 5.7 g/day (Shilling et al., 2001). Long-term usage of creatine did 
not lead to any decrease in overall health. There were also no indications of increased cramping 
(Schilling et al., 2001).  
Watson et al. (2006) did not observe any increases in heat injury or cramping after 80 
minutes of exercise in a dehydrated state in the creatine group versus the placebo group. The 
subjects had exercised for two hours alternating between walking on treadmill at 6.6 ± 0.32 km/h 
and cycling at a pace equivalent to the intensity achieved on the treadmill. Switching from 
cycling to running occurred every 30 minutes. Participants in the study were split evenly into a 
creatine monohydrate supplemental group or placebo group each consuming 21.6 g/day of the 
product for nine days. The data from Watson et al. (2006) further indicated that short-term 
creatine monohydrate use does not negatively affect the thermoregulatory, cardiorespiratory, or 
metabolic systems.  
There are limited studies on the long-term effects of creatine supplementation (Cooper, 
Naclerio, Allgrove, & Jimenez, 2012). There remains uncertainty as to the positive or negative 
outcomes of long-term creatine supplementation. Kim, Kim, Carpentier, and Poortsman (2011) 
suggested that patients with kidney dysfunction, diabetes, hypertension, and reduced glomerular 
rate should abstain from creatine doses greater than three to five grams per day. 
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Enhancement of creatine bioavailability. Creatine (N-(aminoiminomethyl)-N-methyl 
glycine commonly found in various fishes and meats has recently been produced in various 
forms by manufacturers claiming increased bioavailability, solubility, and chemical components 
(Jäger, Purpura, Shao, Inoue, & Kreider, 2011). Creatine has a low solubility in water. However, 
there is a linear relationship between temperature and the solubility of creatine. The hotter the 
temperature of water the higher the solubility of creatine (Jäger et al., 2011). Another factor 
increasing the solubility of creatine is a decreased pH solution. Compared to the creatine 
monohydrate, which dissolves at 14 g/L at 20°C, creatine citrate and creatine pyruvate dissolve 
at a rate of 29 g/L and 54 g/L respectively at 20°C. Since creatine salts can decrease the pH level 
of a solution, creatine salts have an enhanced solubility (Jäger et al., 2011).  
Absorption rate in the intestines and efficiency of consumption by the body’s cells and 
tissues of creatine make up the two basic components of creatine bioavailability (Jäger et al., 
2011). Deldicque et al. (2008) examined the comparisons of creatine consumed in protein or 
beta-glucan (BG) rich bars compared to consumption in via a liquid solution on creatine plasma 
kinetics and excretion. The weeklong supplement protocol used by Deldicque et al. (2008) 
included the following three conditions: two grams powdered creatine consumed with 150 ml of 
watery solution, a protein enriched bar, or a BG rich food bar. The protein bar consisted the 
following nutrients: 19 g of carbohydrates, 14.3 g of protein, 1.3 g of fats, and 0.1 g of fiber. The 
GC bar contained the following: 16.7 g of carbohydrates, 4.1 g of protein, 2.3 g of fats, and 3.2 g 
of fibers about half of which were beta-glucans. Both of the food bars consisted of two grams of 
creatine. Subjects consumed their sources of creatine three times daily. Following the subjects 
first initial two-gram dose of creatine, the amount of creatine excreted within the first 24 hours 
was 8 ± 1.2% for the BG treatment group which was significantly lower than the protein bar and 
24 
 
liquid groups. Following the weeklong supplement period, there were no significant differences 
between the treatment groups in the levels of creatine found in the plasma. It was concluded that 
bioavailability of creatine was not different between the three different treatment groups. Due to 
the amount of viscous polysaccharides found in the BG bar, carbohydrates, fats, and creatine are 
more slowly absorbed. This can explain why the urinary output of creatine was less in the BG 
group during the initial 24 hours after consumption. It was also concluded that creatine has an 
ample amount of bioavailability due to the near complete absorption of creatine as observed by 
the lack of creatine found in the subject’s feces.  
Due to creatine’s absorption rate of nearly 100 %, the observations made by Jäger, 
Harris, Purpura, and Francaux (2007) indicated that various forms of creatine would have 
minimal to no differences in creatine levels during supplement loading. Jäger et al. (2007) 
compared 5.0 g of creatine monohydrate (CM), 6.7 g of tri-creatine citrate (CrC), and 7.3 g 
creatine pyruvate (CrPyr) on creatine concentration and pharmacokinetics. All protocols utilized 
the dissolving of creatine in 450 ml of water. Out of the three creatine supplement forms, the 
ingestion of 4.4 g of CrPyr resulted in the highest amounts of creatine found in the plasma eight 
hours after consumption. The average concentrations were 1.17 times higher in the CrPyr group 
compared to the CrC and 1.29 times higher compared to CM over an eight-hour period following 
ingestion. The acidity of a substance will lower the pH level increasing the solubility of creatine 
associated with that substance. The acidity of pyruvate is greater than citric acid. Jager et al. 
(2007) observed significant increases in plasma creatine with all three forms of creatine. Despite 
the different concentrations found within the three different forms of creatine, any bioavailability 
advantages to one form of creatine over another form of creatine appear minimal because almost 
100 % of CM is absorbed by the body.  
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Creatine effects on muscle strength and torque. Increases in strength, muscle 
hypertrophy, and increases in fat free mass have been associated with creatine supplementation 
in conjunction with a resistance-training program over resistance training alone (Cooper et al., 
2012). Greenhaff et al. (1993) utilized a creatine dosage regimen of five grams of creatine plus 
one gram of glucose versus a placebo plus the glucose for five days. The six subjects who 
consumed the creatine supplement were observed to have higher peak isokinetic torque during 
five sets of 30 unilateral knee extensions using a constant angular velocity of 180°/s on a Cybex 
II isokinetic dynamometer (Lumex Inc., Ronkokoma, NY). The greatest significant differences 
were noted on the second and third sets of leg extensions, p < 0.01 and p < 0.05 respectively. 
During baseline measurements for the second set of knee extensions, the placebo group had 
muscle peak torque of 1855 ± 199 Nm and 1699 ± 248 Nm following the five-day trial. Values 
for the creatine group were 2359 ± 272 Nm during baseline testing and 2489 ± 290 Nm after the 
five-day trial. For the third set, the placebo values were 1717 ± 184 Nm at baseline and 1617 ± 
192 Nm after five days. The values for the creatine group were 2025 ± 229 Nm at baseline and 
2127 ± 241 Nm after the five-day trial. Greenhaff et al. (1993) concluded that elevated muscle 
creatine content resulting from supplementation attenuated loss of peak torque while performing 
repeated isokinetic contractions. This is in contrast to the findings observed by Gilliam, Hohzorn, 
Martin, and Timble et al. (2000).  
Gilliam et al. (2000) had found that creatine supplementation over a five-day period did 
not result in the maintenance of torque in repeated isokinetic contractions in comparison to the 
placebo group. Subjects had performed five sets of 30 maximal voluntary contractions with one-
minute rest between each set. Each repetition included doing both a knee extension and knee 
curl. The maximum torque had declined by about 50% by the fifth set compared to the first set in 
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the placebo and creatine group. For the placebo group, the average peak torque at baseline for the 
first set was 83.90 ± 16.73 Nm and 44.21 ± 10.06 Nm on the 5th set. Post-test torque values were 
87.15 ± 17.27 Nm during the first set and 47.48 ± 8.98 Nm for the 5th set. Torque values for the 
creatine group at baseline were 85.24 ± 13.06 Nm on set one and 37.98 ± 9.79 Nm on the 5th set. 
Post-test torque values were 86.75 ± 13.74 Nm for the first set and 40.54 ± 8.57 Nm on the fifth 
set. The average differences in torque between the two groups were: 1.51 Nm, 2.76 Nm, 0.41 
Nm, 1.11 Nm, and 2.56 Nm for sets number 1, 2, 3, 4, and 5 respectively. Baseline to post-
testing values between group, time, and set were not significant between the placebo and creatine 
groups (p>0.05). Both groups had similar decreases in maximum torque values across all five 
sets. The decrease was significant across all sets regardless of the group (p<0.05). The study 
design and protocol used by Gilliam et al. was nearly identical to the protocol used by Greenhaff 
et al. (1993).  
Zuniga et al. (2012) observed no increased changes in strength compared to a placebo 
group in 1-RM strength measures using a plate loaded leg extension machine for leg extensions 
and a free weight bench for the bench press. Subjects in this study were untrained males who did 
less than four hours per week of physical activity. Subjects were asked to carry on with any 
physical activity they may have been doing prior to the study. Their 1-RM strength was 
determined by having each subject progressively lift heavier loads until a load was achieved in 
which the subjects could not get the full range of motion. Two minutes of rests were given 
between each lift. Subjects had consumed 20 g/day of creatine monohydrate for one full week.  
For the placebo group, the 1-RM for leg extension was 126.82 ± 20.91 kg at baseline and 137.40 
± 18.03 kg during the post-test. The bench press 1-RM for the placebo group was 92.61 ± 25.78 
kg at baseline and 93.93 ± 24.05 kg during post testing. Leg extension 1-RM for the creatine 
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group was 115.44 ± 18.66 at baseline and 126.55 ± 19.71 kg during post-testing. Bench press 1-
RM for the supplemental group was 91.40 ± 23.66 kg at baseline and 93.44 ± 24.60 kg during 
post-testing. It was concluded that creatine supplementation did not have any strength benefits 
for 1-RM upper or lower body strength.  
Increases in isometric knee extensor strength by 24% compared to baseline 
measurements occurred in both male and female subjects after a 14-week strength-training 
program in conjunction with a supplementation dosage 5 g/day creatine monohydrate (Brose, 
Parise, & Tarnopolsky, 2003). Increases for both genders combined in knee extensor strength 
were 46.2 ± 22.5% in the creatine group compared to 22.5 ± 14.4% in the placebo group. For 
men in the creatine group, the knee extensor isometric strength at baseline was 153 ± 28 Nm and 
217 ± 36 Nm after 14 weeks. The male placebo group had baseline values of 156 ± 32 Nm and 
180 ± 29 Nm at 14 weeks. The female creatine group had baseline isometric knee extensor 
strength values of 94 ± 38 Nm and 126 ± 30 Nm at 14 weeks. The female placebo group had 
baseline measures of 89 ± 17 Nm and 113 ± 25 Nm at 14 weeks. Creatine had no effects on 
dynamic 1-RM strength measures for either gender in comparison to the placebo group. 
Increases in strength were due to the training effect (p < 0.01). Increases in isometric dorsi-
flexion by 18% compared to baseline measurements were observed in the creatine monohydrate 
group, but only males, 17.8 ± 11.6% and 2.2 ± 5.6%, in the creatine and placebo group, 
respectively. Isometric dorsi-flexion isometric strength in the male creatine group was 54 ± 14 
Nm and 62 ± 15 Nm at baseline and post-testing, respectively. The male placebo values were 52 
± 8 Nm and 52 ± 10 Nm at baseline and post-testing, respectively. This demonstrated a 
significant increase (p < 0.05) in isometric dorsi-flexion strength between the male creatine and 
placebo groups. Handgrip strength did not show any improvement in either of the sample groups. 
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Improvements based on using a 1 RM protocol were also observed in the following exercises: 
upright chest press, leg press, arm flexion, and knee extension but with no differences in these 
increases between study samples (p < 0.001). Increases in strength in these four exercises were 
related to the effects of training (p < 0.01). 
Creatine’s effects on anaerobic and aerobic performance. Studies examining the effects 
of creatine on anaerobic performance often utilize Wingate tests (Gotshalk et al., 2002; Okudan, 
Belviranli, Pepe, & Gökbel, 2015; Okudan & Gokbel, 2005). There are conflicting results on the 
effectiveness of creatine supplementation on anaerobic performance. A number of studies show 
benefits related to creatine supplementation (Dabidi Roshan, Babaei, Hosseinzadeh, & Arendt-
Nielson, 2013; Eckerson et al., 2004; Gotshalk et al., 2002; Okudan et al., 2015; Okudan & 
Gokbel, 2005). Some studies show creatine to be ineffective (Aedma, Timpmann, Lätt, & Ööpik, 
2015; Reeder, Kazubinski, Foreman, Crauthers, & Lockard, 2013). The enhancement of 
anaerobic performance observed while on creatine supplementation has been regarded as a result 
of the elevated stores PCr and free creatine in the muscle (Eckerson et al., 2004). The stored 
amounts of ATP and PCr are the main contributors of energy supply during maximal 
contractions (Eckerson et al., 2004).  
When comparing anaerobic working capacity (AWC) within moderately to highly active 
females, a significant increase of 22.1% AWC was observed after five days of creatine 
supplementation compared to the control group. AWC is the maximal effort an individual can 
exert and is related to the ATP and phosphocreatine that is stored in the muscle. The dosage 
protocol utilized five grams of creatine plus 18 g of dextrose consumed four times daily. AWC 
was measured using an electronically braked cycle ergometer (Eckerson et al., 2004).  
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Improvements in anaerobic performance consisting of three trials of 30-s Wingate tests 
separated with five minutes of recovery in between were also observed in subjects who had 
consumed creatine with water (Cr.H2O group) compared to a placebo group (Earnest, Snell, 
Rodriguez, Almada, & Mitchell, 1995). The percentages of increase in anaerobic performance on 
the Wingate tests after a 14 day dosage protocol consisting of creatine and water were 13%, 18% 
, and 18% for trials one, two, and three, respectively (P<0.05). Baseline Wingate bike test values 
for the creatine group were 22.65 ± 3.0 kJ, 22.40 ± 2.0 kJ, and 18.54 ± 1.0 kJ for trials 1,2, and 3, 
respectively. Post-test values during post-testing were 25.98 ± 4.0, 24.49 ± 3.0, and 22.73 ± 2.0 
kJ for trials 1, 2, and 3, respectively. Baseline placebo group values were 23. 48 ± 1.0 kJ, 22.08 ± 
2.0 kJ, and 21.15 ± 2.0 kJ for trials 1, 2, and 3, respectively. Placebo post-test values were 23.51 
± 1.0 kJ, 22.32 ± 2.0 kJ, and 21.4 ± 2.0 kJ for trials 1, 2, and 3, respectively. This increase in 
anaerobic performance was related to elevated amounts of PCr in the muscle that have been 
observed in subjects using creatine.  
Another study using a dosage protocol of 20 g/day for four days observed increases in 
maximum power, but no significant differences in average power or fatigue index in both males 
and females (Tarnopolsky & MacLennon, 2000). The peak power averaged over two 30-s 
maximal cycling ergometer trials with four minutes of recovery between each trial was 774 ± 
165 W. Maximal average wattage for the placebo group was 746 ± 163 W. The lactate 
concentration following the two 30-s cycling test was also higher compared to the placebo group. 
Lactate levels for males who were in the supplement group had lactate concentrations of 12.4 ± 
3.2 mmol/L compared to the placebo group which had 10.9 ± 5.3 mmol/L. For females, the 
lactate concentrations in the supplement group were 13.1 ± 4.0 mmol/L compared to 9.5 ± 2.5 
mmol/L for the placebo group.  
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 Chwalbiñska-Moneta (2003) observed a beneficial effect from creatine supplementation 
on elite rowers. Both endurance and AWC were improved during the weeklong endurance 
training protocol. The endurance protocol consisted of rowers performing an incremental test. 
Intensity started at 220 W for three minutes with further increases in workload of 50 W every 
three minutes until subjects requested to stop. There were 40-second breaks between each 
workload to enable blood sampling for lactate concentration readings. Subjects had consumed 
either a placebo or creatine supplementation of 20 g/day for 5 days (Chwalbiñska-Moneta, 
2003). One significant finding at the end of the study was the creatine group being able to row 
12.1 ± 4.5 s more during the anaerobic rowing test compared to the placebo group which rowed 
an additional 2.4 ± 8.2 s. The levels of blood lactate decreased for the supplemental group and 
placebo group during the progressive testing protocol. The decrease in lactate occurred at a lower 
intensity for the supplemental group compared to the placebo group. For the creatine group, the 
blood lactate began to show a decrease from baseline values at around 370 W compared to 
around 420 W for the placebo group. The average amount of lactate at 370 W during baseline 
was just under 4 mmol/L and at post-testing was around 3 to 3.5 mmol/L for the creatine group. 
The placebo group lactate values at 370 W during pre and post-testing were at around 4 mmol/L  
after testing   Another finding observed during the graded test was the difference in the mean 
individual anaerobic threshold (Lat-log) to a greater work intensity post-creatine loading 
compared to the placebo group (Chwalbiñska-Moneta, 2003)  The Lat-log is a measurement 
from the intersection of two linear segments consisting of the log lactate concentration versus the 
log exercise load (Beaver, Wasserman, & Whipp, 1985). The Lat-log for the creatine group went 
from 314.3 ± 5.0 W to 335.6 ± 7.1 W compared to the placebo group which only went from 
308.9 ± 6.9 W to 308.9 ± 5.9 W. There were no significant differences between the supplement 
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group and placebo group after seven days in relation to lactate threshold using a blood lactate 
concentration of 4 mmol/L. Observations of average blood lactate at the LAT-log were increased 
a significant amount (p<0.02) for the creatine group compared to the placebo group. 
Chwalbiñska-Moneta (2003) stated that the decreases in heart rate (HR) along with abating of 
blood lactate levels might have been a result of the training effects, since the subjects were elite 
rowers. The increase in performance ability at maximal intensities are likely due to the increase 
PCr after a loading phase since supplementation increases both creatine and PCr content in the 
muscle.  
More recently, lower lactate levels were observed in men, ages 20 to 30 years, following 
a dosage protocol of 20 g/day of creatine and 60 g/day glucose spread out across four doses over 
a six-day period (Oliver, Joubert, Martin, & Crouse, 2013). Oliver et al. (2013) performed a 
study where they instructed individuals to consume five grams of creatine along with 15 grams 
of glucose four times a day for six days. The subjects were tested on a cycling ergometer starting 
at 30 watts and increasing the wattage by 30 every three minutes until the subject reached a level 
of fatigue where he could no longer maintain a cadence of 70-rpm. During the post-test, there 
was a significantly reduced amount of lactate levels compared to the pre-test as indicated by the 
observation of a significant condition effect (p = .041) and no interaction effect (p = .498). 
Lactate levels were decreased throughout the incremental cycling protocol following 
supplementation. At 180 W the amount of lactate prior to supplementation was around 6.3 
mmol/L. After creatine supplementation, the lactate levels at 180 W were closer to 5.6 mmol/L. 
There was no statistical significance in time it took before participants fatigued (p = .056). The 
power output at the time of fatigue also showed no significant difference after the six days 
creatine loading (p = 0.82). However, no other studies to the author’s knowledge had observed 
32 
 
significant reduction in lactate using an incremental cycling protocol after a loading phase of an 
oral creatine supplementation regimen lasting six days (Oliver et al., 2013). The increased PCr 
content from supplementation is suggested to help with the buffering of the energy needs of the 
cells. Attenuating reliance on the glycolytic energy pathway along with lowering levels of lactate 
production during incremental exercise may be due in part to the increased PCr resulting from 
supplementation (Nelson et al., 2000; Oliver et al., 2013). 
 Muscle fatigue. Muscle activity that results in a performance decrease over time, with 
performance returning to or near normal conditions following period of rest, is often termed 
muscle fatigue (Allen, Lamb, & Westerblad, 2008). Fatigue can also be divided into 
subcategories: low-frequency fatigue and high-frequency fatigue (Rassier & MacIntosh, 2000). 
Low-frequency fatigue (LFF) results in a greater loss of force due to the low versus high 
frequency of stimulation to the muscle. LFF is demonstrated the muscle’s reduced force 
generation capability in response to lower frequency activation (Keeton & Binder-Macleod, 
2006). High-frequency fatigue results from the reduced capability to generate maximal force or 
the ability to respond adequately to the frequencies providing the stimuli to generate maximal 
force (Rassier & MacIntosh, 2000).  
There are a multitude of factors affecting muscle performance which result in muscle 
fatigue. One of the mechanisms of muscle action which indicates the onset of fatigue is the 
reduction of shortening velocity. This mechanism results from the increasing time needed for 
muscle relaxation (Allen et al., 2008). Two major components in the generation of power in 
muscle are contractile force and shortening velocity (Allen et al., 2008; Sasaki & Ishii, 2005). 
Muscle force results from actions of the contractile proteins within the sarcomere. The overlap 
between two major contractile proteins, actin and myosin filaments, contribute to the force-
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length relationship (Sasaki & Ishii, 2005). Shortening velocity involves the maximum isometric 
force and the specific load being applied to the muscle. The faster the rate of muscle shortening, 
the lesser amount of force or torque that is generated (Fenn & Marsh, 1935; Sasaki & Ishii, 
2005). Over time, the decrease in both force and shortening velocity lead to an overall loss of 
performance. Eventually, there comes a point in time when the intensity of the activity cannot be 
maintained. Higher intensity activity shows a more obvious sign of fatigue versus a submaximal 
effort in which fatigue may not present itself as clearly. However, there are differences when it 
comes to complete exhaustion/fatigue versus muscle injury (Allen et al., 2008).  
 It can sometimes be difficult to determine the difference between muscle injury and 
muscle fatigue when it comes to performance. A key point to muscle fatigue is the fact that the 
decline in muscle performance is reversible with usually a short period of rest (Allen et al., 
2008). Low-frequency fatigue can often take up to many days before a there is a return to 
baseline muscle performance (Keeton & Binder-Macleod, 2006). The rate of muscle fatigue can 
vary depending on the strength and duration of the contraction (Allen et al., 2008). At times, it 
can take a number of days of rest to reach the same original intensity or performance following 
muscle fatigue (Allen et al., 2008). Repeated short muscle actions usually have a fast component 
of recovery during the first 30 minutes and a slower component that can last for several hours. 
Sometimes, a small component of weakness may persist beyond 24 hours. Eccentric muscle 
actions increase the potential for muscle damage. With muscle injury, a decline in performance 
also occurs; however, the time to be able to achieve the original performance takes a 
significantly longer time. Decreased force generation in muscle can persist up to several days 
depending on the intensity of the exercise that causes the muscle damage. The most injury prone 
actions are those of muscle lengthening (eccentric actions). Muscle injury also indicates an 
34 
 
inflammatory response, structural abnormalities, membrane damage, activation of satellite cells, 
and regeneration of muscle fibers. The amount of recovery needed for muscle to achieve its 
maximal force production can take considerably longer when there is muscle damage done. This 
muscle damage can result from over stretching of muscle. These physiological processes are not 
typically seen with muscle fatigue (Allen et al., 2008).  
 A maximal or near maximal force exerted by the muscle or doing a 1-repetition 
maximum or lifting a heavy object results in rapid fatigue. Recovery time needed to allow the 
muscle to perform work again can occur within 1-2 seconds following cessation of muscle action 
(Allen et al., 2008; Edwards, Hill, Jones, & Merton, 1977). Activities including walking, 
swimming, running, or any other sustained physical activity or activity resulting in repeated short 
tetani results in a much slower rate of fatigue compared to maximal effort. The recovery time 
with longer sustained activity can be dependent on various factors. There can be a rapid phase of 
recovery where muscle can regain most of its potential work capacity after about five to ten 
minutes of rest. The ability to perform maximal force after a period of sustained activity can be 
achieved after 30 minutes or more of continuous rest (Allen et al., 2008).  
 There are two components that can contribute to fatigue: central and peripheral factors. 
The neuromuscular junction, sarcolemma, and mechanisms involving the contractile proteins, 
myosin and actin, and regulatory proteins, troponin and tropomyosin, along with other proteins 
found in the contractile unit of the sarcomere play a role in the peripheral component. The other 
factor contributing to fatigue comes from a reduced input from the central nervous system. The 
central factor of fatigue originates from pathways above the neuromuscular junction and can 
include both the central and peripheral nerves as well as an inability to generate facilitation of the 
neurons (Schillings, Hoefsloot, Stegeman, & Zwarts, 2003).  
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Schillings et al. (2003) examined a sample group consisting of thirteen males and seven 
females the contributing factors of fatigue during a sustained maximal voluntary contraction 
(MVC) of the biceps brachii muscle. During the first minute of a two-minute MVC, the majority 
of fatigue resulted from peripheral factors. Force at the beginning of MVC was 214. ± 80.1 N 
and after two minutes was 79.6 ± 29.8 N, which was 38.2 ± 7.8% of the original force. There 
were also differences in the duration of force responses from the beginning to the end of muscle 
contraction. Force responses at the beginning were 125.1 ± 9.6 ms to 211.2 ± 40.8 ms, which 
was a 169.1 ± 31.7% change over two minutes of muscle contraction. Two factors contributed to 
this increased duration: reduced maximal contraction and relaxation rates. Maximal contraction 
went from 1.03 ± 0.21 % m/s to 0.81 ± 0.12 % m/s and relaxation went from 0.60 ± 0.11 % m/s 
to 0.35 ± 0.07 % m/s. Central activation failure (CAF) also demonstrated a bigger increase 
during sustained MVC. Two different calculation methods were used to determine CAF. In the 
first method, CAF had increased from 18.1 ± 15.2% after 15 seconds to 39.8 ± 39.9% after two 
minutes. Using the second type of calculation CAF values had gone 16.9 ± 13.6% after 15 
seconds to 29.0 ± 21.1% after two minutes. The large variations in CAF between subjects was 
explained by the fact some subjects had a big increase in CAF, and other subjects had either no 
change or a decrease in CAF. 
After the first minute, peripheral factors leveled off while the increase in fatigue became 
completely due to central fatigue factors. Both peripheral and central factors of fatigue resulted 
in a loss of MVC in the biceps brachii after two minutes, but the greatest amount of force loss 
occurred during the first minute. The decrease in voluntary force as a percentage of MVC went 
from 100% at the onset of the contraction down to about 75% at 30 seconds and 60% at 60 
seconds. At 120 seconds, the voluntary force was at 40% of MVC. Muscle fiber conduction 
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velocity (MFCV) also decreased within the first minute but had minimal changes during the 
second minute. AT 30 seconds, the MFCV was at 75% of the maximum MFCV. At 60 seconds, 
it had dropped to 60% of maximum MFCV. At 120 seconds, MFCV was at 62.5% of the 
maximum amount. It was also noted that central activation varies between different muscle 
groups and that studies can only be compared with other studies if the same muscle was utilized. 
It was concluded that peripheral factors play a key role in the initial decrease in force because the 
exertion of the muscle is at its highest at the beginning of a MVC. Peripheral factors had 
contributed to 89.0% of the voluntary force loss. The increased metabolic demand plus the 
occluded blood flow to the muscle are also increasing the demand on the muscle at the beginning 
of muscle action. If an MVC continues for a prolonged period then it was demonstrated there is 
the probability of an increased challenge in having the continuation of neurons firing possibly 
resulting from central activation failure (Schillings et al., 2003).  
Measuring muscle fatigue. According to Thorstensson and Karlsson (1976), fatigue was 
indicated by a decrease in the amount of maximal force production in 50 subsequent muscle 
contractions involving the vastus lateralis muscle in comparison to the initial contraction. The 
apparatus utilized in this study was an isokinetic dynamometer (Cbyex II, Lumex Inc. N.Y.). 
Thorstenssson and Karlsson (1976) was one of the first studies to examine the effects on rapid 
voluntary isokinetic muscle action. Since that time, many studies have utilized isokinetic 
dynamometers for strength tests, peak torque, and rate of muscle fatigue (Bosquet et al., 2010; 
Gautrey, Mitchell, & Watson, 2013; Gleeson & Mercer, 1996). A factor considered when doing 
isokinetic testing is the rest interval between tests (Bottaro, Russo, & de Oliveira, 2005). 
There is not a clear consensus as to the appropriate rest interval between sets when 
conducting isokinetic muscle testing (Bottaro et al., 2005). One study had indicated that rest 
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intervals greater than three minutes should be the protocol when three sets of knee extensions 
consisting of 10 repetitions are performed during testing (Woods, Bridge, Nelson, Risse, & 
Pincivero, 2004). Another study had observed similar peak torque production with rest periods of 
30, 60, or 90 seconds during two sets of four repetitions with each repetition lasting six seconds 
in elderly individuals (Bottaro et al., 2005). A recovery period of 60 seconds was suggested to be 
sufficient for healthy subjects performing four sets of knee extensions (Parcell, Sawyer, Tricoli, 
& Chinevere, 2002). 
Creatine and fatigue. Some studies have demonstrated the ability for muscle to maintain 
contraction for longer periods of time along with an increase in lean body mass resulting from 
creatine supplementation (Adhihetty & Beal, 2008; van Loon et al., 2003). There is an enormous 
body of literature on the effects of creatine supplementation related to sports performance. 
Creatine supplementation has regularly been demonstrated to improve strength, increase 
hypertrophy, and increase fat free mass in individuals. These improvements on the performance 
parameters listed are enhanced when an individual uses creatine while actively engaged in a 
heavy resistance-training program (Cooper et al., 2012). Previous studies have suggested an 
increase in muscle performance (Cribb et al., 2007; Deldicque et al., 2008). However, Baker, 
Candow, and Farthing (2015) observed no performance enhancements utilizing an acute pre-
exercise creatine supplementation protocol.  
  A study examined muscle fatigue while doing chest press and leg press until muscle 
failure had observed no benefits in consuming 20 g of creatine over a placebo three hours prior 
to exercise. Participants in this study had done three sets at 70 % of 1-RM for both the chest 
press and leg press with each set consisting of as many reps the participant could do. The amount 
of repetitions in subsequent sets decreased identically in both the creatine and placebo group 
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indicating equal progression of muscle fatigue between the two groups. The number of leg press 
repetitions for the first set were around 33 for both groups. Leg press repetitions for the second 
was around 18 with the placebo group performing a slightly higher amount of reps compared to 
the creatine group. The number of leg press repetitions for the 3rd set was around 15 for both 
groups. For the chest press, the number of repetitions was around 13 for both groups. Both 
groups performed about seven repetitions of chest press for the 2nd set. Both groups did around 
five chest press repetitions for the 3rd set with the placebo group performing only slightly greater 
repetitions. It was concluded that ingesting a bolus of creatine three hours prior to exercise had 
no effects on increasing leg press or chest press performance on healthy adult males aged 54 ± 
4.3 years (Baker et al., 2015).  
 A similar study done involving 14 active men showed a decrease in fatigue with 
consuming 25 g of creatine over a period of one week. In this particular study, the subjects were 
instructed to do five sets of bench press exercises until muscle failure in each set. The amount of 
weight that was used was the subject’s 10-rep maximum as determined during the pretests 
(Volek et al., 1997). The other exercise utilized was the jump squat at 30% of the subject’s 1-
RM. The 30% value was chosen because previous research had indicated this was the percentage 
where mechanical power is maximized. Subjects performed five sets of 10 continuous jump 
squats with an emphasis to perform at maximal effort each rep. The rep with the highest recorded 
amount of power was the peak power for that particular set. For both exercises, two minutes of 
rest were given (Volek et al., 1997). Both, the amount of reps performed on the bench press and 
peak power during each set of jump squats, were higher in the creatine group compared to the 
placebo group. Peak power output had increased in all five sets of jump squats as a result of 
creatine supplementation. In the creatine group, there was an average increase of 2.3 repetitions 
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in the first set of bench press exercises. This is similar to a previous study where after 28 days of 
creatine supplementation, there was a four-repetition increase at 70 % of 1-RM in resistance-
trained men (Volek et al., 1997).  
  de Salles Painelli et al. (2014) examined the effects of concurrent exercise sessions 
involving both aerobic and strength exercises while using creatine supplementation. The study 
utilized a loading phase of 20 g/day of creatine for 7 days followed by a maintenance dosage of 5 
g/day. Four testing sessions with 72 hours of recovery between each session were initiated after 
the seven-day loading phase. The protocol used for continuous aerobic exercise was a five-
kilometer treadmill run at 90 % of the subject’s anaerobic threshold. Intermittent aerobic exercise 
utilized a one-minute effort at the subject’s maximum VO2 with one minute of recovery between 
running bouts. An endurance strength assessment consisting of subjects performing four sets of 
leg-press and bench press exercises to failure at 80 % of 1-RM was utilized. The 1-RM and the 
endurance strength assessment were performed 10 minutes after the aerobic exercise session. 
The four concurrent exercise testing protocols used were: continuous aerobic exercise followed 
by 1-RM in, intermittent aerobic exercise followed by 1-RM, continuous aerobic exercise 
followed by endurance strength assessment, and intermittent aerobic exercise followed by the 
endurance strength assessment. In comparing 1-RM maximal dynamic strength in both the leg 
press and bench press, a significant increase (p = 0.04) was observed in the leg-press following 
continuous aerobic exercise in comparison to the control group. A significant increase in the 1-
RM bench-press was also noted in the creatine supplementation group after doing intermittent or 
continuous aerobic exercise in comparison to the control group. The increase in 1-RM bench-
press in the creatine group compared to the placebo group was 1.98% (p = 0.001) following 
continuous exercise. The increase in 1-RM bench-press following intermittent aerobic exercise 
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for the creatine group was 0.72% (p = 0.03) more than the placebo group. There was also a 
statistically significant decrease in the number of leg-press repetitions in the placebo group that 
had done intermittent aerobic exercise prior to the muscle endurance testing. The number of 
repetitions were 20.31% (p = 0.02) lower compared to the creatine group having done continuous 
aerobic exercise prior to the strength endurance testing and 21.69% (p = 0.04) less repetitions 
compared to the creatine group. When comparing the number of leg-press repetitions in the 
creatine group following either continuous or intermittent aerobic activity, there were no 
significant differences (p>0.05). The number of leg press repetitions for the creatine group were 
37 and 33 following continuous and intermittent exercise, respectively. The number of leg-press 
repetitions for the placebo group were 35 and 27 following continuous and intermittent exercise, 
respectively. The number of bench-press repetitions after either continuous or intermittent 
aerobic exercise was 26 compared to 23 repetitions performed by the placebo group (de Salles 
Painelli et al., 2014). A key finding in the study was observing the decreased acute strength 
losses while doing concurrent physical activity session involving intermittent high-intensity 
aerobic efforts in recreationally strength trained males. The data from de Salles Painelli et al. 
(2014) along with previous research suggests that creatine loading has a positive influence on 
attenuating fatigue. As stated by Lanhers et al. (2015), creatine supplementation can be 
beneficial in the lower-limb strength, particularly in bouts lasting three minutes or less.  
Summary 
Many athletes attempting to increase strength gains, lean body mass, and athletic 
performance use creatine supplements. There are many studies that have observed increases 
within these athletic domains (Rawson & Persky, 2007). However, there are also some studies 
41 
 
that indicate that oral creatine supplementation has no beneficial effect in increasing muscle 
performance (Baker et al., 2015; Aedma et al., 2015).  
Results may be dependent to some extent on short-term versus- long-term 
supplementation. Study protocols have ranged from as little as 5-7 days, and other lasing up to 
12 weeks. The dosage protocols also vary within existing research. Some studies have utilized a 
loading dose phase lasting up to seven days. Other studies that have extended several days to 
weeks have not used a loading phase. It is also important to note that many studies have 
examined exercise that typically lasts under three minutes, which utilize more of the glycolytic 
and creatine phosphate systems. These energy pathways can rely more on creatine, especially 
during the first seconds of muscle action.  
Creatine’s effects on muscle fatigue have also been examined through previous research. 
Improvements in maintaining muscle performance relating to fatigue reduction have been 
observed. Such observations have included the increased number of reps or maintenance of peak 
torque on subsequent sets following creatine supplementation (Volek et al., 1997). Creatine has 
also shown been shown to have beneficial effects in attenuating fatigue on individuals who had 
done prior exercise before performing 1-RM strength measures (de Salles Painelli et al., 2014). 
Not all studies have demonstrated such benefits in fatigue reduction as observed by Baker et al. 
(2015). However, participants only consumed either 20 g of a placebo or creatine three hours 
prior to exercise on two separate occasions separated by 72 hours.  
More research is needed on enhanced creatine supplement in relationship to peak power 
output on subsequent sets. Previous research has indicated minimal differences in the 
bioavailability of various forms of creatine since the absorption rate of creatine is near 100%. 
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Rates of absorption may depend on the acidity of the creatine formula (Jäger et al., 2011). 
Results from this study may provide information on the effects of a creatine-electrolyte 
performance supplement on fatigability of muscle compared to standard creatine monohydrate or 
placebo.  
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Chapter III 
Methods and Procedures 
Introduction 
 This study was designed to examine the effects of a six-week creatine-electrolyte 
supplementation compared to creatine monohydrate and placebo on two sets of 30 maximal 
isokinetic knee extensions. The total work performed, mean power, and the degradation of power 
from the first 10 repetitions to the last 10 repetitions was analyzed for both sets of knee 
extensions. This study provided data about the effectiveness two different creatine 
supplementation formulas; creatine monohydrate and a creatine-electrolyte supplement. 
Description of Study Subjects 
 The study included 24 subjects recruited from the university and local gyms around the 
Bellingham area. The subjects had been on a resistance training program for at least six months 
prior the study. There were no specific training regimens that needed to be followed. The 
subjects were asked to maintain their current training program. Participants were excluded from 
the study if they had consumed creatine within six months prior to the experiment. Additional 
exclusionary criteria included having any current or previous kidney, liver, or endocrine disease 
that could result in adverse effects relating to proper fluid balance or the homeostasis of cellular 
creatine levels in the body. 
Design of the Study 
 This study utilized a pretest and post-test experimental design in which subjects were 
assigned to two different supplementation groups or the placebo group. The study also utilized a 
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double blind format in which neither the subjects nor experimenter who interacted with the 
subjects knew who was in which group. Only the lead experimenter knew the group assignments. 
Subjects were randomly assigned to the placebo, creatine monohydrate (CM), or creatine-
electrolyte (CE) groups. Randomization was carried out by giving a box of supplementation that 
had been given a numbered code to match one of the three possible supplementation formulas. In 
order have an equivalent number of participants in each group, each supplement package based 
on each code was given sequentially.  
Supplementation Protocol 
Following random assignment into the placebo, CM, or CE groups, each subject was 
provided with their supplemental package containing their supplement. The CE group consumed 
four grams of an electrolyte formula consisting of 286 mg magnesium chloride, 171 mg 
potassium chloride, and 171 mg calcium chloride, and 114 mg sodium chloride once daily. The 
CM group consumed four grams of a standard creatine monohydrate formula per day. The 
placebo consumed four grams of maltodextrin, carbohydrate solution daily. The supplementation 
period lasted six weeks to allow for adequate saturation of the supplement into the tissues. All 
supplemental formulas had identical appearances. Subjects were instructed to orally consume 
their respected supplement for the duration of the study with approximately 500 ml or 16 fluid 
oz. of water. Orange Crush (The Jel Sert Company, West Chicago, IL) packages were given to 
each subject as an option to help make the consumption of the supplement more palatable. 
Subjects were dropped from the study if they reported not consuming the supplement for more 
than three days. The administration of these solutions were done using a double-blind method. 
Only the lead researcher, not involved with subject testing, was aware of the group assignments.  
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Data Collection Procedures 
 Instrumentation. Maximum torque and fatigue assessments were completed in the 
Applied Neuromechanics Laboratory at Western Washington University using a Biodex System 
4 (Biodex Medical Systems Inc., Shirley, NY) isokinetic dynamometer. The dominant leg was 
used for all tests. Settings for seat height and fore aft were recorded according to the length of 
the subject’s leg and shank to ensure consistency across measures. Proper adjustments were 
made on the chair so that the subject’s lateral femoral epicondyle of the dominant legs were in 
alignment with the center of rotation of the shaft of the dynamometer. Adjustments were made so 
that the back of the seat was in a position where the length of the dynamometer’s arm was 
properly fitted to the subject’s shank. The shank pad was positioned on the distal portion of the 
tibia about one centimeter above the lateral malleolus of the ankle joint, considered the force 
point, and was secured with a Velcro strap (Lee, Kim, & Park, 2013). The hip angle of the 
subject while sitting was 80 degrees. To help reduce excessive movement of the body, shoulder, 
waist, and thigh straps were utilized in accordance with manufacturer instructions. The range of 
motion of the subject’s leg was set to 20 to 100 degrees of knee flexion.  
 Measurement techniques and procedures. The researcher explained the experimental 
procedure to each individual prior to performing the tests. Subjects were informed on the amount 
of time the experiment would take along with other testing procedures and were provided with 
an informed consent form. The informed consent was completed and understood by all 
participants prior to being included in the study. After completion, the participants signed and 
dated the consent form. Participants were allowed to address any additional questions they had 
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about the experiment. Baseline and post-testing measurements were done on the following: 
height, weight, a three-day diet analysis, body water, and body composition. The subjects’ 
physical activity levels were also noted.  
A three-day diet analysis was utilized on two separate occasions during the study. Each 
subject was asked to record his or her dietary intake during these three-day intervals. Subjects 
were asked to maintain their dietary habits throughout the study. The data were then analyzed 
using Nutritionist Pro software (Ayxxya Systems, Stafford, TX). The nutrient and energy levels 
were determined using the dietary analysis.  
Body water measurements including total body water (TBW), intracellular fluid 
compartments (IFC), and extracellular fluid compartments (ECF) were analyzed via the RJL 
Quantum X bioimpedance unit (RJL Systems Inc., Clinton, MI). The sites of electrode placement 
were the wrist and the third metacarpal for the right upper extremity and the ankle and third 
metatarsal for the right lower extremity following the placement of the electrodes, the body 
composition analyzer unit was connected to the electrodes. An alternating current (50 KHz) was 
utilized to measure and record each subject’s resistance and reactance. Calculations for total 
body, intra-cellular and extra-cellular were determined via an online calculator provided by the 
Quantum X Bioelectrical Body Composition Analyzer manufacturing company (“Interactive  
Online BIA,” n.d.).   The subjects were instructed to avoid any exercise during the 12 hours prior 
to the analysis. The tests for all subjects were completed at the same time of day for each subject.  
Body composition consisting of percent body fat, fat free mass, and fat mass was 
assessed utilizing the three-site skinfolds measurement technique (Pescatello, 2014, Box 4.3, p. 
69). The same researcher, to ensure intrarater reliability, performed all skinfold assessments. An 
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estimate of the subject’s body composition was assessed by measuring skinfold thickness at the 
following locations for males: chest, triceps, and subscapular. For females, the skin fold 
measurement sites were triceps, suprailiac, and abdomen. The sum of the three-skin fold 
measurement along with age and race were entered into an equation (Siri) to estimate body 
composition based on body density. Body fat percentage was first calculated by determining 
body density using the Siri equation matching the appropriate three-site formula to determine 
body density (Pescatello, 2014, Box 4.3, p. 69). The Siri model, where the percentage of body fat 
was equal to 495 and divided by body density and then subtracted by 450, was utilized to 
determine the subject’s body fat percentage (Pescatello, 2014, p. 70).    
Prior to conducting the isometric and 1-RM isokinetic testing, the subjects did two sets of 
10 knee-extensor exercises as a task specific warm-up. Due to the participants having done a 
five-minute self-selected warm-up on a cycle ergometer prior to performing bench press and 
squat cluster sets prior to testing done on the dynamometer, no further warm-up was warranted. 
Maximal isokinetic knee extension torque measurement was determined at angular velocities of 
60 °/s and 180 °/s. Isometric maximal voluntary contraction torque for both knee extension and 
flexion was collected at 60 degrees of knee flexion. Three trials for each of the given conditions 
listed above were performed. A two-minute rest period was allowed between trials. Peak 
isokinetic and isometric torques in Newton-meters (Nm) were determined during the maximal 
isokinetic knee extension test and during a subsequent test of maximal isometric muscle action. 
Torques were normalized by dividing by body mass.  Rest intervals were allowed until the 
subject indicated that he/she was fully recovered. After completion of these tests, the subjects 
cooled down for five minutes on a cycle ergometer at an easy pace with no resistance added. 
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  The testing procedures to determine fatigability involved having each subject do a task 
specific warm-up using the dynamometer followed by 30 maximal isokinetic knee extension 
repetitions at 180 °/s. The absolute torque reduction through the trial, from peak maximal torque 
to subsequent minimum peak torque was recorded in Nm. The total work done during the fatigue 
trial, integrated torque with respect to angular displacement, was determined ensuring that no 
greater than 30 repetitions were included in the analysis. The subjects had two minutes of rest 
before performing a second set of 30 repetitions. The subjects then performed a cool down for 
five minutes on a cycle ergometer at an easy pace, without resistance. Fatigue was determined by 
calculating the absolute reduction of torque throughout the trial, which was used to determine the 
fatigue index. The fatigue index was calculated by dividing the total work performed during the 
last 10 repetitions from the total work performed during the first 10 repetitions. 
Data Analysis 
 Statistical analysis was performed using a 3 x 2 mixed ANOVA at an alpha level of p ≤ 
0.05 to determine the effects of a creatine supplement or placebo on muscle fatigability between 
groups across testing times. Statistical analysis was also performed to determine peak isometric 
torque, peak isokinetic torque, dietary variables, physical activity level expenditure, body 
composition, and body water composition between groups from pre to post-test. An effect size 
analysis was used.  Excel (Microsoft Corporation, Redmond, WA) along with SPSS (IBM 
Corporation, Armonk, NY) was used to complete the data analysis.  
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Chapter IV 
Results and Discussion 
Introduction 
 This study tested the null hypothesis that there would be no significant difference in peak 
isokinetic force, peak isometric force, and muscle fatigue from pre-test to post-test when 
comparing three different supplement groups: CE, CM, and placebo. Each subject attended two 
data collection sessions, pre-testing and post-testing, separated by six weeks of supplement 
intervention. Total body water, extracellular water, and intracellular measurements were 
determined by using the Quantum X bioimpedence unit. Body composition was measured using 
the three-site skin-fold caliper test. Total work, mean power, and peak torque measurements 
were obtained by using an isokinetic dynamometer. Peak isokinetic force was tested by having 
the subjects perform three sets of one repetition maximal exertion knee extensor exercise at 60 
°/s and 180 °/s with two minutes of recovery between sets. Peak isometric torque was tested at 
60 degrees of knee flexion by having the subjects perform five-second maximal contractions for 
both knee extension and knee flexion. There was a two-minute rest period between maximal 
contractions of extensor and flexor muscles of the knee. Following peak isokinetic force and 
isometric force measurements, the subjects then spun at a self-selected cadence on Monark 
ergometer for five minutes before commencing the fatigue protocol. Muscle fatigue was 
measured by having the subjects perform 30 repetitions of knee extensions at maximal effort for 
two sets separated by a two-minute recovery period. Fatigue was calculated by the ratio between 
the first 1/3 and the last 1/3 of work for each set. The three-site skin-folds test was utilized to 
measure body composition. Total body, intracellular, and extracellular water were analyzed with 
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the Quantum X Bioelectrical Body Composition Analyzer in accordance with the manufacturer’s 
recommended procedures. Statistical analysis was performed by using mixed ANOVA. 
Results 
 For this study, resistance-trained individuals were recruited for the six-week creatine 
supplementation experiment. The subjects (n = 24; 17 male, 7 female) were randomly assigned 
to one of three groups: placebo, CM, or CE. All 24 subjects completed post-testing for the 
dietary variables and physical activity level expenditure, body composition, and body water 
analysis. One subject did not complete post-testing for fatigue, work, or power. 
 Subject characteristics. Subject demographics for each group are displayed in Table 1. 
No significant differences were observed between groups. Data for dietary variables and physical 
activity demonstrated the only statistical significance was kilocalories out, with the placebo 
group expending more kilocalories than either of the creatine groups at both pre and post-testing 
(p < 0.05). Detailed data is presented in Table 2.  
Table 1. Subject demographics (mean ± SD) 
 
All Subjects Placebo Creatine Monohydrate Creatine-electrolyte 
 
Pre Post Pre Post Pre Post Pre Post 
n 24 8 9 7 
Age (yr) 21.9±3.9 21.9±1.8 22±2.1 22±2.1 22.4±2.1 22.3±1.8 21.7±1.1 21.9±1.1 
Height (m) 1.69±0.09 1.71±0.1 1.71±0.1 1.73±0.1 1.67±0.1 1.68±0.1 1.72±0.1 1.72±0.1 
Mass (kg) 72.5±9.3 73.2±9.5 74.9±12.7 75.4±12.5 70.1±7.5 71.3±8.6 72.9±7.1 72.9±8.2 
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Table 2. Dietary Variables and Physical Activity Level Energy Expenditure (mean ± SD) 
 
 
Placebo Creatine Monohydrate Creatine-electrolyte 
 
Pre Post Pre Post Pre Post 
Energy 
Expended 
(Kcal.d-1) 
3991.6±1201.6* 3937.3±1115.0* 3299.98±335.29 3084.99±554.31 3520.06±417.32 3559.11±439.06 
Dietary 
Energy 
(Kcal.d-1) 
4035.86±205.29 4089.00±198.06 3715.16±65.13 3524.72±277.60 3802.55±292.50 3631.07±305.85 
Dietary 
CHO  
(g.d-1) 
407.25±148.99 423.75±148.74 397.12±82.62 347.70±93.71 354.95±19.40 365.30±45.21 
Dietary 
Fat  
(g.d-1) 
199.03±124.81 211.55±115.61 187.78±38.22 202.08±49.75 175.58±46.49 183.73±33.61 
Dietary 
Protein 
(g.d-1) 
213.15±48.42 219.33±51.34 175.60±24.06 185.20±45.03 179.65±43.82 161.40±40.88 
Energy expenditure was greatest for the placebo group compared to both the creatine-
monohydrate and placebo groups during both pre-testing and post-testing, p<0.05*. 
Body Composition. Data for body fat percentage demonstrated no interaction between time and 
supplement (F[2,21] = 0.466, p = 0.634, ηp2 = 0.43). There was also no main effect for time for 
body fat percentage (F[1, 21] = 2.489, p = 0.130, ηp2 = .106), nor was there any main effect for 
supplement (F[2, 21] = 0.960, p = 0.399, ηp2 = 0.084). No interaction between time and 
supplement was observed for lean body mass (F[2,21] = 0.608, p = 0.554, ηp2 = 0.055). Lean 
body also demonstrated no main effect for time (F[1, 21] = 0.471, p = 0.500, ηp2 = 0.022), nor 
was there any main effect for supplement (F[2, 21] = 0.756, p = 0.482, ηp2 = 0.067). Fat mass 
also demonstrated no statistical significance as there was no interaction between time and 
supplement (F[2, 21] = 0.577, p = 0.570, ηp2 = 0.052). There was also no significance for the 
main effect of time in lean body mass (F[1, 21] = 2.347, p = 0.140, ηp2 = 0.101 or main effect for 
supplement (F[2,21] = 0.923, p = 0.413, ηp2 = 0.081) A medium effect size of time for both fat 
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mass and body fat percentage (ηp2 = 0.10 and ηp2 = 0.11, respectively) were observed. Detailed 
body composition results are displayed in Table 3, Figure 1, and Figure 2.  
Table 3. Body Composition (mean ± SD)  
  Placebo Creatine Monohydrate Creatine-electrolyte  
  Pre-Test Post-Test Pre-Test Post-Test Pre-Test Post-Test 
       
Body Fat (%) 14.75±5.79 15.19±8.32 16.06±8.98 17.53±10.11 11.11±6.26 11.61±6.07 
Lean Body Mass (kg) 63.63±10.57 63.94±11.91 60.14±8.32 58.72±8.59 65±8.85 64.71±9.34 
Fat Mass (kg) 11.16±4.88 11.46±6.25 11.48±6.77 12.7±8.23 7.97±4.12 8.33±3.93 
 
 
Figure 1. Graphical representation of body fat percentage at pre-test and post-test (mean ± 
SD). 
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Figure 2. Graphical representation of lean body mass at pre-test and post-test (mean ± SD). 
 
 
Body water analysis.  
Interactions for total body water or intra-cellular water demonstrated no significant effect 
(F[2, 16] = 0.400, p = 0.677, ηp2 = 0.048) and (F[2, 16] = 0.361, p = 0.703, ηp2 = 0.043) for total 
body water and intracellular water, respectively. A significant interaction in group and time for 
extra-cellular water (F[2, 16] = 4.395, p = 0.03, ηp2 = 0.35) was observed and data is displayed in 
Figure 3. The extra-cellular water in the placebo group increased from 16.8 ± 3.92 to 17.63 ± 
3.31 L and decreased from 17.27 ± 2.23 to 16.7 ± 2.75 L in the creatine-electrolyte group (t(5) = 
-2.515, p = 0.053 and t(5) = 1.19, p = 0.287, respectively). Extra-cellular water remained 
relatively stable from pre-testing to post-testing in the creatine monohydrate group. Body water 
analysis data is displayed in Table 4. Graphical display of these water variables are displayed in 
Figures 4 through 6. 
50.0
55.0
60.0
65.0
70.0
75.0
80.0
Pre Post
L
ea
n
 B
o
d
y
 M
as
s 
(k
g
)
Placebo
Creatine Monohydrate
Creatine-electrolyte
54 
 
 
Table 4. Total Body Water, Intra-Cellular Water, and Extra-Cellular Water (mean ± SD) 
  Placebo Creatine Monohydrate Creatine-electrolyte 
  Pre-Test Post-Test Pre-Test Post-Test Pre-Test Post-Test 
Total Body Water (L) 42.26±7.73 40.51±8.49 36.01±6.20 36.57±5.91 40.5±6.44 40.05±6.20 
Intra-Cellular Water (L) 24±4.76 22.88±5.50 19.91±4.84 20.1±4.36 23.25±4.32 23.33±3.44 
Extra-Cellular Water (L) 16.8±3.92 17.63±3.31 16.07±1.75 16.46±1.94 17.27±2.23 16.7±2.75 
 
 
Figure 3. Interaction effect of group and time on extra-cellular body water 
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Figure 4. Graphical representation of total body water at pre-test and post-test (mean ± 
SD) 
 
Figure 5. Graphical representation of intra-cellular water at pre-test and post-test (mean ± 
SD) 
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Figure 6. Graphical representation of extra-cellular water at pre-test and post-test for all 
three groups (mean ± SD)  
Peak torques. Results for normalized peak isometric torque indicated no significant interaction 
between time and group (F[2, 20] = 1.042, p = 0.371, ηp2  = .091). There were no significant 
main effects for the CE (F[1,20] = 0.390, p = 0.539, ηp2 = 0.019), CM (F[1, 20] = 0.142, p = 
0.710, ηp2 = 0.007), and placebo (F[1, 20] = 2.770, p = 0.112, ηp2 = 0.122). There were no 
significant main effects for normalized peak isokinetic torque at 60 deg/sec for the CE (F[1, 20] 
= 3.021, p = 0.098, ηp2 = 0.131), CM (F[1, 20] = 2.220, p = 0.152, ηp2 = 0.100) and placebo (F[1, 
20] = 0.199, p = 0.660, ηp2 = 0.010). Normalized peak isokinetic torque at 60 deg/sec also 
demonstrated no significant interaction between time and group (F[2, 20] = 2.704, p = 0.91 ηp2 = 
0.213). Although normalized peak isokinetic torque at 180 deg/sec approached significance 
between subjects (F[2, 20] = 1.662, p = 0.075, ηp2=0.150), the results were not statistically 
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significantly different. However, main effects demonstrated statistical significance for CE for 
normalized isokinetic torque at 180 deg/sec (F[1, 20] = 4.890, p = 0.039, ηp2=0.196). No 
significant main effects were observed for CM (F[1, 20] = 0.080, p = 0.781, ηp2 0.004) or the 
placebo (F[1, 20] = 1.550, p = 0.228, ηp2 = 0.072). Descriptive data are presented in Table 5 and 
data are displayed in Figures 7 through 9.  
Table 5. Isometric and isokinetic peak torques (mean ± SD) * p<0.05  
  Placebo Creatine Monohydrate Creatine-electrolyte 
  Pre-Test Post-Test Pre-Test Post-Test Pre-Test Post-Test 
Isometric torque 307.48±43.54 331.19±48.87 331.97±78.67 326.61±81.95 313.12±85.31 322.63±76.82 
Isokinetic torque (60º/s)    278.15±31.28 271.63±47.76 281.05±94.40 259.29±78.45 252.98±67.60 280.12±51.63 
Isokinetic torque (180º/s)   164.65±45.52 181.85±40.13 172.58±69.25 168.68±54.58 164.04±37.62 196.69±39.52* 
   A significant (p<0.05) difference in the amount of torque produced in the CE group from pre-
supplementation testing.                 
 
Figure 7. Graphical representation of peak isometric torque at pre-test and post-test (mean 
± SD) 
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Figure 8. Graphical representation of peak isokinetic torque 60 °/sec at pre-test and post-
test (mean ± SD) 
 
Figure 9. Graphical representation of peak isokinetic torque 180 °/sec at pre-test and post-
test (mean ± SD); *p <0.05, time effect 
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Fatigue, power, and work for repeated sets at maximal effort. Results for the fatigue index 
during two sets consisting of 30 maximal isokinetic knee extensions at 180 deg/sec, with two 
minute rests between sets, demonstrated no significant group or time interaction in set one 
(F[2,20) = 1.847, p = 0.184, ηp2 = 0.156) or set two (F[2,20] = 0.925, p = 0.413, ηp2 = 0.085). 
The data demonstrated no significant main effects for the CE (F[1, 20] = 2.202, p = 0.153, ηp2 = 
0.099), CM (F[1, 20) = 0.558, p = 0.464, ηp2 = 0.027), and placebo (F[1, 20] = 2.795, p = 0.110, 
ηp2 = 0.123) in the first set, nor were there any significant main effects in the second set for the 
CE (F[1, 20] = 0.287, p = 0.598, ηp2 = 0.014), CM (F[1, 20] = 3.276, p = 0.085, ηp2 = 0.141) or 
placebo (F[1, 20] = 0.008, p = 0.931, ηp2 = 0.001).  
No significant group and time interactions for total work were demonstrated in set one 
(F[2, 20] = 0.398, p = 0.677, ηp2 = 0.038) nor in set two (F[2, 20] = 0.187, p = 0.831, ηp2 = 
0.018). There was a significant main effect for total work for CE observed in set one (F[1, 20] = 
6.516, p = 0.019, ηp2 = 0.246) and for placebo (F[1, 20] = 5.580, p = 0.028, ηp2 = 0.218). No 
significant main effects were observed for total work for CM in the first set (F[1, 20] = 2.171, p 
= 0.156, ηp2 = 0.098). No significant main effects in total work performed in set two were 
observed for CE (F[1, 20] = 0.667, p = 0.424, ηp2 = 0.032), CM (F[1, 20] = 0.394, p = 0.537, ηp2 
= 0.019), and placebo (F[1, 20] = 2.165, p = 0.157, ηp2 = 0.098).  
There was also no significant group and time interactions for mean power in set one (F[2, 
20] = 0.398, p = 0.677, ηp2 = 0.038) nor in set two (F[2, 20] = 0.736, p = 0.492, ηp2 = 0.069). In 
set 1 during the post-test, there was statistically significant time effect for work (F[1, 20] = 
13.712, p = 0.001 ηp2= 0.407) for CE. There was also a significant time effect for mean power in 
set 1 during the post-test (F[1, 20] = 11.790, p = 0.003, ηp2= 0.371) for CE.  
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There was no significant time effect for total work or mean power in set two following 
the six-week supplementation period (F[1, 20] = 2.810, p = 0.109, ηp2 = 0.123) and (F[1, 20] = 
1.554, p = 0.227, ηp2 = 0.072), respectively. Data demonstrated significant main effects for mean 
power in set one for CE (F[1, 20] = 6.317, p = 0.021, ηp2 = 0.240). No significant main effects 
for mean power in set one were observed for the CM (F[1, 20] = 1.908, p = 0.182, ηp2 = 0.087) 
or placebo (F[1, 20] = 4.076, p = 0.057, ηp2 = 0.169). No significant main effects were observed 
for mean power during the second set in CE (F[1, 20] = 2.739, p = 0.114, ηp2 = 0.120), CM (F[1, 
20] = 0.086, p = 0.772, ηp2 = 0.004, and placebo (F[1, 20] = 0.021, p = 0.885, ηp2 = 0.001). 
Descriptive data in Table 6 demonstrates the creatine-electrolyte group had significant increases 
in power and work. Table 7 lists the descriptive data for the second set of 30 maximal knee 
extensions. Graphical representations for work ratios, total work, and average power for each set 
during the pre-test and post-test are displayed in Figures 10 through 15. 
Table 6. Normalized power, work, and fatigue index during 30 maximal knee extensions in 
set 1 (mean ± SD). 
Set 1 Placebo Creatine Monohydrate Creatine-electrolyte 
  Pre-Test Post-Test Pre-Test Post-Test Pre-Test Post-Test 
Power (W) 144.3±68.9 164.4±70.3 146.1±53.7 160.6±56.3 157.9±39.7 186±66.7* 
Work (J) 1721.5±619.9 1987.5±617.7 1812.6±612.3 1978.6±723.2 2178.3±488.1 2485±677.6* 
Fatigue Index  1.5±0.6 1.7±0.5 1.8±0.2 1.7±0.3 1.7±0.0 1.9±0.4 
 (p<0.05); CE vs. CM, placebo  
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Table 7. Normalized power, work, and fatigue index during 30 maximal knee extensions in 
set 2 (mean ± SD). 
Set 2 
Placebo Creatine Monohydrate Creatine-electrolyte  
  Pre-Test Post-Test Pre-Test Post-Test Pre-Test Post-Test 
Power (W) 132.7±61.7  134±54.5 121.4±35.2 123.9±27.8 130.9±35.5 145.7±49.4  
Work (J) 1494.4±501.8 1652.2±589.3  1466.1 ±401.2 1533.5±388.6  1702.5 ±363.4  1796.2±450.5 
Fatigue Index 1.9 ±0.5 1.9 ±0.3 2.3 ±0.4 2.0±0.6 2.2 ±0.4 2.1 ±0.2  
 
 
 
Figure 10. Graphical representation of fatigue index for set 1 of 30 maximal knee 
extensions during pre-test and post-test (mean ± SD) 
0
0.5
1
1.5
2
2.5
Pre-Test  Post-Test
F
at
ig
u
e 
In
d
ex
 S
et
 1
Placebo
Creatine Monohydrate
Creatine-electrolyte
62 
 
 
Figure 11. Graphical representation of fatigue index for set 2 of 30 maximal knee 
extensions during pre-test and post-test (mean ± SD) 
 
 
Figure 12. Graphical representation of total work for set 1 of 30 maximal knee extensions 
during pre-test and post-test (mean ± SD) *p <0.05  
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Figure 13. Graphical representation of total work for set 2 of 30 maximal knee extensions 
at pre-test and post-test (mean ± SD) 
  
 
Figure 14. Graphical representation of average power for set 1 of 30 maximal knee 
extensions at pre-test and post-test (mean ± SD); *p<0.05 
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Figure 15. Graphical representation of average power for set 2 of 30 maximal knee 
extensions at pre-test and post-test (mean ± SD) 
Discussion 
 The purpose of this study was to examine if a six-week CE supplementation protocol 
would increase peak isometric power, peak isokinetic power, and improve the fatigue index after 
performing two sets of 30 maximal knee extensions compared to CM and a placebo. The results 
demonstrating a significant time effect for work and mean power did not support the null 
hypothesis that there would be no significant changes in muscle functions following six-weeks of 
supplementation between three different supplement groups. Pairwise comparisons also 
demonstrated a significant difference between the CE group and CM group for normalized peak 
isokinetic torque at 180 deg/sec. Both the placebo and CE group demonstrated increases in peak 
isokinetic torque from pre-testing to post-testing, with the CM group demonstrating a decrease in 
torque from pre-testing to post-testing. A medium to large effect was observed based on partial 
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ηp2 data. The results for the remaining variables examined in the study supported the null 
hypothesis. Based on the results, the CE supplement was useful in promoting greater torque-
generating capabilities for knee extensions at 180 deg/sec. The CE supplement was also 
beneficial for increasing the total amount of work along with increasing the average power 
during the first set of 30 maximal knee extensions at 180 deg/sec. A significant interaction for 
time and group was also observed with extra-cellular water content. Possibly due to the small 
sample sizes in each group, simple effects statistical analysis tests were unable to reveal where 
the interactions took place.  
 Although there was a significant time effect for both total work and mean power in the 
first set of 30 maximal knee extensions, there was no significance for time effect of these 
variables in the second set nor was there any significant interaction for time and group during 
either set of knee extensions in the attenuation of fatigue. The absence of any attenuation of 
fatigue in the current study differed from the observations by Greenhaff et al. (1993) who 
observed the decrement in fatigue following a creatine supplementation protocol that consisted 
of 20 g/day for five days. Compared to the placebo group, the reduction in fatigue from pre-to 
post testing in the CM group was greater than that in the placebo group across all five sets of 30 
maximal knee extensions at 180 deg/sec with one minute of recovery between sets. In the current 
study, the maximum amount of creatine supplementation consumed in one day was 4 g/day. The 
results observed by Greenhaff et al. (1993) may have been in part be due to the greater increase 
in total muscle creatine storage that followed the much larger consumption of creatine on a daily 
basis. The subjects were also described as physically active but not highly trained. Some of the 
subjects in the current study were highly resistance trained which may have had an influence on 
the results. Current training status may elicit different effects on the performance outcome 
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following creatine supplementation. However, Gilliam et al. (2000), utilizing an identical 
supplementation and exercise testing protocol as Greenhaff et al. (1993), observed no significant 
effects from pre to post-testing in the attenuation of fatigue in either the creatine or placebo 
group. Without performing muscle biopsies to determine the effectiveness of creatine uptake of 
the muscle following supplementation, it cannot be assured if creatine loading is taking place and 
thus affecting the results.  
 The absence of any significant gains in 1-RM torque at 60 deg/sec and 180 deg/sec in the 
CM group in the current study is similar to those observed by Zuniga et al. (2012). There was no 
effect on either 1-RM leg extension strength or bench press strength following the seven-day 20 
g/day supplementation protocol (Zuniga et al., 2012). Both study by Zuniga et al. (2012) and the 
current study included a two-minute rest period between each 1-RM set; however, the leg 
extensions were performed on a plate-loaded leg extension resistance-training machine which is 
different from the isokinetic dynamometer that was used in the current study. Zuniga et al. 
(2012) observed a 5.4% increase in mean power but no differences in peak power during two 30-
second Wingate tests separated by seven minutes in the CM group from pre-post testing. It could 
be concluded from Zuniga et al. (2012) and the current study that CM may not always beneficial 
for increasing peak power or 1-RM strength.  
 The use of creatine supplementation by athletes helps to increase the amount of creatine 
and phosphocreatine (PCr) found inside the muscles. The elevated muscular creatine is used 
during quick bouts of anaerobic activity (Allen, 2012; Greenhaff et al., 1994). Phosphocreatine 
stores along with re-synthesis of creatine are elevated during creatine supplementation 
(Greenhaff et al., 1994). The increase athletic performance in the CE group during post-testing 
for the first set of 30 maximal repetitions concurs with previous research (Burke et al., 2003; 
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Izquierdo, Ibañez, González-Badillo, & Gorostiaga, 2002). Contrary to previous research, the 
CM group did not experience any increase in athletic performance. 
 Although all humans share similar anatomical and physiological characteristics, there can 
be biological variability in the initial levels of cellular creatine and phosphorylated creatine 
(Syrotuik & Bell, 2004). Greenhaff et al. (1994) observed the greatest muscle uptake of creatine 
in recreationally active male subjects who had muscle creatine concentrations of less than 120 
mmol/ kg dry matter prior to consuming creatine monohydrate. It was also demonstrated that 
greatest increases in total creatine concentration in the muscle following five days of consuming 
20 g/day creatine monohydrate supplementation occurred in individuals who had lower pre-
feeding levels of creatine concentration. With the combination of pre-feeding levels of creatine 
and supplementation, total creatine concentration did not exceed 155 mmol/ dry matter in any of 
the eight male subjects with supplementation (Greenhaff et al., 1994). Variations in total resting 
muscle creatine monohydrate and phosphorylated creatine were observed after a five-day 
supplementation of 0.3 g/kg a day in 11 recreationally resistance-trained men (Syrotuik & Bell, 
2004). 
 Measurements of resting muscle creatine were obtained from muscle biopsies of the right 
vastus lateralis (Syrotuik & Bell, 2004). To distinguish responders from non-responders 
following the supplementation period, the following amounts of resting muscle phosphorylated 
creatine plus creatine-monohydrate were used to categorize each subject: ≥ 20 mmol/kg dry 
weight (dw), 10-20 mmol/kg dw, < 10 mmol/kg dw for responders, quasi responders, and non-
responders, respectively. Of the eleven subjects, three were considered responders, five were 
quasi responders, and three were non-responders. The average increase in total resting muscle 
creatine and phosphorylated creatine was 29.5, 14.9, and 5.1 mmol/kg dw for the responders, 
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quasi responders, and non-responders, respectively. The large increases in total resting muscle 
creatine after supplementation in responders was suggested to be influenced by the lower levels 
of total creatine content at baseline compared to the baseline mean concentrations of total resting 
muscle creatine for all subjects. Observations from the investigation suggested that individuals 
with lower levels of total resting muscle creatine content prior to supplementation would benefit 
more than individuals with higher levels of total resting creatine content (Syrotuik & Bell, 2004). 
It cannot be inferred as to who were and were not responders in the current study due to not 
performing any muscle biopsies on any of the subjects. Muscle biopsies could potentially be an 
avenue for future research to determine if responsiveness to creatine supplementation can have 
an effect on physical performance outcome measures.  
Another physiological factor potentially affecting an individual’s response to creatine 
supplementation is muscle fiber type (Casey, Constantin-Teodosiu, Howell, Hultman, & 
Greenhaff, 1996; Syrotuik & Bell, 2004). A positive correlation between the changes in 
phosphorylated creatine in type II muscle fibers and the decline in muscle phosphorylated 
creatine during exercise, along with greater increase in total work production, following 
supplementation was observed in subjects who trained in various activities five to six days a 
week (Casey et al., 1996). Previous authors have observed that resting phosphorylated creatine 
concentration in type II muscle fibers is around 12% greater than in type I muscle fibers 
(Greenhaff et al., 1994; Söderlund, Greenhaff, & Hultman, 1992). The decline in phosphorylated 
creatine during 30 seconds exercise at maximal intensity was 10-25% greater in type II muscle 
fibers (Greenhaff et al., 1994.)  
Casey et al. (1996) observed that baseline levels of phosphorylated creatine concentration 
in the nine male subjects were 66.6 ± 4.2 mmol/kg dry matter in type I muscle fibers and 79.3 ± 
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1.5 mmol/kg dry matter in type II muscle fibers. After five days of creatine supplementation of 
20 g/day, phosphorylated creatine concentration was 77.6 ± 3.2 mmol/kg dry matter in type I 
muscle fibers and 91.0 ± 5.8 mmol/kg dry matter in type II muscle fibers. After 30 seconds of 
maximal isokinetic cycling at 80 revolutions per minute (rpm), phosphorylated creatine 
concentrations were 29.9 ± 6.0 mmol/kg dry matter in type I fibers and 17.9 ± 9.8 mmol/kg dry 
matter in type II fibers. Following four minutes of recovery, concentrations were 69.6 ± 3.9 
mmol/kg dry matter in type I fibers and 67.2 ± 4.1 mmol/kg dry matter in type II fibers. After 
another 30-second bout of maximal intensity isokinetic cycling at 80 rpm, phosphorylated 
creatine concentrations were 12.8 ± 3.7 mmol/kg dry matter in type I fibers and 7.4 ± 2.8 
mmol/kg dry matter in type II fibers (Casey et al., 1996). Degradation of phosphorylated creatine 
after maximal intensity exercise was observed to be greater in type II muscle fibers versus type I 
muscle fibers (Casey et al., 1994; Greenhaff et., 1994). Despite the greater decreases in 
phosphorylated creatine concentration seen in type II muscle fibers, supplementation was 
suggested to induce an ergogenic effect by being able to resynthesize ATP due to an increased 
phosphorylated creatine pool in type II muscle fibers (Casey et al., 1996).  
 The potential variables consisting of baseline total muscle creatine levels and muscle 
fiber type composition cannot be dismissed as potential reasons why no significant effects were 
observed between the CM group and placebo groups from pre-testing to post-testing in the 
current study. Since no muscle biopsies were taken from the subjects during the study, attributing 
the absence of any significant effects in peak isokinetic torque, isometric torque, peak power, 
workload, and fatigue index between the CM and placebo groups due to the subjects’ total 
resting creatine concentration and muscle fiber type cannot be confirmed 
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   It has been suggested that creatine alone has limited potential in maximizing the 
activation of the creatine transporter (Spillane et al., 2009). The significant increase seen in both 
the amount of work performed and average power in during the first set of 30 maximal knee 
extension in the CE but not in the CM group in comparison to the placebo group may be related 
to the improved activation of the creatine transporter along with the increased cellular absorption 
of using a creatine and electrolyte combination formula. Attempts at improving cellular 
absorption and transport of creatine to maximize total intramuscular creatine concentration have 
been made by developing various creatine formulas consisting of carbohydrates, electrolytes, and 
esterified alcohol (Spillane et at., 2009). The CE formula used in the current study consisted of 
magnesium chloride, potassium chloride, calcium chloride, sodium chloride. Some of these 
different creatine formulations were suggested to help increase creatine-reuptake by increased 
up-regulation or bypassing the creatine transporter (Spillane et al., 2009). It has also been 
suggested that by combining a cation to creatine, this may enable the molecule to enter through a 
second pathway via the ligand-gated cation channel that is located on the sarcolemma under the 
innervating motor neuron (Selsby, DiSilvestro, & Devor, 2004).  
 However, not all creatine formulas have demonstrated beneficial effects. Spillane et al. 
(2009) observed no significant increases in anaerobic or strength gains in supplementing with 
creatine ethyl ester (CEE) compared to CM or a placebo. The increases in both peak and mean 
anaerobic power observed during a Wingate tests and 1-RM leg press and bench press strength 
were suggested to be due to the four-day per week training protocol for the duration of the study 
since the CEE, CM and placebo group had demonstrated roughly the same increases in 
performance measures. The training protocol involved training both upper and lower extremities. 
This is different from the protocol used in the current study in that the subjects were asked to 
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maintain their current resistance training regimens. In both the current study and the study done 
by Spillane et al. (2009), there is the possibility that the subject’s training regimen may have had 
a bigger impact than the supplementation itself. The daily maintenance dosage was also slightly 
different with 4 g/day in the current study compared to Spillane et al. (2009) having subjects 
consume 5 g/day.  
It could also be speculated that the significantly greater calorie expenditure in the placebo 
group during both pre-testing and post-testing compared to that of the CM and CE groups may 
have affected the results. The placebo group consumed a larger amount of protein compared to 
the supplementation groups. It could be suggested that the placebo group may have consumed 
protein rich foods such as red meat and fish which contain dietary creatine. It cannot be assumed 
that a diet rich in protein resulted from eating meats and fish. Consumption of such foods 
provides about half of the body’s daily need of creatine (Syrotuik & Bell, 2004). When 
comparing non-responders to responders using creatine supplementation, Syrotuik and Bell 
(2004) did not observe any effects relating to protein consumption since both groups had 
consumed high amounts of protein prior to supplementation. It may be important to consider the 
sources of protein, plant versus meat, instead of total protein consumption in future analysis 
comparing different formulations of creatine supplementation. A protein diet primarily from 
foods rich in creatine could potentially blunt the effects of creatine-supplementation.  
 A study investigating the effects of creatine supplementation on total amount of work 
performed during pre-test and post-test conditions was with vegans versus non-vegan subjects 
(Burke et al., 2003). Like the current study, Burke et al. (2003) utilized a protocol involving knee 
extensions on an isokinetic dynamometer at 180 deg/sec. However, the total number of 
repetitions performed was 50. Subjects for the study were recreationally active individuals with 
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at least one year of resistance training but less than 5 years. The loading phase consisted of 
ingesting 0.0625 g/kg per kilogram of lean body tissue mass (LTM) four times daily for one 
week. The dosage was reduced to 0.0625 g/kg per LTM once daily for 49 more days. All 
subjects performed the same high volume eight-week upper and lower body training program 
utilizing a resistance of greater than 70% of 1-RM. Results demonstrated a significant increase (p 
< 0.05) in total work performed in both the non-vegans and vegans consuming creatine 
supplementation compared to the non-vegan and vegan placebo groups. The results are 
congruent to the findings observed with the creatine-electrolyte group in the current study which 
demonstrated a greater amount of total work performed in set 1 compared to the creatine 
monohydrate and placebo groups with a large effect size (ηp2= 0.407). The average total work 
done by the vegans who supplemented with creatine went from approximately 5200 J to 
approximately 6500 J at post-testing. Non-vegans who supplemented with creatine demonstrated 
an increase from approximately 5300 J to approximately 5900 J at post-testing. The larger 
workloads observed by Burke et al. (2003) were most likely due to the greater number of 
repetitions performed, 50 repetitions, versus 30 repetitions in the current study. The fact that 
subjects had only performed three 1-RM leg press and bench press exercises each along with 
having 10 minutes of rest prior to conducing the 50 knee extensions may also have potentially 
contributed to the results observed by Burke et al. (2003). In the current study, a shorter rest 
period coupled with having performed squat and bench press cluster sets along with having 
performed 1-RM isokinetic knee extensions may have affected the results in the current study. 
 An increase in power during 10 repetitions of half-squats followed by a set of completing 
set of half-squats to exhaustion was observed in male handball players following a five-day 
creatine supplementation period (Izquierdo et al., 2002). Similar to the current study, participants 
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were resistance trained. Supplementation involved consuming five grams of creatine 
monohydrate or a maltodextrin placebo four times daily, which was different from the 
supplementation protocol of four grams per day in the current study. A significant increase (p < 
0.01) in the average power during 10 repetitions was demonstrated with 557 ± 107 W and 605 ± 
123 W during pre-testing and post-testing, respectively, in the CM group. This increase in mean 
power was congruent with the increase in mean power in the CE group during 30 repetitions in 
the current study (157 ± 87 W and 186 ± 66.71 W from pre-testing to post-testing, respectively). 
No significant differences in power output were observed in the placebo between pre-testing and 
post-testing (Izquierdo et al., 2002).  
 Congruent to the current study where there were no significant differences in peak 
isokinetic torque at 60 deg/sec, no significant differences were observed in knee extension torque 
in 24 resistance-trained males following six weeks of supplementation with a multi-ingredient 
performance supplement (MIPS) (Ormsbee et al., 2012). Subjects in the MIPS group consumed 
supplementation consisting of whey protein, casein protein, branched-chain amino acids, beta 
alanine, caffeine, and creatine before and after workouts, and once daily on non-training days. 
However, subjects were required to adhere to a progressive resistance-training program utilizing 
1-RM rep ranges from 70-90%. Subjects in the current study were asked to maintain their current 
resistance training habits.  
 There are limitations to the current study which could have affected the results and 
implications for the use of a creatine-electrolyte supplement. Although subjects were asked to 
continue with their resistance-training program, it is possible that some subjects may not have 
adhered to their resistance-training program due to outside circumstances. There is the possibility 
that some subjects may have detrained during the six-week study. It should also be noted that all 
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subjects in the current study had participated in doing bench press and barbell squat cluster-sets 
as part of the study protocol prior to performing the peak isometric torque, peak isokinetic 
torque, and a fatigue protocol test during both pre-testing and post-testing conditions. Due to the 
time frame of the testing protocols, there may not have been enough time for the subject to fully 
recover following the performance of cluster-sets involving squats. A third limitation is that there 
were a small number of subjects in each of the groups. Having a small number of subjects can 
reduce the statistical power of results that are obtained.  This is especially relevant where the 
effect size was large but the p-value did not reach significance, as for the Fatigue Index in set 
one. 
Summary 
 Six weeks of supplementation involving the combination of a creatine formula with 
electrolytes may be beneficial for increasing some aspects of athletic performance. The creatine-
electrolyte group demonstrated an increase in peak isokinetic torque for knee extensions at 180 
deg/sec from pre-testing to post-testing (164.04 ± 37.6 W and 196.69 ± 39.5 W, respectively). 
Likewise, an increase in the amount of work during the first set of 30 maximal knee extensor 
exercises from pre-testing to post-testing (157.9 ± 39.7 W and 186.0 ± 66.7 W, respectively) was 
performed, along with a greater amount of mean power from pre-testing to post-testing (2178.3 ± 
488.1 W and 2485 ± 677.6 J) in the creatine-electrolyte group. The results from the current study 
are similar to some previous research that found similar results. The use of a creatine-electrolyte 
supplement may be beneficial for individuals who want to increase performance in activities 
involving short bouts of effort. 
 
75 
 
Chapter V 
Summary, Conclusions, and Recommendations 
Summary 
 This study investigated the effects of a creatine-electrolyte supplement on resistance 
training performance. The following dependent variables were examined: isometric knee 
extension and flexion torque, isokinetic knee extension torque at 60 deg/sec and 180 deg/sec, 
total work, mean power, and fatigue index. Subjects were randomly assigned to one of three 
groups: placebo, CM, or CE group. Subjects reported to the lab on two occasions for testing. 
Baseline measurements included the testing of body composition through skinfold 
measurements, body water analysis, diet analysis, isometric testing of both the knee flexors and 
extensors, isokinetic testing at 60 and 180 deg/sec for the knee extensors, and two sets of 30 
maximal knee extensors separated with two minutes of recovery. There was a significant 
difference between the creatine monohydrate group and the creatine-electrolyte group for 
isokinetic torque of the knee extensors at 180 deg/sec during post-testing. There was a relatively 
larger increase for torque in the creatine-electrolyte group over the placebo group, with a slight 
decline in torque seen in the creatine monohydrate group. There was also a significant time effect 
for work and mean power for the creatine-electrolyte group during the first set of 30 maximal 
knee extension exercises. Another significant difference observed was the number of kilocalories 
expended for the placebo group compared to both the creatine monohydrate and creatine-
electrolyte groups during both the pre-testing and post-testing. There was also a significant 
interaction with an increase in the amount of extra-cellular water in both the placebo group and 
creatine monohydrate group with a decrement in extra-cellular water in the creatine-electrolyte 
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group. No significant differences or interactions were observed in body composition, total body 
water, intra-cellular water, peak isometric knee extensor/flexor torque, peak knee extensor 
isokinetic torque at 60 deg/sec, fatigue index for both sets of 30 maximal knee extension along 
with total work done and power in the second set of maximal knee extensions.  
Conclusions 
   Supplementation with a creatine-electrolyte substance may be beneficial for increasing 
performance in short duration activities lasting 10 seconds or less in resistance-trained 
individuals. Resistance-trained male and female athletes can use a creatine-electrolyte 
supplement to increase the amount of work along with increasing power for lower body exercises 
such as knee extensions. Since only leg extensions were examined in the current study, the 
results may not universally pertain to all lower body exercises. The fact that there were no 
significant improvements in total work done, mean power, and fatigue index during the second 
set of 30 maximal repetitions is indicative that future research should reexamine the effects of a 
creatine-electrolyte supplement on muscle fatigue along with other attributes of athletic 
performance.  
Recommendations  
 Future research. The results from the current study suggests that a creatine-electrolyte 
supplement may be beneficial for certain aspects of athletic performance. Due to the limitations 
encountered in the current study along with no significant findings in many of the isometric and 
peak isokinetic torque variables, future research should consider re-examining the effects of a 
creatine-electrolyte supplement in a much larger sample. Future research could also focus on the 
effects of a creatine-electrolyte supplement in more diverse samples such as untrained 
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individuals, elderly, and individuals with certain pathologies to examine the potential benefits. 
With a larger sample group, along with controlling for the type of training subjects do during a 
supplementation period, the effects of creatine with an electrolyte component on strength, power, 
and fatigue index can be reexamined on both upper and lower body exercises across multiple 
sets. 
 Practical applications. Results from the current study suggested that a creatine 
supplement formulated with electrolytes may improve sports performance activities of durations 
of less than 10 seconds, particularly for the quadriceps muscle group, for resistance-trained 
individuals. Individuals, particularly those who are doing high volume sets of knee extensor 
exercise could take the supplement on a daily basis over a six-week period and monitor their 
results. 
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Western Washington University 
Health and Human Development Department 
 
Consent to Take Part in a Research Study 
 
Project: Effect of a Multi-ingredient Performance Supplement (MIPS) and Simple 
Creatine on Fatigue and Cluster-Set Velocity in Resistance-Trained Subjects 
 
You are invited to participate in a study investigating the effects of a multi-ingredient 
performance supplement (MIPS), containing creatine and electrolytes (like those in a sports 
drink), standard creatine monohydrate (most common creatine form used) and placebo on fatigue 
and lift velocity in weight-trained subjects. To improve upon past studies, this analysis aims to 
objectively evaluate a soluble creatine supplement versus creatine or placebo on fatigue and lift 
velocity in an athletic population. The results of this study will enhance our understanding of this 
supplement and how it may affect physical performance.   
 
I UNDERSTAND THAT: 
 
1. This experiment will begin with measurement of height, weight, body fat by skinfold 
assessment, and body water determination using a bio-impedance unit. Height will be 
measured with a stadiometer and weight with a standard physician’s balance beam scale. 
Body composition assessment will be completed using skinfold measurements taken at 
three anatomical locations. The three sites used for male subjects will be on the chest, 
back of the arm, and upper back. Female subjects will have skinfold measurements taken 
on the back of the arm, over the hip, and abdomen. For determining total body water, an 
impedance device is used. For this test, you will lie on a table and have electrodes 
attached to your wrists and ankles. It takes less than a minute, and then the electrodes are 
removed. My participation for these tests will be approximately 30 minutes. Height, 
weight, total body water, and body composition will be determined during pre- and post-
testing. 
 
2. Supplementation will be either treatments (creatine and electrolytes, like those in a sports 
drink or creatine monohydrate, the standard creatine used by consumers) or placebo 
(sugar, specifically maltodextran) for 6 weeks in a blinded fashion. Blinded is that neither 
the subject nor the researcher providing the numbered supplement will know whether the 
supplement is the treatment or placebo until the end of the 6-week period. Each week, the 
packet for that week will be picked up at the lab. For this study, consistent dietary and 
exercise programs should be maintained. During the first and sixth week of 
supplementation, I will keep a 3-day diet record and 3-day physical activity record that 
will be submitted for analysis. 
 
3. All subjects will undergo pre- and post-supplementation testing sessions to assess muscle 
fatigue and lift velocity during a cluster set protocol, which allows determined rest 
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intervals within the set of repetitions.  Maximum torque and a fatigue protocol results 
will be determined using a Biodex System 4 (Biodex Medical Systems Inc., Shirley, NY) 
isokinetic dynamometer. A general warm-up will be performed for 5 minutes using a 
cycle ergometer with no resistance added. All tests on the Biodex will be performed with 
the dominant leg. You will sit on the dynamometer’s chair as proper adjustments are 
made, the back of the seat will be adjusted and the length of the dynamometer’s arm will 
be properly fitted to the length of the shank (area between knee and ankle).  
  Your body will be stabilized with two shoulder straps, a waist strap, and a thigh strap, to 
reduce extraneous movements. Once in proper position, you will be instructed to perform 
a task-specific warm-up, consisting of a concentric/concentric knee extension/flexion, 
followed by a 30 second rest at the original starting position.  
  Maximal knee extension isokinetic torque measurement will determined.  Isometric 
maximal voluntary contraction torque for both knee extension and flexion will be 
collected. Three trials for a given condition will be performed. A two minute resting 
period will be allowed between trials. Peak torques will be determined during this test 
and during a subsequent test of maximal isometric muscle action. Rest intervals will be 
allowed until you indicate that you are fully recovered. After the completion of three 
attempts for each of the conditions, you will perform a cool down for 5 minutes on cycle 
ergometer, at an easy pace, with no resistance added. 
  The fatigue test will require you to perform 30 maximal isokinetic knee extension 
repetitions. The absolute torque reduction through the trial, from peak maximal torque to 
subsequent minimum peak torque.  The total work done during fatigue trial will be 
determined. There will be 2 minutes of rest before performing a second set of 30 
repetitions. You will then perform a cool down for 5 minutes on cycle ergometer, at an 
easy pace, with no resistance added. 
 
  On a separate day, estimated one repetition maximums (1RM) for the squat and bench 
press will be determined according to the National Strength and Conditioning 
Association (NSCA) testing procedures. A three repetition maximum will be determined, 
than the O’Conner formula used to estimate the 1RM. You will perform a pre and post 
cluster set test for both the parallel back squat and bench press exercises. The load for 
each exercise will be 80% of the 1RM. The test includes four total clusters, with each 
cluster being comprised of two sets of five repetitions. Rest provided will be 1.5 minutes 
between clusters and 30 seconds between each sub-set. Average velocity for each 
repetition will be measured using an arm band accelerometer (PUSH, Toronto, Canada) 
placed on the right forearm. Data is transmitted and collected with the PUSH Assist 
application (PUSH, Toronto, Canada). The outcome measure will be the change in 
average mean velocities (m/s).  
 
4. There may be risks during the fatigue and velocity tests but this will be minimized with a 
spotter. I understand that exercise can lead to muscular soreness, cramping, pain, and 
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fatigue. During testing, there is a risk of experiencing muscle soreness that should 
disappear after a period of rest. I understand that if exercise testing is painful, I can stop 
at any time. In addition, I am aware that I could experience delayed onset muscle 
soreness (DOMS) after the session that could last for 24-72 hours. The safeguards that 
will be used minimize potential muscle soreness include a warm-up, acclimation, and 
cool down period. If I feel like I cannot or should not perform any of these tasks, I could 
opt out from the participation in this study. 
 
5. Possible benefits include that subjects may be have performance benefits associated with 
supplementation. The results of this study may aid in future research.  
 
6. There is twenty dollars ($20) compensation for my participation in the complete project: 
supplementation, pre- and post-testing. My participation is voluntary, I may choose to 
withdraw my consent and discontinue participation without penalty.  
 
7. All information collected is confidential. My signed consent form will be kept in a locked 
cabinet separate from the data collection forms for the project data. My name will not be 
associated with any of my data collected throughout the study. 
 
8. My signature on this form does not waive my legal rights of protection. 
 
9. Any questions you may have regarding the study procedures will be answered by the 
primary researchers (Dave Suprak, Lorrie Brilla,) who can be contacted at 
Dave.Suprak@wwu.edu (360-650-2586) or Lorrie.Brilla@wwu.edu  (360-650-3056).  
Any questions about your rights as a research subject should be directed to Janai Symons, 
the WWU Research Compliance Officer (RCO), 360-650-3082.  If any injury or adverse 
effect of this research is experienced you should contact Lorrie Brilla, Dave Suprak, or 
the RCO. 
 
 
 
 
 
I have read the above descriptions and agree to participate in this study. 
 
_______________________________________   _____________________ 
Participant’s Signature      Date 
 
_______________________________________ 
Participant’s PRINTED NAME 
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Human Subjects Activity Review 
1. What is your research question, or the specific hypothesis? 
 
  The hypothesis is that there will be a difference in fatigue, total work, and average velocity of 
movement in repeated bout activities between the multi-ingredient supplement (creatine and 
electrolytes), standard creatine monohydrate supplement (creatine monohydrate), and placebo 
(carbohydrate solution) condition. It is specifically hypothesized that the supplementation conditions 
will result in a greater difference in: 
 the rate of fatigue and total work on an isokinetic dynamometer for two sets of 30 repetitions 
with 2 minutes rest between sets; 
 for bench press and squat, and total work performed at 80% 1RM average velocity for each 
repetition when comparing four total clusters, with each cluster being comprised of two sets 
of five repetitions, and rest provided for 1.5 minutes between clusters and 30 seconds 
between each sub-set.  
 
2. What are the potential benefits of the proposed research to the field? 
 
  Fifty years ago, Gatorade, an original multi-ingredient performance supplement was developed, a 
combination of carbohydrate and electrolytes. The standard sports drinks contain 4–8% carbohydrate, 
10–30 mmol/L sodium, and 3–5 mmol/L potassium [1]. Other electrolytes or protein may also be 
included in sports drinks formulations. Sports drinks were the original prototype of multi-ingredient 
performance supplements (MIPS). Much recent research has been reported with various combinations 
of MIPS, complex mixes of nutrients with the common factor being creatine [2-8]. 
 
  One of the most popular and widely researched natural supplements is creatine, which has been 
extensively studied since the 1990’s for performance enhancement and has been quite well supported. 
Creatine has been assigned group A level of supporting evidence by the Australian Institute of Sport 
[1]. Many aspects of creatine supplementation have been reported [9-24]. Increases in body weight, 
both lean body mass [9- 13, 15, 17, 18] and body water [17, 21], are common findings. Training and 
supplementation elicits improvements in muscle strength [9, 11, 12, 14-17, 19, 23] and power [13-17, 
20]. When effect size was calculated in a meta-analysis on creatine supplementation, there were 
greater effects for upper body, repetitive-bout laboratory-based exercise tasks lasting < 30 seconds 
versus lower body, single-bout, field studies, or longer duration physical activity [10]. There were no 
effects between males and females nor training status.  
 
  The benefits of creatine supplementation are well documented, particularly during repeated bouts of 
high-intensity muscular activity. However, most research evaluating the effects of creatine involves 
use of Wingate testing for determining anaerobic peak and mean power plus rate of fatigue [25-33]. 
The Wingate test shows mixed results in response to short-term creatine supplementation, but is 
mostly positive, especially in rate of fatigue and repeated bouts. It has been suggested that the mixed 
results may be an artifact due to not accounting for flywheel inertia [28]. When corrected, non-
significant results became statistically significant. Some research has observed outcomes with graded 
exercise testing, including maximal oxygen consumption and anaerobic threshold [34-39]. The main 
outcomes were no changes in maximal oxygen consumption. However, creatine supplementation can 
alter the contributions of the different metabolic systems. Thus, the body is able to perform the sub-
maximal workloads at a lower oxygen cost with a concomitant reduction in the work performed by 
the cardiovascular system. Ventilatory anaerobic threshold does show improvement [35, 38, 39]. 
Newer technology may allow assessment of cycling propulsive power. Instrumented bicycle pedals 
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for dynamic measurement of propulsive cycling loads are available that may give the sensitivity 
necessary to determine changes in power [40-42]. 
 
  The mechanism best supporting creatine effects is the increased intramuscular creatine concentration 
and restoration. The ergogenic effect is related to an increase in temporal and spatial buffering of 
ATP and to increased muscle buffer capacity [24]. Different formulations of creatine supplementation 
have been studied, with no appreciable differences in outcomes [15-17]. Recently, formulations have 
been developed to improve aqueous solubility, gastrointestinal permeability, and ultimately the 
outcomes associated with creatine [43]. Permeability was improved across Caco-2 human epithelial 
cell monolayers. This type of formulation has potential for improved oral absorption of creatine, and 
may enhance bioavailability, and therefore performance outcomes. 
 
  The purpose of this project is to assess performance outcomes in response to six weeks of a multi-
ingredient performance supplement, which includes creatine and electrolytes. The project will 
determine effects in resistance trained subjects during typical weight training and power activities: 
weight lifting and countermovement vertical jump. Additionally, body composition and total body 
water will be appraised. 
 
 
3. What are the potential benefits, if any, of the proposed research to the subjects? 
 
  The benefit of this research is that subjects’ supplementation may positively impact physical 
performance. The results of this study may aid in directing future research.  
 
4. Answer a), then answer either b) or c) as appropriate. 
 
a. Describe how you will identify the subject population, and how you will contact key 
individuals who will allow you access to that subject population or database. 
  The sample will consist of men and women volunteers from Western Washington University, with 
no musculoskeletal impairment or injury, and who have been weight training regularly for the past six 
months. Flyers will be posted in Wade King Student Rec Center and in Ridgeway Lounge (current 
location of strength equipment for Athletics). We will obtain consent to post flyers. This method of 
recruitment has been used frequently in the past. 
b. Describe how you will recruit a sample from your subject population, including possible use 
of compensation, and the number of subjects to be recruited. 
 
  For this study, 54 women and men will be recruited to participate. The first 54 will be invited to 
participate, with the remainder on a waitlist, if needed. Inclusion for this study demands that subjects 
be free of any musculoskeletal impairment or injury, and who have been weight training regularly for 
the past six months. Participants in this study will be compensated twenty dollars for their full 
participation. 
 
OR 
 
c. Describe how you will access preexisting data about the subjects. 
N/A 
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5. Briefly describe the research methodology. Attach copies of all test 
instruments/questionnaires that will be used. 
 
Description of the Study Population 
  The study sample will consist of fifty-four apparently healthy, recreationally active participants for 
standard creatine supplementation (Cr), multi-ingredient performance supplementation (MIP) and 
placebo (P), a carbohydrate solution.  The multi-ingredient performance supplement contains creatine 
and electrolytes, sodium, potassium, calcium, and magnesium. Subjects will have weight training 
experience for the last 6 months. Subjects will be chosen randomly based on their volunteer responses 
to flyers posted around Western Washington University (WWU) campus. Subjects will be randomly 
assigned to three groups, placebo, Cr, and a multi-ingredient performance supplement, which includes 
creatine. Prerequisite to participation, each subject receives an informed consent form previously 
approved by the institution’s Human Subjects Committee. Subjects who had supplemented creatine in 
their habitual diet within the 60 days prior to orientation or any who were suffering from any kidney, 
liver, or endocrine disease or any disorder that might affect normal cellular levels of creatine or fluid 
balance (or both) will be excluded. The medical history questionnaire will filter any subjects taking 
any substance classified as a diuretic other than caffeine in their habitual diet. Subjects will be 
instructed to keep exercise regimens consistent throughout the study with continued participation in 
their weight training. Training logs will be maintained to confirm compliance. If a subject misses 
more than three supplement days, they will be dropped from the study.  
 
Procedures and Instrumentation 
  The baseline and posttest data included: height, measured by stadiometer, weight, using a balance 
beam scale, body water by bioelectrical impedance (BIA), body composition with air displacement 
plethysmography (ADP), physical activity profile, and specific tests described below. These measures 
will be repeated at the end of the study.  
Diet and Supplementation: The diet analysis aids in description of the study sample. Two separate 3-
day diet records will be kept by the subjects and the records will be analyzed using Nutritionist Pro 
software (Axxya Systems, Stafford, TX). From this data, nutrient and energy levels will be 
determined. Supplementation will be given orally and provided by the manufacturer, with placebo 
appearance identical.  Subjects will be randomly assigned to groups (treatment, hence supplemented 
[S] with creatine and electrolytes similar to a sports drink and placebo [P] which is a carbohydrate 
solution), and these will be administered in a double blind fashion.  The treatment period will be six 
weeks to allow for tissue saturation.  
Body Water:  Total body water (TBW) and both intracellular and extracellular fluid compartments 
(ICF and ECF) will be determined with an RJL Quantum X bioimpedance unit. Electrodes will be 
placed on the right upper and lower extremities, at approximately the wrist and the third metacarpal 
plus the ankle and third metatarsal, respectively. This tool has been used to assess TBW and volume 
of body water compartments, with good reliability and validity [44-46]. The subjects will refrain from 
exercise for at least 12 hours prior to testing. For a full twenty four hours before body water testing, 
subjects will maintain hydration. All tests will be completed at the same time of day for each subject.  
Body Composition:   Body composition (i.e. percent body fat, fat free mass, and fat mass) will be 
assessed using a three-site skinfolds measurement technique. The measurement of skinfold thickness 
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is a valid and reliable method for assessing body composition [67]. The same investigator will 
conduct all skinfold measurements. Male and female subjects will be assessed by use of a three site 
skinfold test, which will provide the researchers with an estimate of the subject’s body density. The 
three sites used for male subjects will be the chest, triceps, and subscapular skinfolds. Female subjects 
will have skinfold measurements taken at the triceps, suprailiac, and abdomen. The sum of the three 
skinfold measurements will be entered into an age and race appropriate equation to estimate body 
density [68]. Once the subject’s body density has been estimated, a subsequent equation (Siri) will be 
used to estimate body composition based on body density [68].  
Exercise Protocols: Subjects will maintain their training throughout the course of the study. A 
physical activity log will be completed for each participant to assess the caloric expenditures of each 
subject during the two three-day diet log periods. This activity log is assigned a kilocalorie 
expenditure value per kilogram body weight in fifteen minute intervals to corresponding exertion 
levels of categorized physical activities, ranging in intensities from one to nine, with one being 
activities such as sleep and nine being activities such as heavy resistance exercise. This assessment is 
referred to as the 3-day the Bouchard method [47].  
 
MIPS and Simple Creatine on Fatigue and Cluster-Set Velocity in Resistance-Trained Subjects 
  This stage will have three groups; a creatine monohydrate [C] group in addition to the creatine and 
electrolytes [M] and placebo [P] groups described previously. The testing battery will focus on 
fatigue or repeated bout outcomes.  
  Maximum torque and a fatigue protocol results will be determined using a Biodex System 4 (Biodex 
Medical Systems Inc., Shirley, NY) isokinetic dynamometer. Each subject will perform a general 
warm-up for 5 minutes using a cycle ergometer with no resistance added. All tests will be performed 
with the dominant leg. Subjects will be acclimated and settings will be recorded for their body 
segments on the dynamometer to ensure consistency across measures. The subject will sit on the 
dynamometer’s chair as proper adjustments are made, ensuring the center of rotation of the shaft of 
the dynamometer is in alignment with the lateral femoral epicondyle of the dominant leg. For that 
purpose, the back of the seat will be adjusted and the length of the dynamometer’s arm will be 
properly fitted to the length of the participant’s shank. The shank pad will be positioned on the distal 
portion of the tibia.  The subject will be positioned sitting with a hip angle at about 80°. The range of 
motion will be from 20° to 80° of knee flexion The participant will be stabilized with two shoulder 
straps, a waist strap, and a thigh strap, to reduce extraneous movements. Once in proper position, each 
subject will be instructed to perform a task-specific warm-up, consisting of with a 
concentric/concentric knee extension/flexion at 60 °.sec-1 angular velocity, followed by a 30 second 
rest at the original starting position of 50° of knee flexion.  
  Maximal knee extension isokinetic torque measurement will determined at an angular velocity of 60 
°.sec-1 and of 180 °.sec-1.  Isometric maximal voluntary contraction torque for both knee extension and 
flexion will be collected at 60 degrees of knee flexion. Three trials for a given condition will be 
performed. A two minute resting period will be allowed between trials. Peak torques will be 
determined during this test and during a subsequent test of maximal isometric muscle action. Rest 
intervals will be allowed until subject indicates they are fully recovered. After the completion of three 
attempts for each of the conditions, subjects will perform a cool down for 5 minutes on cycle 
ergometer, at an easy pace, with no resistance added. 
  The fatigue test will require subjects to perform a task-specific warm-up on the dynamometer 
followed by 30 maximal isokinetic knee extension repetitions. The absolute torque reduction through 
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the trial, from peak maximal torque to subsequent minimum peak torque, will be recorded in Nm.  
The total work done during fatigue trial, integrated torque with respect to time, will be determined 
ensuring that no more than 30 repetitions were included in the analysis. The subject will have 2 
minutes of rest before performing a second set of 30 repetitions. Subjects will perform a cool down 
for 5 minutes on cycle ergometer, at an easy pace, with no resistance added. 
  Subjects will perform a pre and post cluster set test for both the parallel back squat and bench press 
exercises. The load for each exercise will be 80% of their one repetition maximum [48]. The test 
includes four total clusters, with each cluster being comprised of two sets of five repetitions. Rest 
provided will be 1.5 minutes between clusters and 30 seconds between each sub-set. Average velocity 
for each repetition will be measured using an arm band accelerometer (PUSH, Toronto, Canada) 
placed on the subject’s right forearm. Data is transmitted and collected with the PUSH Assist 
application (PUSH, Toronto, Canada). The outcome measure will be the change in average mean 
velocities (m/s). The average mean velocity (m/s) of the first cluster will serve as a baseline to 
measure the change in velocity throughout the test. Average mean velocity (m/s) of each cluster 
thereafter will then be calculated and subtracted from the baseline value to determine the change in 
velocity. These three values will be averaged to determine the overall change in velocity in the cluster 
set test. Data will then be averaged for subjects within their predetermined group.  Values of zero 
represent no change in average velocity (m/s). Positive values represent a relative decrease in average 
velocity (m/s). Negative values represent an increase in average velocity (m/s).   
 
6. Give specific examples (with literature citations) for the use of your test 
instruments/questionnaires, or similar ones, in previous similar studies in your field. 
  Sports drinks were the original prototype of multi-ingredient performance supplements (MIPS). 
Much recent research has been reported with various combinations of MIPS, complex mixes of 
nutrients with the common factor being creatine [2-8]. Creatine is a widely used supplement deemed 
safe by the International Sports Nutrition Society. 
  It is common in studies on creatine effects to evaluate fatigue, power, and velocity of movement. 
Some studies related to this project’s focus would be repeated exercise bouts and fatigue. A 
systematic review and meta-analyses demonstrated creatine supplementation is effective in lower 
extremity physical performance for exercise duration of less than 3 minutes, independent of sample 
characteristic, training protocols, and supplementation doses and duration [54]. Physical tests at high 
intensity and repetitive sets have been used to assess creatine effects. Repeat sets have included the 
Wingate Anaerobic Test (WAnT) [55, 56] and swimming sprints [57]. In a study similar to this 
proposed study, muscle fatigue (five sets of 30 concentric knee extensions at 180 degrees/s) was 
evaluated after ingesting a low dose (≈2.3 g/d; 0.03 g/kg/d) of creatine for 6 weeks [58].  
Significantly increased plasma creatine concentration and enhanced resistance to fatigue during 
repeated bouts of high-intensity contractions were reported. 
  A more recent type of resistance training uses the concept of cluster sets to elicit better performance 
outcomes [59-65]. There are variable rest intervals sued within a set, in contrast to traditional 
resistance training with no within-set rest. Mechanical variables have been measured [60-62, 64, 65] 
with specific attention given to velocity and power in different types of lifts [60-62, 64]. Lower 
lactates are demonstrated in cluster-set protocols [59] and lower perceived exertion reported [63]. 
These cluster-set findings are similar to ones reported for creatine supplementation. No studies have 
yet reported on a combination of a creatine containing supplement and cluster-set protocol on 
performance outcomes.  
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7. Describe how your study design is appropriate to examine your question or specific 
hypothesis. Include a description of controls used, if any. 
  This study will follow a double blind, three-group format analyzed for a 6-week treatment period. 
These groups will consist of two separate supplementation and one placebo assignments. 
Supplementation will be a creatine-electrolyte multi-ingredient performance supplement, standard 
creatine monohydrate, or placebo (carbohydrate solution). Comparisons will between baseline and 
after 6-weeks of, between and within groups, for the selected variables.  Testing procedures will be 
conducted at the same time of day, as much as possible, to avoid confounding factors. 
 
8. Give specific examples (with literature citations) for the use of your study design, or similar 
ones, in previous similar studies in your field. 
 
   A blinded, repeated measures design type is common in sports nutrition research. It has long been a 
recommended design [52] in this area of research. 
 
9. Describe the potential risks to the human subjects involved. 
 
  When conducting any physical activity there are risks of muscle, tendon, or ligament injury present. 
This possibility also exists for the resistance exercises in this project. 
 
10. If the research involves potential risks, describe the safeguards that will be used to minimize 
such risks. 
  Only subjects who have been weight training for a minimum of the past 6 months will be entered 
into the study. To ensure safety of subjects, an introduction to the movements utilized will be 
conducted. The warm–up and trials will be monitored diligently by multiple lab assistants familiar 
with weight training protocols to ensure proper form. To reduce the chance of fatigue resulting in an 
injury, rest periods are given to allow for recovery. The supplementation of creatine and electrolyte 
solutions has been deemed safe with minimal known risks as documented in the International Society 
for Sports Nutrition position stand [53] and Australian Institute of Sports Supplement Framework [1]. 
Describe how you will address privacy and /or confidentiality. 
 Any and all data collected will be kept completely confidential and will be stored and 
analyzed by subject number only.  Only the primary researchers will have access to the 
records. The data will be stored separately from the informed consents to keep the identity 
anonymous. A locked cabinet will be used for hard copy and electronic data. 
 
11. If your research involves the use of schools (pre-kindergarten to university level) or other 
organizations (e.g., community clubs, companies), please attach a clearance letter from an 
administrator from your research site indicating that you have been given permission to 
conduct this research. For pre-kindergarten to grade 12 level schools, an administrator (e.g. 
principal or higher) should issue the permission. For post-secondary level schools the class 
instructor may grant permission. For Western Washington University, this requirement of 
a clearance letter is waived if you are recruiting subjects from a scheduled class. If you are 
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recruiting subjects from a campus group (not a class) at Western Washington University, 
you are required to obtain a clearance letter from a leader or coordinator of the group. 
 
N/A 
12. If your research involves the use of schools (pre-kindergarten to university level)or other 
organizations (e.g., community clubs, companies), and you plan to take still or video 
pictures as part of your research, please complete 
 
a) To d) below: 
a. Who have you contacted at the school district or organization involved, to determine the 
policy on the use of photography in the school or organization? 
 
N/A 
 
b. Explain how your research plan conforms to the policy on the use of photography in the 
school or organization. 
 
N/A 
 
 
c. Attach a copy of the school district or organization policy on the use of photography at the 
schools or organization. 
N/A 
 
d. Explain how you will ensure that the only people recorded in your pictures will be the ones 
that have signed a consent form. 
N/A 
In addition, please attach the following information: 
1. A bibliography relevant to the subject matter of the proposed research. 
See below 
 
2. A copy of the informed consent form (a checklist is attached for you to use as a guide) 
 
See below 
 
3. A current curriculum vitae. 
See below 
4. A copy of the certificate of completion for Human Subjects Training from the online human 
subjects training module, for each person involved in the research who will have any 
contact with the subjects or their data. 
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See below 
5. If your subjects are required to turn in a physical clearance from prior to participation 
include a copy of the blank form. 
N/A 
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Food Diary Completion Form 
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FOOD DIARY PLEASE FOLLOW THESE INSTRUCTIONS CAREFULLY IN COMPLETING THIS 
DIARY 
Beginning with midnight on ____________, write down everything you eat or drink and all vitamin and 
mineral supplements  
Write only one food item or beverage on a line. For example, if you eat oatmeal with sugar and milk, 
write oatmeal on a line, sugar on the next, and milk on the next.  
Keep this record with you so all information can be recorded at the time food and drink are ingested. 
Measure and record the amounts of food served in portion sizes of cups, ounces, tablespoons, teaspoons, 
slices, and inches. 
Indicate how the food was prepared fried, steamed, baked, raw etc    
Be sure to measure and record all those little extras.... gravies, salad dressings, taco sauce, pickles, jelly, 
sugar, margarine, etc. Indicate amounts. 
Consider the following points as you are recording different types of foods: 
Beverages -record amount in cups or ounces 
-list type of milk, such as whole, nonfat, 2%, evaporated 
-indicate type of beverage type, such as fresh, fruit drink,etc. 
Fruits & Vegetables indicate whether fresh, frozen, dried, canned  
-record as portion of cup, piece, number eaten, and size 
-record preparation method  
Breads & Cereals -indicate whether whole wheat, white, sourdough, rye, etc. 
-record portions 
-record anything added to the bread or cereal....jam, sugar,  etc. 
Meats-record in ounces or approximate measurement after cooking 
-record preparation method  
Desserts  
-record portion size and number   
If you have any questions, please call 360-650-2851  
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Appendix D 
Background Information Form 
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BACKGROUND INFORMATION FORM 
Name:         Date:     
Height in inches: ____ Weight in lbs.: ____ 
Age:   Sex:  Birth date:     
Street Address:          
City:      State:   Zip:    
Phone: ____________   
In case of emergency notify:   Name:         
Phone Number: _     Relationship: _      
Have you had a physical examination within the past two years? _    
Name of your physician:_______________ Phone Number:     
Do you have a family history of heart disease?     
If so, describe?            
Do you have any renal problems?         
Do you experience any uncomfortable sensations while exercising?      
              
How active are you? What type of exercise do you engage in and how many times a week do you 
exercise?_____________________________________        
              
Do you drink alcohol?   If so, how much?       
Please list everything not already included on this questionnaire that might cause you problems in a 
strength or jump test: 
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ASF_001 2
ASF_002 3
ASF_003 2
ASF_004 1
ASF_005 2
ASF_006 1
ASF_007 2
ASF_008 3
ASF_009 2
ASF_010 1
ASF_011 3
ASF_012 1
ASF_013 3
ASF_014 1
ASF_015 1
ASF_016 3
ASF_017 2
ASF_018 2
ASF_019 2
ASF_020 1
ASF_021 1
ASF_022 2
ASF_023 3
ASF_024 3
ASF_025 1
ASF_026 1
ASF_027 3
ASF_028 1
ASF_029 2
ASF_030 3
Codes reference ending numbers
Lot #1 = 106 Placebo of maltodextrin
Lot #2 = 105 Creatine monohydrate (4 mg creatine)
Lot #3 = 102 Creatine-electrolyte (4 mg creatine)
Subject supplment grouping
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Subject # Gender Supp # Age Height (In) Height (m) Weight (lbs) Weight (kg) Dominant Limb Age Height (In) Height (m) Weight (lbs) Weight (kg) Dominant Limb
PRE-TEST 133
ASF_001 Male 2 22 62.6 1.5768262 128 58.18181818 Right 22 62 1.561712846 133 60.45454545 Right
ASF_002 Female 3 22 66.9 1.68513854 149 67.72727273 Right 22 66.9 1.685138539 142 64.54545455 Right
ASF_003 Female 2 19 65.748 1.65612091 150 68.18181818 Right 19 65.75 1.656171285 148 67.27272727 Right
ASF_004 Male 1 23 62.99 1.58664987 131 59.54545455 Right 23 63 1.586901763 131 59.54545455 Right
ASF_005 Female 2 22 65 1.6372796 143 65 Right 22 65 1.637279597 146.5 66.59090909 Right
ASF_006 Male 1 23 68.897 1.73544081 157 71.36363636 Right 23 69 1.738035264 159 72.27272727 Right
ASF_007 Male 2 22 64.86 1.63375315 152.1 69.13636364 Right 22 64.86 1.633753149 152 69.09090909 Right
ASF_008 Male 3 20 70 1.76322418 180 81.81818182 Right 20 70 1.763224181 185 84.09090909 Right
ASF_009 Male 2 26 72.0472 1.81479093 162.2 73.72727273 Right 25 72 1.813602015 175 79.54545455 Right
ASF_010 Male 1 26 66.14 1.66599496 173 78.63636364 Right 26 66 1.662468514 171 77.72727273 Right
ASF_011 Male 3 23 65.55 1.6511335 139 63.18181818 Right 23 66 1.662468514 137.5 62.5 Right
ASF_012 Male 1 20 70.886 1.78554156 178 80.90909091 Left 20 7.86 0.197984887 177 80.45454545 Left
ASF_013 Male 3 72.5 167 Right 
ASF_014 Male 1 22 72 1.81360202 171 77.72727273 Right 22 72 1.813602015 174 79.09090909 Right
ASF_015 Male 2 18 68.5039 1.72553904 158 71.81818182 Right 19 68.5 1.725440806 159 72.27272727 Right
ASF_016 Male 3 22 67.5 1.70025189 167 75.90909091 Right 22 67.5 1.700251889 167 75.90909091 Right
ASF_017 Female 2 0 24 67 1.68765743 142 64.54545455 Right 24 67 1.687657431 143 65 Right
ASF_018 Female 2 21 61.75 1.55541562 185 84.09090909 Right 21 67 1.687657431 189 85.90909091 Right
ASF_019 Male 2 68 174 Right 
ASF_020 Female 1 22 65 1.6372796 154 70 Right 22 65 1.637279597 154 70 Right
ASF_021 Male 1 19 75 1.88916877 219.5 99.77272727 Right 19 75 1.889168766 221 100.4545455 Right
ASF_022 Male 2 23 70.75 1.78211587 167 75.90909091 Right 23 70 1.763224181 169 76.81818182 right
ASF_023 Male 3 21 76 1.91435768 160 72.72727273 Right 22 76 1.914357683 162 73.63636364 Right
ASF_024 Male 3 21 65 1.6372796 150 68.18181818 Right 21 66 1.662468514 151 68.63636364 Right
ASF_025 Female 1 21 62 1.56171285 135 61.36363636 Right 21 62 1.561712846 140 63.63636364 Right
ASF_026 1
ASF_027 Male 3 23 66 1.66246851 179 81.36363636 Right 23 66.25 1.668765743 179 81.36363636 Right
Subject # Supp # Resistance Reactants Total Body Water (L)Intra-celluar Extra-cellular Resistance Reactants Total Body Water (L)Intra-celluar Extra-cellular
PRE-TEST POST-TEST
ASF_001 2 443 61.3 37.7 22.8 14.8 432 59.2 38 22.9 15.1
ASF_002 3 688 81 29.3 15.2 14.1 698.6 88.6 28.4 16.8 11.6
ASF_003 2 616.3 67.6 31.3 16.2 15.1 608.2 69.9 31.6 16.5 15.1
ASF_004 1 485.4 56.8 35.2 20.9 14.2 431.9 60.2 39.1 23.6 15.4
ASF_005 2 569 65 32.7 17.3 15.4 574.4 71.7 32.5 17.3 15.2
ASF_006 1 495.4 63.5 41.3 24.2 17.2 492.4 66.3 42.8 25.1 17.7
ASF_007 2 510.1 72.8 36.1 21.4 14.7
ASF_008 3 446.5 55.8 47.3 27.1 20.2 482.4 66 44.4 25.5 18.9
ASF_009 2 499 98.1 49 29.1 19.9 460.5 54.1 48.3 27.6 20.6
ASF_010 1 419.3 63.3 45.1 26.4 18.6
ASF_011 3 484.6 56.7 38.1 22.5 15.6 475.9 55.3 39.1 23.1 16
ASF_012 1 452 60.5 47.8 27.6 20.2
ASF_013 3 401 54.3 55.1 32.3 22.8
ASF_014 1 483.1 57.3 46.1 26.5 19.6 492.5 60.1 45.4 26.1 19.4
ASF_015 2 547.6 66.3 36.4 21.1 15.3 521.7 63.9 39.1 22.7 16.4
ASF_016 3 464.6 62.3 42.5 24.7 17.8 484.5 65.3 41 23.8 17.2
ASF_017 2 590.1 60.5 33.3 17.4 15.9 579.9 59.1 33.9 17.7 16.2
ASF_018 2 660.3 70.9 31.7 15.5 16.1 635.4 68.9 32.6 16 16.6
ASF_019 2 417.4 55.1 47.6 27.6 20
ASF_020 1 601.3 63.9 31.5 16.1 15.3 579.4 53.6 32.5 16.4 16.1
ASF_021 1 479.6 67.8 51.4 28.7 22.7 462.3 64.7 53.1 29.9 23.2
ASF_022 2 483.4 60.5 33.5 19.2 14.3
ASF_023 3 541.9 69.2 45.6 26.6 19 539.4 67.3 45.8 26.6 19.1
ASF_024 3 535.5 74.5 34.6 20.5 14.1
ASF_025 1 578.3 74.3 48.1 27.6 11.8 565.3 76.2 30.2 16.2 14
ASF_027 3 477.2 73.1 40.2 23.4 16.9 463.2 70.9 41.6 24.2 17.4
ASF_028 1  
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Subject # Gender Supp # Site #1 Site #2 Site #3 Sum Body Fat % Lean Body Mass (lbs) Fat Mass (lbs) Site #1 Site #2 Site #3 Sum % BF Lean Body Mass (lbs) Fat Mass (lbs)
PRE-TEST POST-TEST
ASF_001 Male 2 4 7 8 19 4.7 68.9 3.4 3 9.5 9 21.5 5.5 57.1 3.3
ASF_002 Female 3 18.5 11.5 31.5 61.5 24.1 51.4 16.3 16.5 11 33.5 61 24 49.1 15.5
ASF_003 Female 2 21 15.5 24 60.5 23.6 52.1 16.1 21.5 18 25.5 65 25.1 50.4 16.9
ASF_004 Male 1 6 8.5 10.5 25 6.7 55.5 4 4.5 11 10.5 26 7 55.4 4.2
ASF_005 Female 2 22.5 14 31 67.5 26 48.1 16.9 24 14.5 27.5 66 25.6 49.6 17
ASF_006 Male 1 3.5 16.5 19 39 11 63.5 7.9 4 10.5 16.5 31 8.6 66.1 6.2
ASF_007 Male 2 8.5 22.5 12 43 12.1 60.8 8.4 5 19.5 17.5 42 11.9 60.8 8.3
ASF_008 Male 3 6.5 16 15.5 38 10.4 73.3 8.5 5.75 18 18.5 42.25 11.7 74.3 9.8
ASF_009 Male 2 8 13 6.5 27.5 7.8 67.9 5.8 8.5 13 8 29.5 8.4 72.9 6.6
ASF_010 Male 1 13 22.5 15 50.5 14.8 66.2 11.5 10.5 21 1.5 33 13 67.6 10.1
ASF_011 Male 3 10 18 11.5 39.5 11.2 56.1 7.1 5.5 19 10 34.5 9.7 56.5 6
ASF_012 Male 1 9.5 14.5 13 37 10.1 72.7 8.2 8.5 14 12.5 35 9.5 72.8 7.6
ASF_013 Male 3 8 11.5 7 26.5 0
ASF_014 Male 1 9.5 17 7.5 34 12.4 68.1 9.7 5 16 16.5 37.5 10.5 70.8 8.3
ASF_015 Male 2 19.5 26 20.5 66 18.2 58.7 13.1 17.5 25.5 20 63 17.5 59.6 12.7
ASF_016 Male 3 6.5 14 12 32.5 9 69.1 6.8 4.5 11.5 13 29 7.9 70.4 6
ASF_017 Female 2 18 9 20.5 47.5 18.9 52.3 12.2 15.5 11 26.5 53 21.5 51 14
ASF_018 Female 2 28 27.5 48.5 104 28.1 60.4 23.6 26 30 44 100 35.2 55.7 30.2
ASF_019 Male 2 6.5 15 13.5 35 0
ASF_020 Female 1 23.5 24 37.5 85 23.7 53.4 16.6 21.5 24.5 26 72 30.4 48.7 21.3
ASF_021 Male 1 13 29 27 69 19.2 80.6 19.1 13.5 33 21.5 68 18.9 81.5 19
ASF_022 Male 2 4 9.5 6.25 19.75 5.1 72.1 3.8 5 12 9 26 7.1 71.4 5.4
ASF_023 Male 3 3 6.75 6 15.75 3.6 70.1 2.6 3 8 7.5 18.5 4.6 70.3 3.4
ASF_024 Male 3 5.5 21 11 37.5 10.4 61.1 7.1 4 21.5 14 39.5 11 61.1 7.5
ASF_025 Female 1 14 14.5 21 49.5 20.1 49 12.3 17 19 24 60 23.6 48.6 15
ASF_026 1 0 0
ASF_027 Male 3 8 8 14.75 30.75 9.1 73.9 7.4 10 19.5 14 43.5 12.4 71.3 10.1
ASF_028 1 0 0
ASF_029 2 0 0
ASF_030 3 0 0
ASF_031 3 0 0
ASF_032 2 0 0
Mass (kg)
Supplement Group Pre Post  Set 1 Set 2 Set 1 Set 2 Set 1 Set 2 Set 1 Set 2
Creatine-electrolyte ASF_002 67.72727 64.54545 101.1305 104.4793 104.4793 94.41916 149.3201 154.2648 161.8694 146.2832
Creatine-electrolyte ASF_008 81.81818 84.09091 191.7262 179.3747 232.6448 234.8412 234.332 219.2358 276.6587 279.2706
Creatine-electrolyte ASF_011 63.18182 62.5 138.2528 108.3705 133.7243 115.1903 218.8173 171.5217 213.9589 184.3045
Creatine-electrolyte ASF_016 75.90909 75.90909 180.6627 172.4058 213.6362 159.051 237.9988 227.1214 281.437 209.5283
Creatine-electrolyte ASF_023 72.72727 73.63636 150.7534 152.2448 158.9832 129.0061 207.2859 209.3366 215.9031 175.1934
Creatine-electrolyte ASF_024 68.18182 68.63636 144.0557 143.7574 152.882 137.3579 211.2816 210.8442 222.742 200.1241
Creatine-electrolyte ASF_027 81.36364 81.36364 141.6423 114.2412 177.7884 160.3797 174.0855 140.4082 218.5109 197.1147
Creatine Mono ASF_001 58.18182 60.45455 155.8242 133.6565 148.8417 120.2746 267.8228 229.7222 246.2043 198.9505
Creatine Mono ASF_003 68.18182 67.27273 106.4588 112.3702 94.48695 91.77532 156.1396 164.8096 140.4536 136.4228
Creatine Mono ASF_005 65 66.59091 92.48034 99.34078 120.8169 102.7981 142.2774 152.832 181.4316 154.3726
Creatine Mono ASF_007 69.13636 69.09091 160.3797 142.144 158.5087 140.3543 231.9759 205.5994 229.4205 203.1443
Creatine Mono ASF_009 73.72727 79.54545 180.3645 152.2855 189.1637 125.9284 244.6374 206.5524 237.8058 158.31
Creatine Mono ASF_017 64.54545 65 110.6212 94.74456 110.7432 106.1199 171.3849 146.7873 170.3742 163.2613
Creatine Mono ASF_018 84.09091 85.90909 104.6556 106.3232 94.48695 99.15097 124.4553 126.4385 109.9848 115.4138
Creatine Mono ASF_022 75.90909 76.81818 186.4656 153.3295 176.5275 151.2144 245.6434 201.9909 229.7991 196.8471
Placebo ASF_004 59.54545 59.54545 137.4664 133.643 139.012 118.8646 230.8596 224.4386 233.4553 199.6199
Placebo ASF_006 71.36364 72.27273 91.43636 78.50186 111.6516 115.8275 128.1274 110.0026 154.4865 160.2645
Placebo ASF_010 78.63636 77.72727 175.1988 167.3079 192.7024 158.8612 222.7962 212.7615 247.9212 204.3828
Placebo ASF_012 80.90909 80.45455 150.3873 138.185 154.1836 135.0666 185.872 170.7904 191.6407 167.8794
Placebo ASF_014 77.72727 79.09091 194.0989 186.4656 177.2325 166.5758 249.7179 239.8973 224.0871 210.6131
Placebo ASF_015 71.81818 72.27273 181.4084 180.2153 175.7547 159.4849 252.594 250.9327 243.1826 220.6709
Placebo ASF_020 70 70 113.5904 95.61228 94.47339 68.92978 162.272 136.589 134.962 98.47112
Placebo ASF_025 61.36364 63.63636 106.5537 95.34112 113.6447 113.6447 173.6431 155.3707 178.5845 178.5845
Peak Torque (Nm) Peak Torque/Body Weight (Nm/kg)
Pre Post Pre Post
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Mass (kg)
Supplement Group Pre Post WKF1/3 WKL1/3 WKF1/3 WKL1/3 WKF1/3 WKL1/3 WKF1/3 WKL1/3 Set 1 Set 2 Set 1 Set 2 Set 1 Set 2 Set 1 Set 2
Creatine-electrolyte ASF_002 67.72727 64.54545 580.8 381.6 672.9 311.4 548.7 383.3 537.9 308.2 1.522013 2.160886 1.431516 1.745295 100 92.8 80.5 84.6
Creatine-electrolyte ASF_008 81.81818 84.09091 1234.4 705.7 942.1 458.1 1455.4 831.4 1218.4 546 1.749185 2.056538 1.750541 2.231502 223 187.3 299.3 243.6
Creatine-electrolyte ASF_011 63.18182 62.5 835.6 420.8 672.1 289.6 885.5 504.4 663.8 334.7 1.985741 2.320787 1.755551 1.983269 155.4 116.2 167.8 124.9
Creatine-electrolyte ASF_016 75.90909 75.90909 1041.9 544.1 1071.8 413 1463.6 614.5 957.5 411.2 1.914905 2.595157 2.381774 2.328551 173.9 154.7 227.1 157.5
Creatine-electrolyte ASF_023 72.72727 73.63636 826.8 572 960.4 417 1129.1 484.5 782 374.4 1.445455 2.303118 2.330444 2.088675 149.9 135.5 159.5 118
Creatine-electrolyte ASF_024 68.18182 68.63636 730.1 397.3 659.9 246.1 859.8 427.7 665.4 296.5 1.837654 2.68143 2.010288 2.244182 178.6 143.1 185.5 143.5
Creatine-electrolyte ASF_027 81.36364 81.36364 797.7 632.3 545.4 373.2 1076.3 689.7 907.2 400.5 1.261585 1.461415 1.560534 2.265169 124.3 86.5 182.3 147.7
Creatine Mono ASF_001 58.18182 60.45455 614.1 273.3 448 189.8 655.1 320 508 205.1 2.246981 2.360379 2.047188 2.476841 133.3 100.9 153 111.6
Creatine Mono ASF_003 68.18182 67.27273 627.5 394.6 658.4 329.1 444.4 410.1 460.6 388.9 1.590218 2.000608 1.083638 1.184366 106.2 105.1 103.4 101
Creatine Mono ASF_005 65 66.59091 462.7 270.4 541.5 311.9 744.7 400.5 614.4 343.8 1.711169 1.736133 1.859426 1.787086 92.7 108 132.4 113.6
Creatine Mono ASF_007 69.13636 69.09091 901.1 532.3 792.3 295.6 903.3 632.7 744 618.1 1.692842 2.680311 1.427691 1.203689 159.6 120.6 157.8 131.7
Creatine Mono ASF_009 73.72727 79.54545 1189.3 662.7 1052.6 415 1399.1 810.2 860.7 389.9 1.794628 2.536386 1.726858 2.207489 207.8 157.7 247.1 129.8
Creatine Mono ASF_017 64.54545 65 615.4 311.8 589.5 202 732.4 346.8 658.6 262 1.973701 2.918317 2.11188 2.51374 115.3 89 135.9 112.3
Creatine Mono ASF_018 84.09091 85.90909 617.7 336.9 605.2 271.4 560.2 323.3 570.4 233.2 1.833482 2.229919 1.732756 2.445969 110.9 98.4 109.1 103.8
Creatine Mono ASF_022 75.90909 76.81818 925.2 564.1 802.8 413.4 1061.7 630.3 918.6 441.4 1.640135 1.941945 1.684436 2.081106 243.2 191.4 246 187
Placebo ASF_004 59.54545 59.54545 838.3 473.9 742.8 365.7 953.7 533.6 727.9 449.5 1.768939 2.031173 1.787294 1.619355 164.4 141.7 161.9 137.4
Placebo ASF_006 71.36364 72.27273 128.8 204.9 216.7 209.9 422.6 458.8 531.5 289.4 0.628599 1.032396 0.921099 1.836558 22.7 27.2 81.8 72.3
Placebo ASF_010 78.63636 77.72727 956.4 427.3 884.2 334.5 967.1 468.7 1062.6 447.1 2.23824 2.643348 2.063367 2.37665 208 196.9 284 210.8
Placebo ASF_012 80.90909 80.45455 848.2 486.4 701.7 402.8 750.7 460.9 611.8 396.9 1.743832 1.742056 1.62877 1.541446 183.9 152.6 177.7 152.9
Placebo ASF_014 77.72727 79.09091 925.6 552.2 852.1 449.8 1120.4 705.4 1018.5 578.3 1.676204 1.894398 1.588319 1.761197 218.4 193 205.4 179.4
Placebo ASF_015 71.81818 72.27273 436.7 681.9 866.7 395.8 980.7 628.3 879.9 379.7 0.640416 2.189742 1.560879 2.317356 160.6 176.8 201.6 150.1
Placebo ASF_020 70 70 493.6 341.4 428.8 271.4 396.9 157.7 243.6 122.8 1.445811 1.579956 2.516804 1.983713 71.7 62.7 64.8 42.5
Placebo ASF_025 61.36364 63.63636 572 319.5 502.6 245.1 648.1 386.4 550.6 297.9 1.790297 2.050592 1.677277 1.848271 124.4 111 146 126.3
Post Pre Post
Work (Joules)
Work (Joules) Post Ratio Power (W)
Set 1 Set 2 Set 1 Set 2 Pre
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Mass (kg) Peak Torque 180 deg/s (Nm)
Supplement Group Pre Post Pre Post Pre Post Pre Post Pre Post
Creatine-electrolyte ASF_002 67.72727 64.54545 129.75 122.57 191.58 189.89 85.55 82.30 126.32 127.50
Creatine-electrolyte ASF_008 81.81818 84.09091 297.20 259.91 363.24 309.08 153.61 182.36 187.75 216.86
Creatine-electrolyte ASF_011 63.18182 62.5 139.11 180.87 220.17 289.39 80.40 135.04 127.25 216.06
Creatine-electrolyte ASF_016 75.90909 75.90909 253.81 271.03 334.36 357.04 175.31 186.15 230.94 245.23
Creatine-electrolyte ASF_023 72.72727 73.63636 159.04 217.07 218.68 294.78 109.82 160.26 151.00 217.63
Creatine-electrolyte ASF_024 68.18182 68.63636 162.97 180.19 239.02 262.53 121.62 128.40 178.37 187.07
Creatine-electrolyte ASF_027 81.36364 81.36364 165.82 210.02 203.80 258.12 119.31 135.45 146.64 166.47
0.087964 0.082499 0.01539 0.0190727
186.81 205.95 252.98 280.12 120.80 144.28 164.04 196.69
58.53624 47.10587 62.58326 47.79659155 31.72606 33.20085 34.83152 36.5857
Creatine Mono ASF_001 58.18182 60.45455 238.8951 226.5572 410.601 374.7562362 146.2928 137.8867 251.4407 228.0832
Creatine Mono ASF_003 68.18182 67.27273 138.9713 114.431 203.8246 170.1001869 102.6354 62.09646 150.5319 92.30555
Creatine Mono ASF_005 65 66.59091 186.2894 198.8985 286.5991 298.6871568 106.4317 107.7875 163.7411 161.8652
Creatine Mono ASF_007 69.13636 69.09091 164.054 180.0526 237.2904 260.6024814 118.3629 123.2439 171.2021 178.3793
Creatine Mono ASF_009 73.72727 79.54545 221.4051 223.9811 300.3028 281.5762715 161.0712 154.8344 218.4689 194.649
Creatine Mono ASF_017 64.54545 65 134.0904 124.0573 207.7457 190.8574496 26.70961 89.48398 41.38109 137.6677
Creatine Mono ASF_018 84.09091 85.90909 148.1909 139.7848 176.227 162.7125011 112.6685 93.8226 133.9841 109.2115
Creatine Mono ASF_022 75.90909 76.81818 323.227 257.3342 425.808 334.9913269 189.6789 189.9501 249.8764 247.2723
194.3904 183.1371 281.0498 259.2854513 120.4814 119.8882 172.5783 168.6792
60.35003 49.25324 88.30334 73.38147664 45.38255 38.00535 64.777 51.05356
Placebo ASF_004 59.54545 59.54545 206.0843 183.4422 346.0958 308.0708172 141.0051 133.0057 236.8024 223.3684
Placebo ASF_006 71.36364 72.27273 198.7629 202.8304 278.5213 280.6457881 74.16324 111.3127 103.923 154.0175
Placebo ASF_010 78.63636 77.72727 223.9811 280.2476 284.8315 360.5524291 144.3946 189.2722 183.6232 243.5081
Placebo ASF_012 80.90909 80.45455 231.9805 178.0189 286.7174 221.2664252 155.6479 110.3636 192.3738 137.1751
Placebo ASF_014 77.72727 79.09091 210.2874 220.1848 270.5451 278.3946187 150.767 173.0024 193.9692 218.7386
Placebo ASF_015 71.81818 72.27273 177.2054 164.8675 246.7417 228.1185016 113.3464 120.2611 157.8241 166.3989
Placebo ASF_020 70 70 174.7649 189.6789 249.6642 270.9699014 95.99191 111.3127 137.1313 159.0181
Placebo ASF_025 61.36364 63.63636 160.8 143.1744 262.0445 224.9883041 68.46881 97.07657 111.5788 152.5489
197.9833 195.3056 278.1452 271.6258482 117.9731 130.7009 164.6532 181.8467
23.45935 38.7397 29.26166 44.67633548 32.78329 30.8835 42.57694 37.54223
Peak Torque 60 deg/s (Nm) Peak Torque 60 deg/s (Nm/Kg) Peak Torque 180 deg/s (Nm/Kg)
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Mass (kg)
Supplment Group Pre Post Pre Post Pre Post
Creatine-electrolyte ASF_002 67.72727 64.54545 180.595 142.2253 266.65 220.35
Creatine-electrolyte ASF_008 81.81818 84.09091 270.0789 259.5036 330.10 308.60
Creatine-electrolyte ASF_011 63.18182 62.5 204.0506 216.5241 322.96 346.44
Creatine-electrolyte ASF_016 75.90909 75.90909 309.2621 340.0391 407.41 447.96
Creatine-electrolyte ASF_023 72.72727 73.63636 312.516 283.5015 429.71 385.00
Creatine-electrolyte ASF_024 68.18182 68.63636 139.2425 185.0691 204.22 269.64
Creatine-electrolyte ASF_027 81.36364 81.36364 187.7808 228.1842 230.79 280.45
0.303486
313.12 322.63
78.98 71.12
Creatine Mono ASF_001 58.18182 60.45455 253.1312 270.8924 435.07 448.09
Creatine Mono ASF_003 68.18182 67.27273 195.2378 150.4958 286.35 223.71
Creatine Mono ASF_005 65 66.59091 209.2027 245.403 321.85 368.52
Creatine Mono ASF_007 69.13636 69.09091 185.4759 174.087 268.28 251.97
Creatine Mono ASF_009 73.72727 79.54545 267.2317 285.942 362.46 359.47
Creatine Mono ASF_017 64.54545 65 164.4607 206.8978 254.80 318.30
Creatine Mono ASF_018 84.09091 85.90909 226.8283 206.4911 269.74 240.36
Creatine Mono ASF_022 75.90909 76.81818 347.0894 309.1265 457.24 402.41
0.373036
331.97 326.61
73.59 76.66
Placebo ASF_004 59.54545 59.54545 225.2014 212.3211 378.20 356.57
Placebo ASF_006 71.36364 72.27273 230.6246 244.3184 323.17 338.05
Placebo ASF_010 78.63636 77.72727 271.5703 314.6853 345.35 404.86
Placebo ASF_012 80.90909 80.45455 222.4897 228.7265 274.99 284.29
Placebo ASF_014 77.72727 79.09091 230.0823 272.5194 296.01 344.56
Placebo ASF_015 71.81818 72.27273 185.6115 186.425 258.45 257.95
Placebo ASF_020 70 70 179.5103 205.6776 256.44 293.83
Placebo ASF_025 61.36364 63.63636 200.7966 235.0988 327.22 369.44
0.022878
307.48 331.19
40.72 45.72
Peak Isometric TQ (Nm) Peak Isometric TQ (Nm/kg)
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Appendix F 
Statistical Output 
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Between-Subjects Factors 
 N 
Supplement 1.00 8 
2.00 9 
3.00 7 
 
 
Within-Subjects Factors 
Measure:   Bodyfat   
time 
Dependent 
Variable 
1 BFPre 
2 BFPost 
 
 
Descriptive Statistics 
 
Supplement Mean Std. Deviation N 
BFPre 1.00 14.7500 5.78841 8 
2.00 16.0556 8.98848 9 
3.00 11.1143 6.25365 7 
Total 14.1792 7.26989 24 
BFPost 1.00 15.1875 8.32817 8 
2.00 17.5333 10.11793 9 
3.00 11.6143 6.06999 7 
Total 15.0250 8.50531 24 
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Multivariate Testsa 
Effect Value F 
Hypothesis 
df Error df Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powerc 
time Pillai's Trace .106 2.489b 1.000 21.000 .130 .106 2.489 .325 
Wilks' Lambda .894 2.489b 1.000 21.000 .130 .106 2.489 .325 
Hotelling's 
Trace 
.119 2.489b 1.000 21.000 .130 .106 2.489 .325 
Roy's Largest 
Root 
.119 2.489b 1.000 21.000 .130 .106 2.489 .325 
time * 
Supplement 
Pillai's Trace .043 .466b 2.000 21.000 .634 .043 .932 .116 
Wilks' Lambda .957 .466b 2.000 21.000 .634 .043 .932 .116 
Hotelling's 
Trace 
.044 .466b 2.000 21.000 .634 .043 .932 .116 
Roy's Largest 
Root 
.044 .466b 2.000 21.000 .634 .043 .932 .116 
a. Design: Intercept + Supplement  
 Within Subjects Design: time 
b. Exact statistic 
c. Computed using alpha = .05 
 
 
Mauchly's Test of Sphericitya 
Measure:   Bodyfat   
Within Subjects 
Effect Mauchly's W 
Approx. Chi-
Square df Sig. 
Epsilonb 
Greenhouse-
Geisser Huynh-Feldt Lower-bound 
time 1.000 .000 0 . 1.000 1.000 1.000 
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is 
proportional to an identity matrix. 
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a. Design: Intercept + Supplement  
 Within Subjects Design: time 
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in 
the Tests of Within-Subjects Effects table. 
 
 
Tests of Within-Subjects Effects 
Measure:   Bodyfat   
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
time Sphericity 
Assumed 
7.697 1 7.697 2.489 .130 .106 2.489 .325 
Greenhouse-
Geisser 
7.697 1.000 7.697 2.489 .130 .106 2.489 .325 
Huynh-Feldt 7.697 1.000 7.697 2.489 .130 .106 2.489 .325 
Lower-bound 7.697 1.000 7.697 2.489 .130 .106 2.489 .325 
time * 
Supplement 
Sphericity 
Assumed 
2.883 2 1.441 .466 .634 .043 .932 .116 
Greenhouse-
Geisser 
2.883 2.000 1.441 .466 .634 .043 .932 .116 
Huynh-Feldt 2.883 2.000 1.441 .466 .634 .043 .932 .116 
Lower-bound 2.883 2.000 1.441 .466 .634 .043 .932 .116 
Error(time) Sphericity 
Assumed 
64.937 21 3.092      
Greenhouse-
Geisser 
64.937 
21.00
0 
3.092      
Huynh-Feldt 
64.937 
21.00
0 
3.092      
Lower-bound 
64.937 
21.00
0 
3.092      
a. Computed using alpha = .05 
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Tests of Within-Subjects Contrasts 
Measure:   Bodyfat   
Source time 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
time Linear 7.697 1 7.697 2.489 .130 .106 2.489 .325 
time * 
Supplement 
Linear 
2.883 2 1.441 .466 .634 .043 .932 .116 
Error(time) Linear 64.937 21 3.092      
a. Computed using alpha = .05 
 
 
Tests of Between-Subjects Effects 
Measure:   Bodyfat   
Transformed Variable:   Average   
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
Intercept 9816.018 1 9816.018 80.017 .000 .792 80.017 1.000 
Supplement 235.434 2 117.717 .960 .399 .084 1.919 .194 
Error 2576.151 21 122.674      
a. Computed using alpha = .05 
 
 
 
Estimated Marginal Means 
 
 
 
1. Grand Mean 
Measure:   Bodyfat   
Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
14.376 1.607 11.034 17.718 
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2. Supplement 
 
 
 
Estimates 
Measure:   Bodyfat   
Supplement Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 14.969 2.769 9.210 20.727 
2.00 16.794 2.611 11.365 22.223 
3.00 11.364 2.960 5.208 17.520 
 
 
Pairwise Comparisons 
Measure:   Bodyfat   
(I) Supplement (J) Supplement 
Mean Difference 
(I-J) Std. Error Sig.a 
95% Confidence Interval for 
Differencea 
Lower Bound Upper Bound 
1.00 2.00 -1.826 3.806 1.000 -11.725 8.074 
3.00 3.604 4.053 1.000 -6.940 14.149 
2.00 1.00 1.826 3.806 1.000 -8.074 11.725 
3.00 5.430 3.947 .550 -4.837 15.697 
3.00 1.00 -3.604 4.053 1.000 -14.149 6.940 
2.00 -5.430 3.947 .550 -15.697 4.837 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Bonferroni. 
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Univariate Tests 
Measure:   Bodyfat   
 
Sum of 
Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
Contrast 117.717 2 58.858 .960 .399 .084 1.919 .194 
Error 1288.075 21 61.337      
The F tests the effect of Supplement. This test is based on the linearly independent pairwise comparisons among the 
estimated marginal means. 
a. Computed using alpha = .05 
 
 
 
3. time 
 
 
 
Estimates 
Measure:   Bodyfat   
time Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
1 13.973 1.496 10.863 17.084 
2 14.778 1.749 11.141 18.416 
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Pairwise Comparisons 
Measure:   Bodyfat   
(I) time (J) time 
Mean Difference 
(I-J) Std. Error Sig.a 
95% Confidence Interval for 
Differencea 
Lower Bound Upper Bound 
1 2 -.805 .510 .130 -1.866 .256 
2 1 .805 .510 .130 -.256 1.866 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Bonferroni. 
 
 
Multivariate Tests 
 Value F Hypothesis df Error df Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powerb 
Pillai's trace .106 2.489a 1.000 21.000 .130 .106 2.489 .325 
Wilks' lambda .894 2.489a 1.000 21.000 .130 .106 2.489 .325 
Hotelling's trace .119 2.489a 1.000 21.000 .130 .106 2.489 .325 
Roy's largest 
root 
.119 2.489a 1.000 21.000 .130 .106 2.489 .325 
Each F tests the multivariate effect of time. These tests are based on the linearly independent pairwise comparisons 
among the estimated marginal means. 
a. Exact statistic 
b. Computed using alpha = .05 
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4. Supplement * time 
Measure:   Bodyfat   
Supplement time Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 1 14.750 2.577 9.391 20.109 
2 15.188 3.013 8.921 21.454 
2.00 1 16.056 2.429 11.003 21.108 
2 17.533 2.841 11.625 23.442 
3.00 1 11.114 2.755 5.385 16.843 
2 11.614 3.221 4.915 18.314 
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Post Hoc Tests 
 
 
 
 
Supplement 
 
 
 
Multiple Comparisons 
Measure:   Bodyfat   
Bonferroni   
(I) Supplement (J) Supplement 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -1.8257 3.80557 1.000 -11.7253 8.0739 
3.00 3.6045 4.05334 1.000 -6.9397 14.1486 
2.00 1.00 1.8257 3.80557 1.000 -8.0739 11.7253 
3.00 5.4302 3.94685 .550 -4.8370 15.6973 
3.00 1.00 -3.6045 4.05334 1.000 -14.1486 6.9397 
2.00 -5.4302 3.94685 .550 -15.6973 4.8370 
Based on observed means. 
 The error term is Mean Square(Error) = 61.337. 
 
 
 
General Linear Model 
 
 
 
Within-Subjects Factors 
Measure:   LeanMass   
time 
Dependent 
Variable 
1 LeanPre 
2 LeanPost 
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Between-Subjects Factors 
 N 
Supplement 1.00 8 
2.00 9 
3.00 7 
 
 
Descriptive Statistics 
 
Supplement Mean Std. Deviation N 
LeanPre 1.00 63.6250 10.56703 8 
2.00 60.1444 8.31897 9 
3.00 65.0000 8.85344 7 
Total 62.7208 9.10857 24 
LeanPost 1.00 63.9375 11.90725 8 
2.00 58.7222 8.59284 9 
3.00 64.7143 9.33746 7 
Total 62.2083 9.96419 24 
 
 
Multivariate Testsa 
Effect Value F 
Hypothesis 
df 
Error 
df Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powerc 
time Pillai's Trace .022 .471b 1.000 21.000 .500 .022 .471 .101 
Wilks' Lambda .978 .471b 1.000 21.000 .500 .022 .471 .101 
Hotelling's 
Trace 
.022 .471b 1.000 21.000 .500 .022 .471 .101 
Roy's Largest 
Root 
.022 .471b 1.000 21.000 .500 .022 .471 .101 
time * 
Supplement 
Pillai's Trace .055 .608b 2.000 21.000 .554 .055 1.216 .138 
Wilks' Lambda .945 .608b 2.000 21.000 .554 .055 1.216 .138 
Hotelling's 
Trace 
.058 .608b 2.000 21.000 .554 .055 1.216 .138 
Roy's Largest 
Root 
.058 .608b 2.000 21.000 .554 .055 1.216 .138 
a. Design: Intercept + Supplement  
 Within Subjects Design: time 
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b. Exact statistic 
c. Computed using alpha = .05 
 
 
Mauchly's Test of Sphericitya 
Measure:   LeanMass   
Within Subjects 
Effect 
Mauchly's 
W 
Approx. 
Chi-Square df Sig. 
Epsilonb 
Greenhous
e-Geisser 
Huynh-
Feldt 
Lower-
bound 
time 1.000 .000 0 . 1.000 1.000 1.000 
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed 
dependent variables is proportional to an identity matrix. 
a. Design: Intercept + Supplement  
 Within Subjects Design: time 
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected 
tests are displayed in the Tests of Within-Subjects Effects table. 
 
 
Tests of Within-Subjects Effects 
Measure:   LeanMass   
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
time Sphericity 
Assumed 
2.569 1 2.569 .471 .500 .022 .471 .101 
Greenhouse-
Geisser 
2.569 1.000 2.569 .471 .500 .022 .471 .101 
Huynh-Feldt 2.569 1.000 2.569 .471 .500 .022 .471 .101 
Lower-bound 2.569 1.000 2.569 .471 .500 .022 .471 .101 
time * 
Supplement 
Sphericity 
Assumed 
6.627 2 3.313 .608 .554 .055 1.216 .138 
Greenhouse-
Geisser 
6.627 2.000 3.313 .608 .554 .055 1.216 .138 
Huynh-Feldt 6.627 2.000 3.313 .608 .554 .055 1.216 .138 
Lower-bound 6.627 2.000 3.313 .608 .554 .055 1.216 .138 
Error(time) Sphericity 
Assumed 
114.466 21 5.451      
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Greenhouse-
Geisser 
114.466 
21.00
0 
5.451      
Huynh-Feldt 
114.466 
21.00
0 
5.451      
Lower-bound 
114.466 
21.00
0 
5.451      
a. Computed using alpha = .05 
 
 
Tests of Within-Subjects Contrasts 
Measure:   LeanMass   
Source time 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Paramete
r 
Observed 
Powera 
time Line
ar 
2.569 1 2.569 .471 .500 .022 .471 .101 
time * 
Supplement 
Line
ar 
6.627 2 3.313 .608 .554 .055 1.216 .138 
Error(time) Line
ar 
114.466 21 5.451      
a. Computed using alpha = .05 
 
 
Tests of Between-Subjects Effects 
Measure:   LeanMass   
Transformed Variable:   Average   
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
Intercept 
186669.853 1 186669.853 
1032.29
9 
.000 .980 1032.299 1.000 
Suppleme
nt 
273.271 2 136.636 .756 .482 .067 1.511 .161 
Error 
3797.414 21 180.829      
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a. Computed using alpha = .05 
 
 
1. Grand Mean 
Measure:   LeanMass   
Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
62.691 1.951 58.633 66.748 
 
 
Estimates 
Measure:   LeanMass   
Supplement Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 63.781 3.362 56.790 70.773 
2.00 59.433 3.170 52.842 66.025 
3.00 64.857 3.594 57.383 72.331 
 
 
Pairwise Comparisons 
Measure:   LeanMass   
(I) Supplement (J) Supplement 
Mean 
Difference (I-J) Std. Error Sig.a 
95% Confidence Interval for 
Differencea 
Lower Bound Upper Bound 
1.00 2.00 4.348 4.620 1.000 -7.671 16.367 
3.00 -1.076 4.921 1.000 -13.878 11.726 
2.00 1.00 -4.348 4.620 1.000 -16.367 7.671 
3.00 -5.424 4.792 .811 -17.889 7.042 
3.00 1.00 1.076 4.921 1.000 -11.726 13.878 
2.00 5.424 4.792 .811 -7.042 17.889 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Bonferroni. 
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Multivariate Tests 
 Value F 
Hypothesis 
df Error df Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powerb 
Pillai's trace .022 .471a 1.000 21.000 .500 .022 .471 .101 
Wilks' lambda .978 .471a 1.000 21.000 .500 .022 .471 .101 
Hotelling's 
trace 
.022 .471a 1.000 21.000 .500 .022 .471 .101 
Roy's largest 
root 
.022 .471a 1.000 21.000 .500 .022 .471 .101 
Each F tests the multivariate effect of time. These tests are based on the linearly independent pairwise comparisons 
among the estimated marginal means. 
a. Exact statistic 
b. Computed using alpha = .05 
 
 
4. Supplement * time 
Measure:   LeanMass   
Supplement time Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 1 63.625 3.278 56.807 70.443 
2 63.938 3.541 56.574 71.301 
2.00 1 60.144 3.091 53.717 66.572 
2 58.722 3.338 51.780 65.665 
3.00 1 65.000 3.505 57.712 72.288 
2 64.714 3.785 56.842 72.586 
 
 
 
 
Within-Subjects Factors 
Measure:   Fatmass   
time 
Dependent 
Variable 
1 FMPre 
2 FMPost 
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Between-Subjects Factors 
 N 
Supplement 1.00 8 
2.00 9 
3.00 7 
 
 
Descriptive Statistics 
 
Supplement Mean Std. Deviation N 
FMPre 1.00 11.1625 4.88202 8 
2.00 11.4778 6.77104 9 
3.00 7.9714 4.11733 7 
Total 10.3500 5.48381 24 
FMPost 1.00 11.4625 6.24864 8 
2.00 12.7111 8.23323 9 
3.00 8.3286 3.92756 7 
Total 11.0167 6.54806 24 
 
 
Multivariate Testsa 
Effect Value F 
Hypothesis 
df 
Error 
df Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powerc 
time Pillai's Trace .101 2.347b 1.000 21.000 .140 .101 2.347 .310 
Wilks' Lambda .899 2.347b 1.000 21.000 .140 .101 2.347 .310 
Hotelling's 
Trace 
.112 2.347b 1.000 21.000 .140 .101 2.347 .310 
Roy's Largest 
Root 
.112 2.347b 1.000 21.000 .140 .101 2.347 .310 
time * 
Supplement 
Pillai's Trace .052 .577b 2.000 21.000 .570 .052 1.154 .133 
Wilks' Lambda .948 .577b 2.000 21.000 .570 .052 1.154 .133 
Hotelling's 
Trace 
.055 .577b 2.000 21.000 .570 .052 1.154 .133 
Roy's Largest 
Root 
.055 .577b 2.000 21.000 .570 .052 1.154 .133 
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a. Design: Intercept + Supplement  
 Within Subjects Design: time 
b. Exact statistic 
c. Computed using alpha = .05 
 
 
Mauchly's Test of Sphericitya 
Measure:   Fatmass   
Within Subjects 
Effect 
Mauchly's 
W 
Approx. Chi-
Square df Sig. 
Epsilonb 
Greenhouse-
Geisser 
Huynh-
Feldt 
Lower-
bound 
time 1.000 .000 0 . 1.000 1.000 1.000 
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables 
is proportional to an identity matrix. 
a. Design: Intercept + Supplement  
 Within Subjects Design: time 
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are 
displayed in the Tests of Within-Subjects Effects table. 
 
 
Tests of Within-Subjects Effects 
Measure:   Fatmass   
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Paramet
er 
Observe
d Powera 
time Sphericity 
Assumed 
4.715 1 4.715 2.347 .140 .101 2.347 .310 
Greenhouse-
Geisser 
4.715 1.000 4.715 2.347 .140 .101 2.347 .310 
Huynh-Feldt 4.715 1.000 4.715 2.347 .140 .101 2.347 .310 
Lower-bound 4.715 1.000 4.715 2.347 .140 .101 2.347 .310 
time * 
Supplement 
Sphericity 
Assumed 
2.318 2 1.159 .577 .570 .052 1.154 .133 
Greenhouse-
Geisser 
2.318 2.000 1.159 .577 .570 .052 1.154 .133 
Huynh-Feldt 2.318 2.000 1.159 .577 .570 .052 1.154 .133 
Lower-bound 2.318 2.000 1.159 .577 .570 .052 1.154 .133 
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Error(time) Sphericity 
Assumed 
42.199 21 2.009      
Greenhouse-
Geisser 
42.199 
21.00
0 
2.009      
Huynh-Feldt 
42.199 
21.00
0 
2.009      
Lower-bound 
42.199 
21.00
0 
2.009      
a. Computed using alpha = .05 
 
 
Tests of Within-Subjects Contrasts 
Measure:   Fatmass   
Source time 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
time Linea
r 
4.715 1 4.715 2.347 .140 .101 2.347 .310 
time * 
Supplement 
Linea
r 
2.318 2 1.159 .577 .570 .052 1.154 .133 
Error(time) Linea
r 
42.199 21 2.009      
a. Computed using alpha = .05 
 
 
Tests of Between-Subjects Effects 
Measure:   Fatmass   
Transformed Variable:   Average   
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
Intercept 
5255.536 1 5255.536 73.514 .000 .778 73.514 1.000 
Suppleme
nt 
132.025 2 66.012 .923 .413 .081 1.847 .188 
Error 
1501.292 21 71.490      
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a. Computed using alpha = .05 
 
 
1. Grand Mean 
Measure:   Fatmass   
Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
10.519 1.227 7.968 13.070 
 
 
2. Supplement 
 
 
 
Estimates 
Measure:   Fatmass   
Supplement Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 11.313 2.114 6.917 15.708 
2.00 12.094 1.993 7.950 16.239 
3.00 8.150 2.260 3.451 12.849 
 
 
Pairwise Comparisons 
Measure:   Fatmass   
(I) Supplement (J) Supplement 
Mean Difference 
(I-J) Std. Error Sig.a 
95% Confidence Interval for 
Differencea 
Lower Bound Upper Bound 
1.00 2.00 -.782 2.905 1.000 -8.339 6.775 
3.00 3.162 3.094 .955 -4.887 11.212 
2.00 1.00 .782 2.905 1.000 -6.775 8.339 
3.00 3.944 3.013 .614 -3.893 11.782 
3.00 1.00 -3.162 3.094 .955 -11.212 4.887 
2.00 -3.944 3.013 .614 -11.782 3.893 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Bonferroni. 
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Univariate Tests 
Measure:   Fatmass   
 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
Contrast 66.012 2 33.006 .923 .413 .081 1.847 .188 
Error 750.646 21 35.745      
The F tests the effect of Supplement. This test is based on the linearly independent pairwise comparisons among the 
estimated marginal means. 
a. Computed using alpha = .05 
 
 
Estimates 
Measure:   Fatmass   
time Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
1 10.204 1.129 7.857 12.551 
2 10.834 1.349 8.028 13.640 
 
 
Pairwise Comparisons 
Measure:   Fatmass   
(I) time (J) time 
Mean Difference 
(I-J) Std. Error Sig.a 
95% Confidence Interval for 
Differencea 
Lower Bound Upper Bound 
1 2 -.630 .411 .140 -1.486 .225 
2 1 .630 .411 .140 -.225 1.486 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Bonferroni. 
 
 
Multivariate Tests 
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 Value F 
Hypothesis 
df Error df Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powerb 
Pillai's trace 
.101 2.347a 1.000 21.000 .140 .101 2.347 .310 
Wilks' lambda 
.899 2.347a 1.000 21.000 .140 .101 2.347 .310 
Hotelling's 
trace 
.112 2.347a 1.000 21.000 .140 .101 2.347 .310 
Roy's largest 
root 
.112 2.347a 1.000 21.000 .140 .101 2.347 .310 
Each F tests the multivariate effect of time. These tests are based on the linearly independent pairwise 
comparisons among the estimated marginal means. 
a. Exact statistic 
b. Computed using alpha = .05 
 
 
4. Supplement * time 
Measure:   Fatmass   
Supplement time Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 1 11.163 1.945 7.118 15.207 
2 11.462 2.325 6.627 16.298 
2.00 1 11.478 1.833 7.665 15.291 
2 12.711 2.192 8.152 17.270 
3.00 1 7.971 2.079 3.648 12.295 
2 8.329 2.486 3.160 13.498 
 
 
 
General Linear Model 
 
 
 
Within-Subjects Factors 
Measure:   TBW   
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time 
Dependent 
Variable 
1 TBWPre 
2 TBWPost 
 
 
Between-Subjects Factors 
 N 
Supplement 1.00 6 
2.00 7 
3.00 6 
 
 
Descriptive Statistics 
 
Supplement Mean Std. Deviation N 
TBWPre 1.00 42.2667 7.73218 6 
2.00 36.0143 6.20227 7 
3.00 40.5000 6.44267 6 
Total 39.4053 6.96854 19 
TBWPost 1.00 40.5167 8.48656 6 
2.00 36.5714 5.91882 7 
3.00 40.0500 6.19540 6 
Total 38.9158 6.76505 19 
 
 
Multivariate Testsa 
Effect Value F 
Hypothesis 
df Error df Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powerc 
time Pillai's Trace .016 .264b 1.000 16.000 .615 .016 .264 .077 
Wilks' Lambda .984 .264b 1.000 16.000 .615 .016 .264 .077 
Hotelling's 
Trace 
.016 .264b 1.000 16.000 .615 .016 .264 .077 
Roy's Largest 
Root 
.016 .264b 1.000 16.000 .615 .016 .264 .077 
Pillai's Trace .048 .400b 2.000 16.000 .677 .048 .800 .104 
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time * 
Supplement 
Wilks' Lambda .952 .400b 2.000 16.000 .677 .048 .800 .104 
Hotelling's 
Trace 
.050 .400b 2.000 16.000 .677 .048 .800 .104 
Roy's Largest 
Root 
.050 .400b 2.000 16.000 .677 .048 .800 .104 
a. Design: Intercept + Supplement  
 Within Subjects Design: time 
b. Exact statistic 
c. Computed using alpha = .05 
 
 
Mauchly's Test of Sphericitya 
Measure:   TBW   
Within Subjects 
Effect Mauchly's W 
Approx. Chi-
Square df Sig. 
Epsilonb 
Greenhouse-
Geisser Huynh-Feldt Lower-bound 
time 1.000 .000 0 . 1.000 1.000 1.000 
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is 
proportional to an identity matrix. 
a. Design: Intercept + Supplement  
 Within Subjects Design: time 
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in 
the Tests of Within-Subjects Effects table. 
 
 
Tests of Within-Subjects Effects 
Measure:   TBW   
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
time Sphericity 
Assumed 
2.834 1 2.834 .264 .615 .016 .264 .077 
Greenhouse-
Geisser 
2.834 1.000 2.834 .264 .615 .016 .264 .077 
Huynh-Feldt 2.834 1.000 2.834 .264 .615 .016 .264 .077 
Lower-bound 2.834 1.000 2.834 .264 .615 .016 .264 .077 
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time * 
Supplement 
Sphericity 
Assumed 
8.605 2 4.303 .400 .677 .048 .800 .104 
Greenhouse-
Geisser 
8.605 2.000 4.303 .400 .677 .048 .800 .104 
Huynh-Feldt 8.605 2.000 4.303 .400 .677 .048 .800 .104 
Lower-bound 8.605 2.000 4.303 .400 .677 .048 .800 .104 
Error(time) Sphericity 
Assumed 
172.064 16 10.754      
Greenhouse-
Geisser 
172.064 16.000 10.754      
Huynh-Feldt 172.064 16.000 10.754      
Lower-bound 172.064 16.000 10.754      
a. Computed using alpha = .05 
 
 
Tests of Within-Subjects Contrasts 
Measure:   TBW   
Source time 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
time Linear 2.834 1 2.834 .264 .615 .016 .264 .077 
time * 
Supplement 
Linear 
8.605 2 4.303 .400 .677 .048 .800 .104 
Error(time) Linear 172.064 16 10.754      
a. Computed using alpha = .05 
 
 
Tests of Between-Subjects Effects 
Measure:   TBW   
Transformed Variable:   Average   
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
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Intercept 
58440.687 1 58440.687 704.404 .000 .978 704.404 1.000 
Supplement 
189.770 2 94.885 1.144 .343 .125 2.287 .216 
Error 
1327.436 16 82.965      
a. Computed using alpha = .05 
 
 
General Linear Model 
 
 
 
Within-Subjects Factors 
Measure:   Intra   
time 
Dependent 
Variable 
1 IntraPre 
2 IntraPost 
 
 
Between-Subjects Factors 
 N 
Supplement 1.00 6 
2.00 7 
3.00 6 
 
 
Descriptive Statistics 
 
Supplement Mean Std. Deviation N 
IntraPre 1.00 24.0000 4.76151 6 
2.00 19.9143 4.83991 7 
3.00 23.2500 4.32516 6 
Total 22.2579 4.77264 19 
IntraPost 1.00 22.8833 5.50833 6 
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2.00 20.1000 4.36310 7 
3.00 23.3333 3.43725 6 
Total 22.0000 4.50691 19 
 
 
Multivariate Testsa 
Effect Value F 
Hypothesis 
df Error df Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powerc 
time Pillai's Trace .010 .167b 1.000 16.000 .688 .010 .167 .067 
Wilks' Lambda .990 .167b 1.000 16.000 .688 .010 .167 .067 
Hotelling's 
Trace 
.010 .167b 1.000 16.000 .688 .010 .167 .067 
Roy's Largest 
Root 
.010 .167b 1.000 16.000 .688 .010 .167 .067 
time * 
Supplement 
Pillai's Trace .043 .361b 2.000 16.000 .703 .043 .722 .098 
Wilks' Lambda .957 .361b 2.000 16.000 .703 .043 .722 .098 
Hotelling's 
Trace 
.045 .361b 2.000 16.000 .703 .043 .722 .098 
Roy's Largest 
Root 
.045 .361b 2.000 16.000 .703 .043 .722 .098 
a. Design: Intercept + Supplement  
 Within Subjects Design: time 
b. Exact statistic 
c. Computed using alpha = .05 
 
 
Mauchly's Test of Sphericitya 
Measure:   Intra   
Within Subjects Effect Mauchly's W 
Approx. Chi-
Square df Sig. 
Epsilonb 
Greenhouse-
Geisser Huynh-Feldt Lower-bound 
time 1.000 .000 0 . 1.000 1.000 1.000 
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is 
proportional to an identity matrix. 
a. Design: Intercept + Supplement  
 Within Subjects Design: time 
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b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the 
Tests of Within-Subjects Effects table. 
 
 
Tests of Within-Subjects Effects 
Measure:   Intra   
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
time Sphericity 
Assumed 
.754 1 .754 .167 .688 .010 .167 .067 
Greenhouse-
Geisser 
.754 1.000 .754 .167 .688 .010 .167 .067 
Huynh-Feldt .754 1.000 .754 .167 .688 .010 .167 .067 
Lower-bound .754 1.000 .754 .167 .688 .010 .167 .067 
time * 
Supplement 
Sphericity 
Assumed 
3.251 2 1.625 .361 .703 .043 .722 .098 
Greenhouse-
Geisser 
3.251 2.000 1.625 .361 .703 .043 .722 .098 
Huynh-Feldt 3.251 2.000 1.625 .361 .703 .043 .722 .098 
Lower-bound 3.251 2.000 1.625 .361 .703 .043 .722 .098 
Error(time) Sphericity 
Assumed 
72.083 16 4.505      
Greenhouse-
Geisser 
72.083 16.000 4.505      
Huynh-Feldt 72.083 16.000 4.505      
Lower-bound 72.083 16.000 4.505      
a. Computed using alpha = .05 
 
 
Tests of Within-Subjects Contrasts 
Measure:   Intra   
Source time 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
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time Linear .754 1 .754 .167 .688 .010 .167 .067 
time * 
Supplement 
Linear 
3.251 2 1.625 .361 .703 .043 .722 .098 
Error(time) Linear 72.083 16 4.505      
a. Computed using alpha = .05 
 
 
Tests of Between-Subjects Effects 
Measure:   Intra   
Transformed Variable:   Average   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
Intercept 18708.023 1 18708.023 498.579 .000 .969 498.579 1.000 
Supplement 99.931 2 49.965 1.332 .292 .143 2.663 .246 
Error 600.363 16 37.523      
a. Computed using alpha = .05 
 
 
General Linear Model 
 
 
 
Within-Subjects Factors 
Measure:   MEASURE_1   
time 
Dependent 
Variable 
1 ExtraPre 
2 ExtraPost 
 
 
Between-Subjects Factors 
 N 
Group 1 6 
2 7 
3 6 
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Multivariate Testsa 
Effect Value F Hypothesis df Error df Sig. 
time Pillai's Trace .074 1.275b 1.000 16.000 .275 
Wilks' Lambda .926 1.275b 1.000 16.000 .275 
Hotelling's Trace .080 1.275b 1.000 16.000 .275 
Roy's Largest Root .080 1.275b 1.000 16.000 .275 
time * Group Pillai's Trace .355 4.395b 2.000 16.000 .030 
Wilks' Lambda .645 4.395b 2.000 16.000 .030 
Hotelling's Trace .549 4.395b 2.000 16.000 .030 
Roy's Largest Root .549 4.395b 2.000 16.000 .030 
a. Design: Intercept + Group  
 Within Subjects Design: time 
b. Exact statistic 
 
 
Mauchly's Test of Sphericitya 
Measure:   MEASURE_1   
Within Subjects 
Effect Mauchly's W 
Approx. Chi-
Square df Sig. 
Epsilonb 
Greenhouse-
Geisser Huynh-Feldt Lower-bound 
time 
1.000 .000 0 . 1.000 1.000 1.000 
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is 
proportional to an identity matrix. 
a. Design: Intercept + Group  
 Within Subjects Design: time 
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in 
the Tests of Within-Subjects Effects table. 
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Tests of Within-Subjects Effects 
Measure:   MEASURE_1   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
time Sphericity Assumed .447 1 .447 1.275 .275 
Greenhouse-Geisser .447 1.000 .447 1.275 .275 
Huynh-Feldt .447 1.000 .447 1.275 .275 
Lower-bound .447 1.000 .447 1.275 .275 
time * Group Sphericity Assumed 3.081 2 1.540 4.395 .030 
Greenhouse-Geisser 3.081 2.000 1.540 4.395 .030 
Huynh-Feldt 3.081 2.000 1.540 4.395 .030 
Lower-bound 3.081 2.000 1.540 4.395 .030 
Error(time) Sphericity Assumed 5.608 16 .350   
Greenhouse-Geisser 5.608 16.000 .350   
Huynh-Feldt 5.608 16.000 .350   
Lower-bound 5.608 16.000 .350   
 
 
Tests of Within-Subjects Contrasts 
Measure:   MEASURE_1   
Source time 
Type III Sum of 
Squares df Mean Square F Sig. 
time Linear .447 1 .447 1.275 .275 
time * Group Linear 3.081 2 1.540 4.395 .030 
Error(time) Linear 5.608 16 .350   
 
 
Tests of Between-Subjects Effects 
Measure:   MEASURE_1   
Transformed Variable:   Average   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Intercept 10695.905 1 10695.905 746.170 .000 
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Group 6.502 2 3.251 .227 .800 
Error 229.350 16 14.334   
 
 
 
Within-Subjects Factors 
   
Measure: IsometricTQ_Norm 
   
Time 
Dependent 
Variable    
1 Pre_IsometricTQ
_Norm 
   
2 Post_IsomericT
Q_Norm 
   
     
Between-Subjects Factors 
 
  
Value 
Label N  
Supplement 1.00 MagnaPo
wer 
7 
 
2.00 Creatine 
Monohyd
rate 
8 
 
3.00 Placebo 8 
 
     
Descriptive Statistics 
Supplement Mean 
Std. 
Deviatio
n N 
Pre_IsometricT
Q_Norm 
MagnaPower 313.1199 85.30822 7 
Creatine 
Monohydrate 
331.9734 78.66844 8 
Placebo 307.4790 43.53621 8 
Total 317.7156 68.37937 23 
Post_IsomericT
Q_Norm 
MagnaPower 322.6330 76.82159 7 
Creatine 
Monohydrate 
326.6052 81.94821 8 
Placebo 331.1936 48.87351 8 
Total 326.9923 67.22205 23 
     
Box's Test of Equality of 
Covariance Matricesa 
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Box's M 5.041 
   
F .717 
   
df1 6 
   
df2 8714.141 
   
Sig. .636 
   
Tests the null hypothesis that the 
observed covariance matrices of the 
dependent variables are equal 
across groups. 
   
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
 
 
   
Multivariate Testsa 
Effect Value F 
Hypoth
esis df Error df Sig. 
Parti
al 
Eta 
Squa
red 
Nonce
nt. 
Param
eter 
Obser
ved 
Power
c 
Time Pillai's Trace .057 1.21
6b 
1.000 20.000 .283 .057 1.216 .183 
Wilks' 
Lambda 
.943 1.21
6b 
1.000 20.000 .283 .057 1.216 .183 
Hotelling's 
Trace 
.061 1.21
6b 
1.000 20.000 .283 .057 1.216 .183 
Roy's Largest 
Root 
.061 1.21
6b 
1.000 20.000 .283 .057 1.216 .183 
Time * Supplement Pillai's Trace .094 1.04
2b 
2.000 20.000 .371 .094 2.083 .206 
Wilks' 
Lambda 
.906 1.04
2b 
2.000 20.000 .371 .094 2.083 .206 
Hotelling's 
Trace 
.104 1.04
2b 
2.000 20.000 .371 .094 2.083 .206 
Roy's Largest 
Root 
.104 1.04
2b 
2.000 20.000 .371 .094 2.083 .206 
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
b. Exact statistic 
c. Computed using alpha = .05 
          
Mauchly's Test of Sphericitya 
  
Measure: IsometricTQ_Norm 
  
Within Subjects Effect Mauchly's W df Sig. Epsilonb   
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Approx. 
Chi-
Square 
Greenho
use-
Geisser 
Huy
nh-
Feldt 
Low
er-
boun
d   
Time 1.000 0.000 0   1.000 1.00
0 
1.00
0   
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed 
dependent variables is proportional to an identity matrix. 
  
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
  
b. May be used to adjust the degrees of freedom for the averaged tests of significance. 
Corrected tests are displayed in the Tests of Within-Subjects Effects table. 
  
 
 
Tests of Within-Subjects Effects 
Measure: IsometricTQ_Norm 
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
Time Sphericity 
Assumed 
987.831 1 987.831 1.216 .283 .057 1.216 .183 
Greenhouse-
Geisser 
987.831 1.000 987.831 1.216 .283 .057 1.216 .183 
Huynh-Feldt 987.831 1.000 987.831 1.216 .283 .057 1.216 .183 
Lower-bound 987.831 1.000 987.831 1.216 .283 .057 1.216 .183 
Time * Supplement Sphericity 
Assumed 
1691.902 2 845.951 1.042 .371 .094 2.083 .206 
Greenhouse-
Geisser 
1691.902 2.000 845.951 1.042 .371 .094 2.083 .206 
Huynh-Feldt 1691.902 2.000 845.951 1.042 .371 .094 2.083 .206 
Lower-bound 1691.902 2.000 845.951 1.042 .371 .094 2.083 .206 
Error(Time) Sphericity 
Assumed 
16242.746 20 812.137           
Greenhouse-
Geisser 
16242.746 20.000 812.137           
Huynh-Feldt 16242.746 20.000 812.137           
Lower-bound 16242.746 20.000 812.137           
a. Computed using alpha = .05 
          
Tests of Within-Subjects Contrasts 
Measure: IsometricTQ_Norm 
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
Time Linear 987.831 1 987.831 1.216 .283 .057 1.216 .183 
Time * Supplement Linear 1691.902 2 845.951 1.042 .371 .094 2.083 .206 
Error(Time) Linear 16242.746 20 812.137           
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a. Computed using alpha = .05 
          
Levene's Test of Equality of Error Variancesa 
     
  F df1 df2 Sig.      
Pre_IsometricTQ_Norm 1.991 2 20 .163 
     
Post_IsomericTQ_Norm 1.449 2 20 .258 
     
Tests the null hypothesis that the error variance of the dependent variable is 
equal across groups. 
     
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
     
 
Tests of Between-Subjects Effects 
 
Measure: IsometricTQ_Norm  
 Transformed Variable: Average 
 
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera  
Intercept 4755552.090 1 4755552.090 519.309 .000 .963 519.309 1.000 
 
Supplement 1195.950 2 597.975 .065 .937 .006 .131 .059 
 
Error 183149.333 20 9157.467           
 
a. Computed using alpha = .05 
 
          
          
Estimated Marginal Means         
          
1. Grand Mean 
      
Measure: IsometricTQ_Norm 
      
Mean Std. Error 
95% Confidence Interval       
Lower 
Bound Upper Bound       
322.167 14.137 292.677 351.657 
      
          
2. Supplement 
     
Measure: IsometricTQ_Norm 
     
Supplement Mean 
Std. 
Error 
95% Confidence Interval      
Lower Bound 
Upper 
Bound      
MagnaPower 317.876 25.575 264.527 371.226 
     
Creatine 
Monohydrate 
329.289 23.924 279.385 379.193 
     
Placebo 319.336 23.924 269.432 369.240 
     
          
3. Time 
     
Measure: IsometricTQ_Norm 
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Time Mean 
Std. 
Error 
95% Confidence Interval      
Lower Bound 
Upper 
Bound      
1 317.524 14.792 286.668 348.380 
     
2 326.811 14.710 296.127 357.494 
     
          
          
4. Supplement * Time         
          
Estimates 
    
Measure: IsometricTQ_Norm 
    
Supplement Mean Std. Error 
95% Confidence Interval     
Lower 
Bound 
Upper 
Bound     
MagnaPower 1 313.120 26.760 257.300 368.940 
    
2 322.633 26.611 267.124 378.142 
    
Creatine 
Monohydrate 
1 331.973 25.032 279.758 384.189 
    
2 326.605 24.892 274.681 378.529 
    
Placebo 1 307.479 25.032 255.264 359.694 
    
2 331.194 24.892 279.270 383.118 
    
          
Pairwise Comparisons 
  
Measure: IsometricTQ_Norm 
  
Supplement 
Mean 
Difference (I-J) Std. Error Sig.a 
95% Confidence Interval 
for Differencea   
Lower 
Bound 
Upper 
Bound   
MagnaPower 1 2 -9.513 15.233 .539 -41.288 22.262 
  
2 1 9.513 15.233 .539 -22.262 41.288 
  
Creatine 
Monohydrate 
1 2 5.368 14.249 .710 -24.355 35.091 
  
2 1 -5.368 14.249 .710 -35.091 24.355 
  
Placebo 1 2 -23.715 14.249 .112 -53.438 6.008 
  
2 1 23.715 14.249 .112 -6.008 53.438 
  
Based on estimated marginal means 
  
a. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
  
          
Multivariate Tests 
Supplement Value F 
Hypothesis 
df Error df Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powerb 
MagnaPower Pillai's trace .019 .390a 1.000 20.000 .539 .019 .390 .091 
Wilks' lambda .981 .390a 1.000 20.000 .539 .019 .390 .091 
Hotelling's trace .020 .390a 1.000 20.000 .539 .019 .390 .091 
Roy's largest 
root 
.020 .390a 1.000 20.000 .539 .019 .390 .091 
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Creatine 
Monohydrate 
Pillai's trace .007 .142a 1.000 20.000 .710 .007 .142 .065 
Wilks' lambda .993 .142a 1.000 20.000 .710 .007 .142 .065 
Hotelling's trace .007 .142a 1.000 20.000 .710 .007 .142 .065 
Roy's largest 
root 
.007 .142a 1.000 20.000 .710 .007 .142 .065 
Placebo Pillai's trace .122 2.770a 1.000 20.000 .112 .122 2.770 .354 
Wilks' lambda .878 2.770a 1.000 20.000 .112 .122 2.770 .354 
Hotelling's trace .138 2.770a 1.000 20.000 .112 .122 2.770 .354 
Roy's largest 
root 
.138 2.770a 1.000 20.000 .112 .122 2.770 .354 
Each F tests the multivariate simple effects of Time within each level combination of the other effects shown. These tests are based on the linearly independent 
pairwise comparisons among the estimated marginal means. 
a. Exact statistic 
b. Computed using alpha = .05 
 
General Linear Model         
          
          
[DataSet0] U:\Thesis_Data.sav         
          
Within-Subjects Factors 
        
Measure: Iso_TQ_60_Deg_Normalized 
        
Time Dependent Variable         
1 Pre_Iso_TQ_60_Deg_Norm
alized 
        
2 Post_Iso_TQ_60_Deg_Nor
malized 
        
          
Between-Subjects Factors 
      
  
Value 
Label N       
Supplement 1.00 Creatine-
elec 
7 
      
2.00 Creatine 
Monohydr
ate 
8 
      
3.00 Placebo 8 
      
          
Descriptive Statistics 
     
Supplement Mean 
Std. 
Deviation N      
Creatine-Electrolyte 252.9774 67.59765 7 
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Pre_Iso_TQ_60_Deg_Norm
alized 
Creatine Monohydrate 281.0498 94.40025 8 
     
Placebo 278.1452 31.28203 8 
     
Total 271.4957 67.46410 23 
     
Post_Iso_TQ_60_Deg_Nor
malized 
Creatine-Electrolyte 280.1186 51.62622 7 
     
Creatine Monohydrate 259.2855 78.44810 8 
     
Placebo 271.6258 47.76101 8 
     
Total 269.9183 59.04322 23 
     
          
Box's Test of Equality of Covariance Matricesa 
        
Box's M 9.200 
        
F 1.309 
        
df1 6 
        
df2 8714.141 
        
Sig. .249 
        
Tests the null hypothesis that the observed covariance 
matrices of the dependent variables are equal across groups. 
        
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
        
          
Multivariate Testsa 
Effect Value F 
Hypothe
sis df Error df Sig. 
Partial 
Eta 
Square
d 
Noncen
t. 
Parame
ter 
Observ
ed 
Powerc 
Time Pillai's Trace .000 .002b 1.000 20.000 .965 .000 .002 .050 
Wilks' Lambda 1.000 .002b 1.000 20.000 .965 .000 .002 .050 
Hotelling's Trace .000 .002b 1.000 20.000 .965 .000 .002 .050 
Roy's Largest Root .000 .002b 1.000 20.000 .965 .000 .002 .050 
Time * Supplement Pillai's Trace .213 2.704b 2.000 20.000 .091 .213 5.408 .474 
Wilks' Lambda .787 2.704b 2.000 20.000 .091 .213 5.408 .474 
Hotelling's Trace .270 2.704b 2.000 20.000 .091 .213 5.408 .474 
Roy's Largest Root .270 2.704b 2.000 20.000 .091 .213 5.408 .474 
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a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
b. Exact statistic 
c. Computed using alpha = .05 
          
Mauchly's Test of Sphericitya 
  
Measure: Iso_TQ_60_Deg_Normalized 
  
Within Subjects Effect Mauchly's W 
Approx. 
Chi-
Square df Sig. 
Epsilonb   
Greenhou
se-
Geisser 
Huyn
h-
Feldt 
Lower-
bound   
Time 1.000 0.000 0   1.000 1.000 1.000 
  
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional to an 
identity matrix. 
  
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
  
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the Tests of Within-
Subjects Effects table. 
  
          
Tests of Within-Subjects Effects 
Measure: Iso_TQ_60_Deg_Normalized 
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Square
d 
Noncen
t. 
Parame
ter 
Observ
ed 
Powera 
Time Sphericity Assumed 1.662 1 1.662 .002 .965 .000 .002 .050 
Greenhouse-Geisser 1.662 1.000 1.662 .002 .965 .000 .002 .050 
Huynh-Feldt 1.662 1.000 1.662 .002 .965 .000 .002 .050 
Lower-bound 1.662 1.000 1.662 .002 .965 .000 .002 .050 
Time * Supplement Sphericity Assumed 4614.388 2 2307.19
4 
2.704 .091 .213 5.408 .474 
Greenhouse-Geisser 4614.388 2.000 2307.19
4 
2.704 .091 .213 5.408 .474 
Huynh-Feldt 4614.388 2.000 2307.19
4 
2.704 .091 .213 5.408 .474 
Lower-bound 4614.388 2.000 2307.19
4 
2.704 .091 .213 5.408 .474 
Error(Time) Sphericity Assumed 17066.053 20 853.303           
Greenhouse-Geisser 17066.053 20.000 853.303           
Huynh-Feldt 17066.053 20.000 853.303           
Lower-bound 17066.053 20.000 853.303           
a. Computed using alpha = .05 
          
Tests of Within-Subjects Contrasts 
Measure: Iso_TQ_60_Deg_Normalized 
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Square
d 
Noncen
t. 
Parame
ter 
Observ
ed 
Powera 
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Time Linear 1.662 1 1.662 .002 .965 .000 .002 .050 
Time * Supplement Linear 4614.388 2 2307.19
4 
2.704 .091 .213 5.408 .474 
Error(Time) Linear 17066.053 20 853.303           
a. Computed using alpha = .05 
          
Levene's Test of Equality of Error Variancesa 
     
  F df1 df2 Sig.      
Pre_Iso_TQ_60_Deg_Norm
alized 
4.318 2 20 .028 
     
Post_Iso_TQ_60_Deg_Nor
malized 
1.700 2 20 .208 
     
Tests the null hypothesis that the error variance of the dependent variable is equal across groups. 
     
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
     
          
Tests of Between-Subjects Effects 
 
Measure: Iso_TQ_60_Deg_Normalized  
 Transformed Variable: Average 
 
Source Type III Sum of Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squar
ed 
Noncen
t. 
Parame
ter 
Observ
ed 
Powera  
Intercept 3353363.739 1 3353363.
739 
433.760 .000 .956 433.760 1.000 
 
Supplement 526.176 2 263.088 .034 .967 .003 .068 .054 
 
Error 154618.531 20 7730.927           
 
a. Computed using alpha = .05 
 
          
          
Estimated Marginal Means         
          
1. Time 
     
Measure: Iso_TQ_60_Deg_Normalized 
     
Time Mean Std. Error 
95% Confidence 
Interval      
Lower 
Bound 
Upper 
Bound      
1 270.724 14.524 240.428 301.020 
     
2 270.343 12.797 243.648 297.038 
     
          
          
2. Supplement * Time         
          
Estimates 
    
Measure: Iso_TQ_60_Deg_Normalized 
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Supplement Mean Std. Error 
95% Confidence 
Interval     
Lower 
Bound 
Upper 
Bound     
MagnaPower 1 252.977 26.274 198.170 307.784 
    
2 280.119 23.151 231.826 328.412 
    
Creatine Monohydrate 1 281.050 24.577 229.783 332.317 
    
2 259.285 21.656 214.112 304.459 
    
Placebo 1 278.145 24.577 226.878 329.412 
    
2 271.626 21.656 226.452 316.800 
    
          
Pairwise Comparisons 
  
Measure: Iso_TQ_60_Deg_Normalized 
  
Supplement 
Mean 
Differenc
e (I-J) 
Std. 
Error Sig.a 
95% Confidence 
Interval for 
Differencea   
Lower 
Boun
d 
Upper 
Bound   
MagnaPower 1 2 -27.141 15.614 .098 -
59.71
2 
5.429 
  
2 1 27.141 15.614 .098 -5.429 59.712 
  
Creatine Monohydrate 1 2 21.764 14.606 .152 -8.703 52.231 
  
2 1 -21.764 14.606 .152 -
52.23
1 
8.703 
  
Placebo 1 2 6.519 14.606 .660 -
23.94
8 
36.986 
  
2 1 -6.519 14.606 .660 -
36.98
6 
23.948 
  
Based on estimated marginal means 
  
a. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
  
          
Multivariate Tests 
Supplement Value F 
Hypothe
sis df Error df Sig. 
Partial 
Eta 
Square
d 
Noncen
t. 
Parame
ter 
Observ
ed 
Powerb 
MagnaPower Pillai's trace .131 3.021a 1.000 20.000 .098 .131 3.021 .380 
Wilks' lambda .869 3.021a 1.000 20.000 .098 .131 3.021 .380 
Hotelling's trace .151 3.021a 1.000 20.000 .098 .131 3.021 .380 
Roy's largest root .151 3.021a 1.000 20.000 .098 .131 3.021 .380 
Creatine Monohydrate Pillai's trace .100 2.220a 1.000 20.000 .152 .100 2.220 .295 
Wilks' lambda .900 2.220a 1.000 20.000 .152 .100 2.220 .295 
Hotelling's trace .111 2.220a 1.000 20.000 .152 .100 2.220 .295 
Roy's largest root .111 2.220a 1.000 20.000 .152 .100 2.220 .295 
Placebo Pillai's trace .010 .199a 1.000 20.000 .660 .010 .199 .071 
Wilks' lambda .990 .199a 1.000 20.000 .660 .010 .199 .071 
Hotelling's trace .010 .199a 1.000 20.000 .660 .010 .199 .071 
Roy's largest root .010 .199a 1.000 20.000 .660 .010 .199 .071 
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Each F tests the multivariate simple effects of Time within each level combination of the other effects shown. These tests are based on the linearly independent 
pairwise comparisons among the estimated marginal means. 
a. Exact statistic 
b. Computed using alpha = .05 
          
3. Grand Mean 
      
Measure: Iso_TQ_60_Deg_Normalized 
      
Mean Std. Error 
95% Confidence Interval       
Lower 
Bound 
Upper 
Bound       
270.534 12.990 243.438 297.630 
      
          
4. Supplement 
     
Measure: Iso_TQ_60_Deg_Normalized 
     
Supplement Mean Std. Error 
95% Confidence 
Interval      
Lower 
Bound 
Upper 
Bound      
MagnaPower 266.548 23.499 217.530 315.566 
     
Creatine Monohydrate 270.168 21.981 224.315 316.020 
     
Placebo 274.886 21.981 229.033 320.738 
     
          
          
 
 
Within-Subjects Factors 
        
Measure: Peak_Iso_TQ_180DEG_Norm 
        
Time Dependent Variable         
1 Pre_Iso_TQ_180DEG_N
orm 
        
2 Post_Iso_TQ_180Deg_N
orm 
        
          
Between-Subjects Factors 
      
  
Value 
Label N       
Supplement 1.00 MagnaPow
er 
7 
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2.00 Creatine 
Monohydra
te 
8 
      
3.00 Placebo 8 
      
          
Descriptive Statistics 
     
Supplement Mean 
Std. 
Deviation N      
Pre_Iso_TQ_180DEG_N
orm 
MagnaPower 164.0401 37.62234 7 
     
Creatine Monohydrate 172.5783 69.24952 8 
     
Placebo 164.6532 45.51666 8 
     
Total 167.2232 50.86375 23 
     
Post_Iso_TQ_180Deg_N
orm 
MagnaPower 196.6898 39.51707 7 
     
Creatine Monohydrate 168.6792 54.57855 8 
     
Placebo 181.8467 40.13433 8 
     
Total 181.7842 44.93726 23 
     
          
Box's Test of Equality of Covariance Matricesa 
        
Box's M 2.915 
        
F .415 
        
df1 6 
        
df2 8714.141 
        
Sig. .870 
        
Tests the null hypothesis that the observed covariance 
matrices of the dependent variables are equal across 
groups. 
        
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
        
          
Multivariate Testsa 
Effect Value F 
Hypothes
is df Error df Sig. 
Partial 
Eta 
Squared 
Noncent
. 
Paramet
er 
Observe
d 
Powerc 
Time Pillai's Trace .150 3.521b 1.000 20.000 .075 .150 3.521 .431 
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Wilks' Lambda .850 3.521b 1.000 20.000 .075 .150 3.521 .431 
Hotelling's Trace .176 3.521b 1.000 20.000 .075 .150 3.521 .431 
Roy's Largest Root .176 3.521b 1.000 20.000 .075 .150 3.521 .431 
Time * Supplement Pillai's Trace .143 1.662b 2.000 20.000 .215 .143 3.324 .308 
Wilks' Lambda .857 1.662b 2.000 20.000 .215 .143 3.324 .308 
Hotelling's Trace .166 1.662b 2.000 20.000 .215 .143 3.324 .308 
Roy's Largest Root .166 1.662b 2.000 20.000 .215 .143 3.324 .308 
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
b. Exact statistic 
c. Computed using alpha = .05 
          
Mauchly's Test of Sphericitya 
  
Measure: Peak_Iso_TQ_180DEG_Norm 
  
Within Subjects Effect Mauchly's W 
Approx. 
Chi-Square df Sig. 
Epsilonb   
Greenhous
e-Geisser 
Huynh
-Feldt 
Lower-
bound   
Time 1.000 0.000 0   1.000 1.000 1.000 
  
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional to an 
identity matrix. 
  
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
  
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the Tests of 
Within-Subjects Effects table. 
  
          
Tests of Within-Subjects Effects 
Measure: Peak_Iso_TQ_180DEG_Norm 
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Noncent
. 
Paramet
er 
Observe
d 
Powera 
Time Sphericity Assumed 2686.546 1 2686.546 3.521 .075 .150 3.521 .431 
Greenhouse-Geisser 2686.546 1.000 2686.546 3.521 .075 .150 3.521 .431 
Huynh-Feldt 2686.546 1.000 2686.546 3.521 .075 .150 3.521 .431 
Lower-bound 2686.546 1.000 2686.546 3.521 .075 .150 3.521 .431 
Time * Supplement Sphericity Assumed 2536.019 2 1268.010 1.662 .215 .143 3.324 .308 
Greenhouse-Geisser 2536.019 2.000 1268.010 1.662 .215 .143 3.324 .308 
Huynh-Feldt 2536.019 2.000 1268.010 1.662 .215 .143 3.324 .308 
Lower-bound 2536.019 2.000 1268.010 1.662 .215 .143 3.324 .308 
Error(Time) Sphericity Assumed 15258.783 20 762.939           
Greenhouse-Geisser 15258.783 20.000 762.939           
Huynh-Feldt 15258.783 20.000 762.939           
Lower-bound 15258.783 20.000 762.939           
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a. Computed using alpha = .05 
          
Tests of Within-Subjects Contrasts 
Measure: Peak_Iso_TQ_180DEG_Norm 
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Noncent
. 
Paramet
er 
Observe
d 
Powera 
Time Linear 2686.546 1 2686.546 3.521 .075 .150 3.521 .431 
Time * Supplement Linear 2536.019 2 1268.010 1.662 .215 .143 3.324 .308 
Error(Time) Linear 15258.783 20 762.939           
a. Computed using alpha = .05 
          
Levene's Test of Equality of Error Variancesa 
     
  F df1 df2 Sig.      
Pre_Iso_TQ_180DEG_N
orm 
.875 2 20 .432 
     
Post_Iso_TQ_180Deg_N
orm 
.610 2 20 .553 
     
Tests the null hypothesis that the error variance of the dependent variable is equal across groups. 
     
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
     
          
Tests of Between-Subjects Effects 
 
Measure: Peak_Iso_TQ_180DEG_Norm  
 Transformed Variable: Average 
 
Source Type III Sum of Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Square
d 
Noncent
. 
Paramet
er 
Observe
d 
Powera  
Intercept 1399141.793 1 1399141.7
93 
337.951 .000 .944 337.951 1.000 
 
Supplement 746.352 2 373.176 .090 .914 .009 .180 .062 
 
Error 82801.374 20 4140.069           
 
a. Computed using alpha = .05 
 
          
          
Estimated Marginal Means         
          
1. Grand Mean 
      
Measure: Peak_Iso_TQ_180DEG_Norm 
      
Mean Std. Error 
95% Confidence Interval       
Lower 
Bound 
Upper 
Bound       
174.748 9.506 154.919 194.576 
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2. Supplement 
     
Measure: Peak_Iso_TQ_180DEG_Norm 
     
Supplement Mean Std. Error 
95% Confidence 
Interval      
Lower 
Bound 
Upper 
Bound      
MagnaPower 180.365 17.196 144.494 216.236 
     
Creatine Monohydrate 170.629 16.086 137.074 204.183 
     
Placebo 173.250 16.086 139.695 206.804 
     
          
3. Time 
     
Measure: Peak_Iso_TQ_180DEG_Norm 
     
Time Mean Std. Error 
95% Confidence 
Interval      
Lower 
Bound 
Upper 
Bound      
1 167.091 11.111 143.914 190.267 
     
2 182.405 9.517 162.554 202.257 
     
          
          
4. Supplement * Time         
          
Estimates 
    
Measure: Peak_Iso_TQ_180DEG_Norm 
    
Supplement Mean Std. Error 
95% Confidence 
Interval     
Lower 
Bound 
Upper 
Bound     
MagnaPower 1 164.040 20.100 122.111 205.969 
    
2 196.690 17.216 160.777 232.603 
    
Creatine Monohydrate 1 172.578 18.802 133.358 211.799 
    
2 168.679 16.104 135.086 202.273 
    
Placebo 1 164.653 18.802 125.433 203.874 
    
2 181.847 16.104 148.253 215.440 
    
          
Pairwise Comparisons 
  
Measure: Peak_Iso_TQ_180DEG_Norm 
  
Supplement 
Mean 
Difference 
(I-J) 
Std. 
Error Sig.b 
95% Confidence 
Interval for 
Differenceb   
Lower 
Bound 
Upper 
Bound   
MagnaPower 1 2 -32.650* 14.764 .039 -
63.447 
-1.852 
  
2 1 32.650* 14.764 .039 1.852 63.447 
  
Creatine Monohydrate 1 2 3.899 13.811 .781 -
24.909 
32.708 
  
2 1 -3.899 13.811 .781 -
32.708 
24.909 
  
Placebo 1 2 -17.193 13.811 .228 -
46.002 
11.615 
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2 1 17.193 13.811 .228 -
11.615 
46.002 
  
Based on estimated marginal means 
  
*. The mean difference is significant at the .05 level. 
  
b. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
  
          
Multivariate Tests 
Supplement Value F 
Hypothes
is df Error df Sig. 
Partial 
Eta 
Squared 
Noncent
. 
Paramet
er 
Observe
d 
Powerb 
MagnaPower Pillai's trace .196 4.890a 1.000 20.000 .039 .196 4.890 .558 
Wilks' lambda .804 4.890a 1.000 20.000 .039 .196 4.890 .558 
Hotelling's trace .245 4.890a 1.000 20.000 .039 .196 4.890 .558 
Roy's largest root .245 4.890a 1.000 20.000 .039 .196 4.890 .558 
Creatine Monohydrate Pillai's trace .004 .080a 1.000 20.000 .781 .004 .080 .058 
Wilks' lambda .996 .080a 1.000 20.000 .781 .004 .080 .058 
Hotelling's trace .004 .080a 1.000 20.000 .781 .004 .080 .058 
Roy's largest root .004 .080a 1.000 20.000 .781 .004 .080 .058 
Placebo Pillai's trace .072 1.550a 1.000 20.000 .228 .072 1.550 .220 
Wilks' lambda .928 1.550a 1.000 20.000 .228 .072 1.550 .220 
Hotelling's trace .077 1.550a 1.000 20.000 .228 .072 1.550 .220 
Roy's largest root .077 1.550a 1.000 20.000 .228 .072 1.550 .220 
Each F tests the multivariate simple effects of Time within each level combination of the other effects shown. These tests are based on the linearly independent 
pairwise comparisons among the estimated marginal means. 
a. Exact statistic 
b. Computed using alpha = .05 
          
 
 
Within-Subjects Factors 
        
Measure: WLRatio_Set1 
        
Time Dependent Variable         
1 Pre_WLRatio_Set1 
        
2 Post_WLRatio_Set1 
        
          
Between-Subjects Factors 
      
  Value Label N       
Supplement 1.00 MagnaPower 7 
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2.00 Creatine 
Monohydrate 
8 
      
3.00 Placebo 8 
      
          
Descriptive Statistics 
     
Supplement Mean 
Std. 
Deviation N      
Pre_WLRatio_Set1 MagnaPower 1.6738 .26866 7 
     
Creatine 
Monohydrate 
1.8104 .21354 8 
     
Placebo 1.4915 .57230 8 
     
Total 1.6579 .39624 23 
     
Post_WLRatio_Set1 MagnaPower 1.8887 .36664 7 
     
Creatine 
Monohydrate 
1.7092 .33188 8 
     
Placebo 1.7180 .45487 8 
     
Total 1.7669 .37992 23 
     
          
Box's Test of Equality of Covariance 
Matricesa 
        
Box's M 11.146 
        
F 1.586 
        
df1 6 
        
df2 8714.141 
        
Sig. .147 
        
Tests the null hypothesis that the observed 
covariance matrices of the dependent 
variables are equal across groups. 
        
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
        
          
Multivariate Testsa 
Effect Value F 
Hypothesis 
df Error df Sig. 
Partial 
Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powerc 
Time Pillai's Trace .091 2.007b 1.000 20.000 .172 .091 2.007 .271 
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Wilks' Lambda .909 2.007b 1.000 20.000 .172 .091 2.007 .271 
Hotelling's Trace .100 2.007b 1.000 20.000 .172 .091 2.007 .271 
Roy's Largest Root .100 2.007b 1.000 20.000 .172 .091 2.007 .271 
Time * Supplement Pillai's Trace .156 1.847b 2.000 20.000 .184 .156 3.694 .339 
Wilks' Lambda .844 1.847b 2.000 20.000 .184 .156 3.694 .339 
Hotelling's Trace .185 1.847b 2.000 20.000 .184 .156 3.694 .339 
Roy's Largest Root .185 1.847b 2.000 20.000 .184 .156 3.694 .339 
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
b. Exact statistic 
c. Computed using alpha = .05 
          
Mauchly's Test of Sphericitya 
  
Measure: WLRatio_Set1 
  
Within Subjects 
Effect Mauchly's W 
Approx. Chi-
Square df Sig. 
Epsilonb   
Greenhouse-
Geisser 
Huynh-
Feldt 
Lower-
bound   
Time 1.000 0.000 0   1.000 1.000 1.000 
  
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional to an 
identity matrix. 
  
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
  
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the Tests of 
Within-Subjects Effects table. 
  
          
Tests of Within-Subjects Effects 
Measure: WLRatio_Set1 
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
Time Sphericity Assumed .147 1 .147 2.007 .172 .091 2.007 .271 
Greenhouse-Geisser .147 1.000 .147 2.007 .172 .091 2.007 .271 
Huynh-Feldt .147 1.000 .147 2.007 .172 .091 2.007 .271 
Lower-bound .147 1.000 .147 2.007 .172 .091 2.007 .271 
Time * Supplement Sphericity Assumed .271 2 .136 1.847 .184 .156 3.694 .339 
Greenhouse-Geisser .271 2.000 .136 1.847 .184 .156 3.694 .339 
Huynh-Feldt .271 2.000 .136 1.847 .184 .156 3.694 .339 
Lower-bound .271 2.000 .136 1.847 .184 .156 3.694 .339 
Error(Time) Sphericity Assumed 1.468 20 .073           
Greenhouse-Geisser 1.468 20.000 .073           
Huynh-Feldt 1.468 20.000 .073           
Lower-bound 1.468 20.000 .073           
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a. Computed using alpha = .05 
          
Tests of Within-Subjects Contrasts 
Measure: WLRatio_Set1 
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
Time Linear .147 1 .147 2.007 .172 .091 2.007 .271 
Time * Supplement Linear .271 2 .136 1.847 .184 .156 3.694 .339 
Error(Time) Linear 1.468 20 .073           
a. Computed using alpha = .05 
          
Levene's Test of Equality of Error Variancesa 
     
  F df1 df2 Sig.      
Pre_WLRatio_Set1 3.687 2 20 .043 
     
Post_WLRatio_Set1 .208 2 20 .814 
     
Tests the null hypothesis that the error variance of the dependent variable is equal across 
groups. 
     
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
     
          
Tests of Between-Subjects Effects 
 
Measure: WLRatio_Set1  
 Transformed Variable: Average 
 
Source 
Type III Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera  
Intercept 134.804 1 134.804 585.698 .000 .967 585.698 1.000 
 
Supplement .288 2 .144 .625 .545 .059 1.250 .140 
 
Error 4.603 20 .230           
 
a. Computed using alpha = .05 
 
          
          
Estimated Marginal Means         
          
1. Grand Mean 
      
Measure: WLRatio_Set1 
      
Mean Std. Error 
95% Confidence Interval       
Lower 
Bound 
Upper 
Bound       
1.715 .071 1.567 1.863 
      
          
2. Supplement 
     
Measure: WLRatio_Set1 
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Supplement Mean Std. Error 
95% Confidence Interval      
Lower 
Bound 
Upper 
Bound      
MagnaPower 1.781 .128 1.514 2.049 
     
Creatine 
Monohydrate 
1.760 .120 1.510 2.010 
     
Placebo 1.605 .120 1.355 1.855 
     
          
3. Time 
     
Measure: WLRatio_Set1 
     
Time Mean Std. Error 
95% Confidence Interval      
Lower 
Bound 
Upper 
Bound      
1 1.659 .082 1.489 1.829 
     
2 1.772 .081 1.602 1.941 
     
          
          
4. Supplement * Time         
          
Estimates 
    
Measure: WLRatio_Set1 
    
Supplement Mean Std. Error 
95% Confidence Interval     
Lower 
Bound 
Upper 
Bound     
MagnaPower 1 1.674 .147 1.366 1.981 
    
2 1.889 .147 1.582 2.195 
    
Creatine 
Monohydrate 
1 1.810 .138 1.523 2.098 
    
2 1.709 .138 1.422 1.996 
    
Placebo 1 1.492 .138 1.204 1.779 
    
2 1.718 .138 1.431 2.005 
    
          
Pairwise Comparisons 
  
Measure: WLRatio_Set1 
  
Supplement 
Mean 
Difference 
(I-J) Std. Error Sig.a 
95% Confidence 
Interval for 
Differencea   
Lower 
Bound 
Upper 
Bound   
MagnaPower 1 2 -.215 .145 .153 -.517 .087 
  
2 1 .215 .145 .153 -.087 .517 
  
Creatine 
Monohydrate 
1 2 .101 .135 .464 -.181 .384 
  
2 1 -.101 .135 .464 -.384 .181 
  
Placebo 1 2 -.226 .135 .110 -.509 .056 
  
2 1 .226 .135 .110 -.056 .509 
  
Based on estimated marginal means 
  
a. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
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Multivariate Tests 
Supplement Value F 
Hypothesis 
df Error df Sig. 
Partial 
Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powerb 
MagnaPower Pillai's trace .099 2.202a 1.000 20.000 .153 .099 2.202 .293 
Wilks' lambda .901 2.202a 1.000 20.000 .153 .099 2.202 .293 
Hotelling's trace .110 2.202a 1.000 20.000 .153 .099 2.202 .293 
Roy's largest root .110 2.202a 1.000 20.000 .153 .099 2.202 .293 
Creatine 
Monohydrate 
Pillai's trace .027 .558a 1.000 20.000 .464 .027 .558 .110 
Wilks' lambda .973 .558a 1.000 20.000 .464 .027 .558 .110 
Hotelling's trace .028 .558a 1.000 20.000 .464 .027 .558 .110 
Roy's largest root .028 .558a 1.000 20.000 .464 .027 .558 .110 
Placebo Pillai's trace .123 2.795a 1.000 20.000 .110 .123 2.795 .357 
Wilks' lambda .877 2.795a 1.000 20.000 .110 .123 2.795 .357 
Hotelling's trace .140 2.795a 1.000 20.000 .110 .123 2.795 .357 
Roy's largest root .140 2.795a 1.000 20.000 .110 .123 2.795 .357 
Each F tests the multivariate simple effects of Time within each level combination of the other effects shown. These tests are based on the linearly independent 
pairwise comparisons among the estimated marginal means. 
a. Exact statistic 
b. Computed using alpha = .05 
          
          
 
Within-Subjects Factors 
        
Measure: WLRatio_Set2 
        
Time Dependent Variable         
1 Pre_WLRatio_Set2 
        
2 Post_WLRatio_Set2 
        
          
Between-Subjects Factors 
      
  Value Label N       
Supplement 1.00 MagnaPower 7 
      
2.00 Creatine 
Monohydrate 
8 
      
3.00 Placebo 8 
      
          
Descriptive Statistics 
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Supplement Mean 
Std. 
Deviation N      
Pre_WLRatio_Set2 MagnaPower 2.2256 .40336 7 
     
Creatine 
Monohydrate 
2.3005 .40128 8 
     
Placebo 1.8955 .47153 8 
     
Total 2.1368 .44697 23 
     
Post_WLRatio_Set2 MagnaPower 2.1267 .20502 7 
     
Creatine 
Monohydrate 
1.9875 .54554 8 
     
Placebo 1.9106 .30256 8 
     
Total 2.0031 .37861 23 
     
          
Box's Test of Equality of Covariance 
Matricesa 
        
Box's M 7.402 
        
F 1.054 
        
df1 6 
        
df2 8714.141 
        
Sig. .388 
        
Tests the null hypothesis that the observed 
covariance matrices of the dependent 
variables are equal across groups. 
        
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
        
          
Multivariate Testsa 
Effect Value F 
Hypothesis 
df Error df Sig. 
Partial 
Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powerc 
Time Pillai's Trace .077 1.676b 1.000 20.000 .210 .077 1.676 .234 
Wilks' Lambda .923 1.676b 1.000 20.000 .210 .077 1.676 .234 
Hotelling's Trace .084 1.676b 1.000 20.000 .210 .077 1.676 .234 
Roy's Largest Root .084 1.676b 1.000 20.000 .210 .077 1.676 .234 
Time * Supplement Pillai's Trace .085 .925b 2.000 20.000 .413 .085 1.851 .187 
Wilks' Lambda .915 .925b 2.000 20.000 .413 .085 1.851 .187 
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Hotelling's Trace .093 .925b 2.000 20.000 .413 .085 1.851 .187 
Roy's Largest Root .093 .925b 2.000 20.000 .413 .085 1.851 .187 
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
b. Exact statistic 
c. Computed using alpha = .05 
          
Mauchly's Test of Sphericitya 
  
Measure: WLRatio_Set2 
  
Within Subjects 
Effect Mauchly's W 
Approx. Chi-
Square df Sig. 
Epsilonb   
Greenhouse-
Geisser 
Huynh-
Feldt 
Lower-
bound   
Time 1.000 0.000 0   1.000 1.000 1.000 
  
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional to an 
identity matrix. 
  
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
  
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the Tests of 
Within-Subjects Effects table. 
  
          
Tests of Within-Subjects Effects 
Measure: WLRatio_Set2 
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
Time Sphericity Assumed .200 1 .200 1.676 .210 .077 1.676 .234 
Greenhouse-Geisser .200 1.000 .200 1.676 .210 .077 1.676 .234 
Huynh-Feldt .200 1.000 .200 1.676 .210 .077 1.676 .234 
Lower-bound .200 1.000 .200 1.676 .210 .077 1.676 .234 
Time * Supplement Sphericity Assumed .221 2 .111 .925 .413 .085 1.851 .187 
Greenhouse-Geisser .221 2.000 .111 .925 .413 .085 1.851 .187 
Huynh-Feldt .221 2.000 .111 .925 .413 .085 1.851 .187 
Lower-bound .221 2.000 .111 .925 .413 .085 1.851 .187 
Error(Time) Sphericity Assumed 2.392 20 .120           
Greenhouse-Geisser 2.392 20.000 .120           
Huynh-Feldt 2.392 20.000 .120           
Lower-bound 2.392 20.000 .120           
a. Computed using alpha = .05 
          
Tests of Within-Subjects Contrasts 
Measure: WLRatio_Set2 
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Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
Time Linear .200 1 .200 1.676 .210 .077 1.676 .234 
Time * Supplement Linear .221 2 .111 .925 .413 .085 1.851 .187 
Error(Time) Linear 2.392 20 .120           
a. Computed using alpha = .05 
          
Levene's Test of Equality of Error Variancesa 
     
  F df1 df2 Sig.      
Pre_WLRatio_Set2 .069 2 20 .933 
     
Post_WLRatio_Set2 4.483 2 20 .025 
     
Tests the null hypothesis that the error variance of the dependent variable is equal across 
groups. 
     
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
     
          
Tests of Between-Subjects Effects 
 
Measure: WLRatio_Set2  
 Transformed Variable: Average 
 
Source 
Type III Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera  
Intercept 197.160 1 197.160 929.119 .000 .979 929.119 1.000 
 
Supplement .692 2 .346 1.629 .221 .140 3.259 .303 
 
Error 4.244 20 .212           
 
a. Computed using alpha = .05 
 
          
          
Estimated Marginal Means         
          
1. Grand Mean 
      
Measure: WLRatio_Set2 
      
Mean Std. Error 
95% Confidence Interval       
Lower 
Bound 
Upper 
Bound       
2.074 .068 1.932 2.216 
      
          
2. Supplement 
     
Measure: WLRatio_Set2 
     
Supplement Mean Std. Error 
95% Confidence Interval      
Lower 
Bound 
Upper 
Bound      
MagnaPower 2.176 .123 1.919 2.433 
     
Creatine 
Monohydrate 
2.144 .115 1.904 2.384 
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Placebo 1.903 .115 1.663 2.143 
     
          
3. Time 
     
Measure: WLRatio_Set2 
     
Time Mean Std. Error 
95% Confidence Interval      
Lower 
Bound 
Upper 
Bound      
1 2.141 .089 1.954 2.327 
     
2 2.008 .081 1.840 2.176 
     
          
          
4. Supplement * Time         
          
Estimates 
    
Measure: WLRatio_Set2 
    
Supplement Mean Std. Error 
95% Confidence Interval     
Lower 
Bound 
Upper 
Bound     
MagnaPower 1 2.226 .162 1.888 2.563 
    
2 2.127 .146 1.823 2.431 
    
Creatine 
Monohydrate 
1 2.300 .151 1.985 2.616 
    
2 1.988 .136 1.703 2.272 
    
Placebo 1 1.895 .151 1.580 2.211 
    
2 1.911 .136 1.626 2.195 
    
          
Pairwise Comparisons 
  
Measure: WLRatio_Set2 
  
Supplement 
Mean 
Difference 
(I-J) Std. Error Sig.a 
95% Confidence 
Interval for 
Differencea   
Lower 
Bound 
Upper 
Bound   
MagnaPower 1 2 .099 .185 .598 -.287 .485 
  
2 1 -.099 .185 .598 -.485 .287 
  
Creatine 
Monohydrate 
1 2 .313 .173 .085 -.048 .674 
  
2 1 -.313 .173 .085 -.674 .048 
  
Placebo 1 2 -.015 .173 .931 -.376 .346 
  
2 1 .015 .173 .931 -.346 .376 
  
Based on estimated marginal means 
  
a. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
  
          
Multivariate Tests 
Supplement Value F 
Hypothesis 
df Error df Sig. 
Partial 
Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powerb 
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MagnaPower Pillai's trace .014 .287a 1.000 20.000 .598 .014 .287 .080 
Wilks' lambda .986 .287a 1.000 20.000 .598 .014 .287 .080 
Hotelling's trace .014 .287a 1.000 20.000 .598 .014 .287 .080 
Roy's largest root .014 .287a 1.000 20.000 .598 .014 .287 .080 
Creatine 
Monohydrate 
Pillai's trace .141 3.276a 1.000 20.000 .085 .141 3.276 .406 
Wilks' lambda .859 3.276a 1.000 20.000 .085 .141 3.276 .406 
Hotelling's trace .164 3.276a 1.000 20.000 .085 .141 3.276 .406 
Roy's largest root .164 3.276a 1.000 20.000 .085 .141 3.276 .406 
Placebo Pillai's trace .000 .008a 1.000 20.000 .931 .000 .008 .051 
Wilks' lambda 1.000 .008a 1.000 20.000 .931 .000 .008 .051 
Hotelling's trace .000 .008a 1.000 20.000 .931 .000 .008 .051 
Roy's largest root .000 .008a 1.000 20.000 .931 .000 .008 .051 
Each F tests the multivariate simple effects of Time within each level combination of the other effects shown. These tests are based on the linearly independent 
pairwise comparisons among the estimated marginal means. 
a. Exact statistic 
b. Computed using alpha = .05 
          
          
 
Within-Subjects Factors 
        
Measure: Workload_Set1 
        
Time Dependent Variable         
1 Pre_Workload_Set
1 
        
2 Post_Workload_Set
1 
        
          
Between-Subjects Factors 
      
  Value Label N       
Supplement 1.00 MagnaPowe
r 
7 
      
2.00 Creatine 
Monohydrat
e 
8 
      
3.00 Placebo 8 
      
          
Descriptive Statistics 
     
Supplement Mean Std. Deviation N      
Pre_Workload_Set
1 
MagnaPower 2178.3143 488.07486 7 
     
Creatine 
Monohydrate 
1812.6375 612.31062 8 
     
Placebo 1721.5000 619.93139 8 
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Total 1892.2304 587.78305 23 
     
Post_Workload_Set
1 
MagnaPower 2485.5714 677.57840 7 
     
Creatine 
Monohydrate 
1978.5500 723.21383 8 
     
Placebo 1987.4875 617.65494 8 
     
Total 2135.9696 684.78925 23 
     
          
Box's Test of Equality of Covariance 
Matricesa 
        
Box's M 8.778 
        
F 1.249 
        
df1 6 
        
df2 8714.141 
        
Sig. .278 
        
Tests the null hypothesis that the observed 
covariance matrices of the dependent 
variables are equal across groups. 
        
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
        
          
Multivariate Testsa 
Effect Value F 
Hypothesis 
df Error df Sig. 
Partial 
Eta 
Squared 
Noncent. 
Paramete
r 
Observe
d Powerc 
Time Pillai's Trace .407 13.712b 1.000 20.000 .001 .407 13.712 .941 
Wilks' Lambda .593 13.712b 1.000 20.000 .001 .407 13.712 .941 
Hotelling's Trace .686 13.712b 1.000 20.000 .001 .407 13.712 .941 
Roy's Largest Root .686 13.712b 1.000 20.000 .001 .407 13.712 .941 
Time * Supplement Pillai's Trace .038 .398b 2.000 20.000 .677 .038 .795 .105 
Wilks' Lambda .962 .398b 2.000 20.000 .677 .038 .795 .105 
Hotelling's Trace .040 .398b 2.000 20.000 .677 .038 .795 .105 
Roy's Largest Root .040 .398b 2.000 20.000 .677 .038 .795 .105 
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
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b. Exact statistic 
c. Computed using alpha = .05 
          
Mauchly's Test of Sphericitya 
  
Measure: Workload_Set1 
  
Within Subjects 
Effect Mauchly's W 
Approx. 
Chi-Square df Sig. 
Epsilonb   
Greenhouse
-Geisser 
Huynh-
Feldt 
Lower-
bound   
Time 1.000 0.000 0   1.000 1.000 1.000 
  
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional to an 
identity matrix. 
  
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
  
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the Tests of 
Within-Subjects Effects table. 
  
          
Tests of Within-Subjects Effects 
Measure: Workload_Set1 
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Paramete
r 
Observe
d Powera 
Time Sphericity Assumed 695358.722 1 695358.72
2 
13.712 .001 .407 13.712 .941 
Greenhouse-
Geisser 
695358.722 1.000 695358.72
2 
13.712 .001 .407 13.712 .941 
Huynh-Feldt 695358.722 1.000 695358.72
2 
13.712 .001 .407 13.712 .941 
Lower-bound 695358.722 1.000 695358.72
2 
13.712 .001 .407 13.712 .941 
Time * Supplement Sphericity Assumed 40328.780 2 20164.390 .398 .677 .038 .795 .105 
Greenhouse-
Geisser 
40328.780 2.000 20164.390 .398 .677 .038 .795 .105 
Huynh-Feldt 40328.780 2.000 20164.390 .398 .677 .038 .795 .105 
Lower-bound 40328.780 2.000 20164.390 .398 .677 .038 .795 .105 
Error(Time) Sphericity Assumed 1014261.19
7 
20 50713.060           
Greenhouse-
Geisser 
1014261.19
7 
20.000 50713.060           
Huynh-Feldt 1014261.19
7 
20.000 50713.060           
Lower-bound 1014261.19
7 
20.000 50713.060           
a. Computed using alpha = .05 
          
Tests of Within-Subjects Contrasts 
Measure: Workload_Set1 
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Paramete
r 
Observe
d Powera 
Time Linear 695358.722 1 695358.72
2 
13.712 .001 .407 13.712 .941 
Time * Supplement Linear 40328.780 2 20164.390 .398 .677 .038 .795 .105 
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Error(Time) Linear 1014261.19
7 
20 50713.060           
a. Computed using alpha = .05 
          
Levene's Test of Equality of Error Variancesa 
     
  F df1 df2 Sig.      
Pre_Workload_Set
1 
.482 2 20 .624 
     
Post_Workload_Set
1 
.115 2 20 .892 
     
Tests the null hypothesis that the error variance of the dependent variable is equal across 
groups. 
     
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
     
          
Tests of Between-Subjects Effects 
 
Measure: Workload_Set1  
 Transformed Variable: Average 
 
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Paramete
r 
Observed 
Powera  
Intercept 188318292.987 1 188318292.98
7 
254.207 .000 .927 254.207 1.000 
 
Supplement 2046623.327 2 1023311.663 1.381 .274 .121 2.763 .262 
 
Error 14816141.833 20 740807.092           
 
a. Computed using alpha = .05 
 
          
          
Estimated Marginal Means         
          
1. Grand Mean 
      
Measure: Workload_Set1 
      
Mean Std. Error 
95% Confidence Interval       
Lower 
Bound Upper Bound       
2027.343 127.155 1762.103 2292.584 
      
          
2. Supplement 
     
Measure: Workload_Set1 
     
Supplement Mean Std. Error 
95% Confidence Interval      
Lower Bound 
Upper 
Bound      
MagnaPower 2331.943 230.032 1852.104 2811.782 
     
Creatine 
Monohydrate 
1895.594 215.175 1446.746 2344.442 
     
Placebo 1854.494 215.175 1405.646 2303.342 
     
          
3. Time 
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Measure: Workload_Set1 
     
Time Mean Std. Error 
95% Confidence Interval      
Lower Bound 
Upper 
Bound      
1 1904.151 121.322 1651.078 2157.224 
     
2 2150.536 140.824 1856.782 2444.291 
     
          
          
4. Supplement * Time         
          
Estimates 
    
Measure: Workload_Set1 
    
Supplement Mean Std. Error 
95% Confidence Interval     
Lower 
Bound 
Upper 
Bound     
MagnaPower 1 2178.314 219.480 1720.488 2636.141 
    
2 2485.571 254.761 1954.150 3016.993 
    
Creatine 
Monohydrate 
1 1812.638 205.304 1384.380 2240.895 
    
2 1978.550 238.307 1481.451 2475.649 
    
Placebo 1 1721.500 205.304 1293.243 2149.757 
    
2 1987.488 238.307 1490.388 2484.587 
    
          
Pairwise Comparisons 
  
Measure: Workload_Set1 
  
Supplement 
Mean 
Difference (I-
J) Std. Error Sig.b 
95% Confidence 
Interval for 
Differenceb   
Lower 
Bound 
Upper 
Bound   
MagnaPower 1 2 -307.257* 120.372 .019 -
558.349 
-56.165 
  
2 1 307.257* 120.372 .019 56.165 558.349 
  
Creatine 
Monohydrate 
1 2 -165.913 112.598 .156 -
400.787 
68.962 
  
2 1 165.913 112.598 .156 -68.962 400.787 
  
Placebo 1 2 -265.987* 112.598 .028 -
500.862 
-31.113 
  
2 1 265.987* 112.598 .028 31.113 500.862 
  
Based on estimated marginal means 
  
*. The mean difference is significant at the .05 level. 
  
b. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
  
          
Multivariate Tests 
Supplement Value F 
Hypothesis 
df Error df Sig. 
Partial 
Eta 
Squared 
Noncent. 
Paramete
r 
Observe
d Powerb 
MagnaPower Pillai's trace .246 6.516a 1.000 20.000 .019 .246 6.516 .680 
Wilks' lambda .754 6.516a 1.000 20.000 .019 .246 6.516 .680 
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Hotelling's trace .326 6.516a 1.000 20.000 .019 .246 6.516 .680 
Roy's largest root .326 6.516a 1.000 20.000 .019 .246 6.516 .680 
Creatine 
Monohydrate 
Pillai's trace .098 2.171a 1.000 20.000 .156 .098 2.171 .289 
Wilks' lambda .902 2.171a 1.000 20.000 .156 .098 2.171 .289 
Hotelling's trace .109 2.171a 1.000 20.000 .156 .098 2.171 .289 
Roy's largest root .109 2.171a 1.000 20.000 .156 .098 2.171 .289 
Placebo Pillai's trace .218 5.580a 1.000 20.000 .028 .218 5.580 .613 
Wilks' lambda .782 5.580a 1.000 20.000 .028 .218 5.580 .613 
Hotelling's trace .279 5.580a 1.000 20.000 .028 .218 5.580 .613 
Roy's largest root .279 5.580a 1.000 20.000 .028 .218 5.580 .613 
Each F tests the multivariate simple effects of Time within each level combination of the other effects shown. These tests are based on the linearly independent 
pairwise comparisons among the estimated marginal means. 
a. Exact statistic 
b. Computed using alpha = .05 
          
          
 
Within-Subjects Factors 
        
Measure: Workload_Set2 
        
Time Dependent Variable         
1 Pre_Workload_Set
2 
        
2 Post_Workload_Set
2 
        
          
Between-Subjects Factors 
      
  Value Label N       
Supplement 1.00 MagnaPowe
r 
7 
      
2.00 Creatine 
Monohydrat
e 
8 
      
3.00 Placebo 8 
      
          
Descriptive Statistics 
     
Supplement Mean Std. Deviation N      
Pre_Workload_Set
2 
MagnaPower 1702.5429 363.41779 7 
     
Creatine 
Monohydrate 
1466.1375 401.15449 8 
     
Placebo 1494.4000 501.76841 8 
     
Total 1547.9174 422.38984 23 
     
MagnaPower 1796.1857 450.49496 7 
     
182 
 
Post_Workload_Set
2 
Creatine 
Monohydrate 
1533.4500 388.59367 8 
     
Placebo 1652.2125 589.26232 8 
     
Total 1654.7217 474.96935 23 
     
          
Box's Test of Equality of Covariance 
Matricesa 
        
Box's M 2.861 
        
F .407 
        
df1 6 
        
df2 8714.141 
        
Sig. .875 
        
Tests the null hypothesis that the observed 
covariance matrices of the dependent 
variables are equal across groups. 
        
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
        
          
Multivariate Testsa 
Effect Value F 
Hypothesis 
df Error df Sig. 
Partial 
Eta 
Squared 
Noncent. 
Paramete
r 
Observe
d Powerc 
Time Pillai's Trace .123 2.810b 1.000 20.000 .109 .123 2.810 .358 
Wilks' Lambda .877 2.810b 1.000 20.000 .109 .123 2.810 .358 
Hotelling's Trace .141 2.810b 1.000 20.000 .109 .123 2.810 .358 
Roy's Largest Root .141 2.810b 1.000 20.000 .109 .123 2.810 .358 
Time * Supplement Pillai's Trace .018 .187b 2.000 20.000 .831 .018 .375 .075 
Wilks' Lambda .982 .187b 2.000 20.000 .831 .018 .375 .075 
Hotelling's Trace .019 .187b 2.000 20.000 .831 .018 .375 .075 
Roy's Largest Root .019 .187b 2.000 20.000 .831 .018 .375 .075 
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
b. Exact statistic 
c. Computed using alpha = .05 
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Mauchly's Test of Sphericitya 
  
Measure: Workload_Set2 
  
Within Subjects 
Effect Mauchly's W 
Approx. 
Chi-Square df Sig. 
Epsilonb   
Greenhouse
-Geisser 
Huynh-
Feldt 
Lower-
bound   
Time 1.000 0.000 0   1.000 1.000 1.000 
  
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional to an 
identity matrix. 
  
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
  
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the Tests of 
Within-Subjects Effects table. 
  
          
Tests of Within-Subjects Effects 
Measure: Workload_Set2 
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Paramete
r 
Observe
d Powera 
Time Sphericity Assumed 129325.569 1 129325.56
9 
2.810 .109 .123 2.810 .358 
Greenhouse-
Geisser 
129325.569 1.000 129325.56
9 
2.810 .109 .123 2.810 .358 
Huynh-Feldt 129325.569 1.000 129325.56
9 
2.810 .109 .123 2.810 .358 
Lower-bound 129325.569 1.000 129325.56
9 
2.810 .109 .123 2.810 .358 
Time * Supplement Sphericity Assumed 17252.037 2 8626.019 .187 .831 .018 .375 .075 
Greenhouse-
Geisser 
17252.037 2.000 8626.019 .187 .831 .018 .375 .075 
Huynh-Feldt 17252.037 2.000 8626.019 .187 .831 .018 .375 .075 
Lower-bound 17252.037 2.000 8626.019 .187 .831 .018 .375 .075 
Error(Time) Sphericity Assumed 920410.057 20 46020.503           
Greenhouse-
Geisser 
920410.057 20.000 46020.503           
Huynh-Feldt 920410.057 20.000 46020.503           
Lower-bound 920410.057 20.000 46020.503           
a. Computed using alpha = .05 
          
Tests of Within-Subjects Contrasts 
Measure: Workload_Set2 
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Paramete
r 
Observe
d Powera 
Time Linear 129325.569 1 129325.56
9 
2.810 .109 .123 2.810 .358 
Time * Supplement Linear 17252.037 2 8626.019 .187 .831 .018 .375 .075 
Error(Time) Linear 920410.057 20 46020.503           
a. Computed using alpha = .05 
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Levene's Test of Equality of Error Variancesa 
     
  F df1 df2 Sig.      
Pre_Workload_Set
2 
.701 2 20 .508 
     
Post_Workload_Set
2 
.575 2 20 .572 
     
Tests the null hypothesis that the error variance of the dependent variable is equal across 
groups. 
     
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
     
          
Tests of Between-Subjects Effects 
 
Measure: Workload_Set2  
 Transformed Variable: Average 
 
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Paramete
r 
Observed 
Powera  
Intercept 118395005.461 1 118395005.46
1 
317.148 .000 .941 317.148 1.000 
 
Supplement 484317.141 2 242158.571 .649 .533 .061 1.297 .143 
 
Error 7466220.176 20 373311.009           
 
a. Computed using alpha = .05 
 
          
          
Estimated Marginal Means         
          
1. Grand Mean 
      
Measure: Workload_Set2 
      
Mean Std. Error 
95% Confidence Interval       
Lower 
Bound Upper Bound       
1607.488 90.264 1419.200 1795.776 
      
          
2. Supplement 
     
Measure: Workload_Set2 
     
Supplement Mean Std. Error 
95% Confidence Interval      
Lower Bound 
Upper 
Bound      
MagnaPower 1749.364 163.294 1408.738 2089.991 
     
Creatine 
Monohydrate 
1499.794 152.748 1181.167 1818.420 
     
Placebo 1573.306 152.748 1254.680 1891.933 
     
          
3. Time 
     
Measure: Workload_Set2 
     
Time Mean Std. Error 
95% Confidence Interval      
Lower Bound 
Upper 
Bound      
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1 1554.360 89.636 1367.383 1741.337 
     
2 1660.616 101.339 1449.227 1872.005 
     
          
          
4. Supplement * Time         
          
Estimates 
    
Measure: Workload_Set2 
    
Supplement Mean Std. Error 
95% Confidence Interval     
Lower 
Bound 
Upper 
Bound     
MagnaPower 1 1702.543 162.158 1364.288 2040.798 
    
2 1796.186 183.329 1413.769 2178.603 
    
Creatine 
Monohydrate 
1 1466.138 151.685 1149.729 1782.546 
    
2 1533.450 171.488 1175.732 1891.168 
    
Placebo 1 1494.400 151.685 1177.992 1810.808 
    
2 1652.213 171.488 1294.494 2009.931 
    
          
Pairwise Comparisons 
  
Measure: Workload_Set2 
  
Supplement 
Mean 
Difference (I-
J) Std. Error Sig.a 
95% Confidence 
Interval for 
Differencea   
Lower 
Bound 
Upper 
Bound   
MagnaPower 1 2 -93.643 114.668 .424 -
332.836 
145.550 
  
2 1 93.643 114.668 .424 -
145.550 
332.836 
  
Creatine 
Monohydrate 
1 2 -67.313 107.262 .537 -
291.057 
156.432 
  
2 1 67.313 107.262 .537 -
156.432 
291.057 
  
Placebo 1 2 -157.813 107.262 .157 -
381.557 
65.932 
  
2 1 157.813 107.262 .157 -65.932 381.557 
  
Based on estimated marginal means 
  
a. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
  
          
Multivariate Tests 
Supplement Value F 
Hypothesis 
df Error df Sig. 
Partial 
Eta 
Squared 
Noncent. 
Paramete
r 
Observe
d Powerb 
MagnaPower Pillai's trace .032 .667a 1.000 20.000 .424 .032 .667 .122 
Wilks' lambda .968 .667a 1.000 20.000 .424 .032 .667 .122 
Hotelling's trace .033 .667a 1.000 20.000 .424 .032 .667 .122 
Roy's largest root .033 .667a 1.000 20.000 .424 .032 .667 .122 
Creatine 
Monohydrate 
Pillai's trace .019 .394a 1.000 20.000 .537 .019 .394 .092 
Wilks' lambda .981 .394a 1.000 20.000 .537 .019 .394 .092 
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Hotelling's trace .020 .394a 1.000 20.000 .537 .019 .394 .092 
Roy's largest root .020 .394a 1.000 20.000 .537 .019 .394 .092 
Placebo Pillai's trace .098 2.165a 1.000 20.000 .157 .098 2.165 .288 
Wilks' lambda .902 2.165a 1.000 20.000 .157 .098 2.165 .288 
Hotelling's trace .108 2.165a 1.000 20.000 .157 .098 2.165 .288 
Roy's largest root .108 2.165a 1.000 20.000 .157 .098 2.165 .288 
Each F tests the multivariate simple effects of Time within each level combination of the other effects shown. These tests are based on the linearly independent 
pairwise comparisons among the estimated marginal means. 
a. Exact statistic 
b. Computed using alpha = .05 
          
 
 
Within-Subjects Factors 
        
Measure: Power_Set1 
        
Time 
Dependent 
Variable         
1 Pre_Power_Set1 
        
2 Post_Power_Set1 
        
          
Between-Subjects Factors 
      
  Value Label N       
Supplement 1.00 MagnaPower 7 
      
2.00 Creatine 
Monohydrate 
8 
      
3.00 Placebo 8 
      
          
Descriptive Statistics 
     
Supplement Mean 
Std. 
Deviation N      
Pre_Power_Set1 MagnaPower 157.8714 39.73687 7 
     
Creatine 
Monohydrate 
146.1250 53.73564 8 
     
Placebo 144.2625 67.86507 8 
     
Total 149.0522 53.39516 23 
     
Post_Power_Set1 MagnaPower 186.0000 66.71304 7 
     
Creatine 
Monohydrate 
160.5875 56.27792 8 
     
Placebo 165.4000 70.33148 8 
     
Total 169.9957 62.58444 23 
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Box's Test of Equality of Covariance 
Matricesa 
        
Box's M 7.859 
        
F 1.119 
        
df1 6 
        
df2 8714.141 
        
Sig. .348 
        
Tests the null hypothesis that the 
observed covariance matrices of the 
dependent variables are equal across 
groups. 
        
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
        
          
Multivariate Testsa 
Effect Value F 
Hypothesis 
df Error df Sig. 
Partial 
Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powerc 
Time Pillai's Trace .371 11.790b 1.000 20.000 .003 .371 11.790 .904 
Wilks' Lambda .629 11.790b 1.000 20.000 .003 .371 11.790 .904 
Hotelling's Trace .590 11.790b 1.000 20.000 .003 .371 11.790 .904 
Roy's Largest 
Root 
.590 11.790b 1.000 20.000 .003 .371 11.790 .904 
Time * 
Supplement 
Pillai's Trace .038 .398b 2.000 20.000 .677 .038 .796 .105 
Wilks' Lambda .962 .398b 2.000 20.000 .677 .038 .796 .105 
Hotelling's Trace .040 .398b 2.000 20.000 .677 .038 .796 .105 
Roy's Largest 
Root 
.040 .398b 2.000 20.000 .677 .038 .796 .105 
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
b. Exact statistic 
c. Computed using alpha = .05 
          
Mauchly's Test of Sphericitya 
  
Measure: Power_Set1 
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Within Subjects 
Effect Mauchly's W 
Approx. Chi-
Square df Sig. 
Epsilonb   
Greenhouse-
Geisser 
Huynh-
Feldt 
Lower-
bound   
Time 1.000 0.000 0   1.000 1.000 1.000 
  
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional to an 
identity matrix. 
  
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
  
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the Tests of 
Within-Subjects Effects table. 
  
          
Tests of Within-Subjects Effects 
Measure: Power_Set1 
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
Time Sphericity 
Assumed 
5168.966 1 5168.966 11.790 .003 .371 11.790 .904 
Greenhouse-
Geisser 
5168.966 1.000 5168.966 11.790 .003 .371 11.790 .904 
Huynh-Feldt 5168.966 1.000 5168.966 11.790 .003 .371 11.790 .904 
Lower-bound 5168.966 1.000 5168.966 11.790 .003 .371 11.790 .904 
Time * 
Supplement 
Sphericity 
Assumed 
348.852 2 174.426 .398 .677 .038 .796 .105 
Greenhouse-
Geisser 
348.852 2.000 174.426 .398 .677 .038 .796 .105 
Huynh-Feldt 348.852 2.000 174.426 .398 .677 .038 .796 .105 
Lower-bound 348.852 2.000 174.426 .398 .677 .038 .796 .105 
Error(Time) Sphericity 
Assumed 
8768.196 20 438.410           
Greenhouse-
Geisser 
8768.196 20.000 438.410           
Huynh-Feldt 8768.196 20.000 438.410           
Lower-bound 8768.196 20.000 438.410           
a. Computed using alpha = .05 
          
Tests of Within-Subjects Contrasts 
Measure: Power_Set1 
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
Time Linear 5168.966 1 5168.966 11.790 .003 .371 11.790 .904 
Time * 
Supplement 
Linear 348.852 2 174.426 .398 .677 .038 .796 .105 
Error(Time) Linear 8768.196 20 438.410           
a. Computed using alpha = .05 
          
Levene's Test of Equality of Error Variancesa 
     
  F df1 df2 Sig.      
Pre_Power_Set1 1.218 2 20 .317 
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Post_Power_Set1 .107 2 20 .899 
     
Tests the null hypothesis that the error variance of the dependent variable is equal across 
groups. 
     
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
     
          
Tests of Between-Subjects Effects 
 
Measure: Power_Set1  
 Transformed Variable: Average 
 
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera  
Intercept 1173547.714 1 1173547.714 171.750 .000 .896 171.750 1.000 
 
Supplement 3117.718 2 1558.859 .228 .798 .022 .456 .081 
 
Error 136658.061 20 6832.903           
 
a. Computed using alpha = .05 
 
          
          
Estimated Marginal Means         
          
1. Grand Mean 
      
Measure: Power_Set1 
      
Mean Std. Error 
95% Confidence Interval       
Lower Bound 
Upper 
Bound       
160.041 12.212 134.567 185.515 
      
          
2. Supplement 
     
Measure: Power_Set1 
     
Supplement Mean Std. Error 
95% Confidence Interval      
Lower 
Bound 
Upper 
Bound      
MagnaPower 171.936 22.092 125.852 218.019 
     
Creatine 
Monohydrate 
153.356 20.665 110.249 196.463 
     
Placebo 154.831 20.665 111.724 197.938 
     
          
3. Time 
     
Measure: Power_Set1 
     
Time Mean Std. Error 
95% Confidence Interval      
Lower 
Bound 
Upper 
Bound      
1 149.420 11.626 125.169 173.670 
     
2 170.663 13.500 142.503 198.822 
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4. Supplement * Time         
          
Estimates 
    
Measure: Power_Set1 
    
Supplement Mean Std. Error 
95% Confidence Interval     
Lower 
Bound 
Upper 
Bound     
MagnaPower 1 157.871 21.032 114.000 201.743 
    
2 186.000 24.422 135.057 236.943 
    
Creatine 
Monohydrate 
1 146.125 19.673 105.087 187.163 
    
2 160.588 22.845 112.935 208.240 
    
Placebo 1 144.263 19.673 103.225 185.300 
    
2 165.400 22.845 117.747 213.053 
    
          
Pairwise Comparisons 
  
Measure: Power_Set1 
  
Supplement 
Mean 
Difference 
(I-J) Std. Error Sig.b 
95% Confidence 
Interval for 
Differenceb   
Lower 
Bound 
Upper 
Bound   
MagnaPower 1 2 -28.129* 11.192 .021 -51.475 -4.783 
  
2 1 28.129* 11.192 .021 4.783 51.475 
  
Creatine 
Monohydrate 
1 2 -14.463 10.469 .182 -36.301 7.376 
  
2 1 14.463 10.469 .182 -7.376 36.301 
  
Placebo 1 2 -21.138 10.469 .057 -42.976 .701 
  
2 1 21.138 10.469 .057 -.701 42.976 
  
Based on estimated marginal means 
  
*. The mean difference is significant at the .05 level. 
  
b. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
  
          
Multivariate Tests 
Supplement Value F 
Hypothesis 
df Error df Sig. 
Partial 
Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powerb 
MagnaPower Pillai's trace .240 6.317a 1.000 20.000 .021 .240 6.317 .667 
Wilks' lambda .760 6.317a 1.000 20.000 .021 .240 6.317 .667 
Hotelling's trace .316 6.317a 1.000 20.000 .021 .240 6.317 .667 
Roy's largest root .316 6.317a 1.000 20.000 .021 .240 6.317 .667 
Creatine 
Monohydrate 
Pillai's trace .087 1.908a 1.000 20.000 .182 .087 1.908 .260 
Wilks' lambda .913 1.908a 1.000 20.000 .182 .087 1.908 .260 
Hotelling's trace .095 1.908a 1.000 20.000 .182 .087 1.908 .260 
Roy's largest root .095 1.908a 1.000 20.000 .182 .087 1.908 .260 
Placebo Pillai's trace .169 4.076a 1.000 20.000 .057 .169 4.076 .485 
191 
 
Wilks' lambda .831 4.076a 1.000 20.000 .057 .169 4.076 .485 
Hotelling's trace .204 4.076a 1.000 20.000 .057 .169 4.076 .485 
Roy's largest root .204 4.076a 1.000 20.000 .057 .169 4.076 .485 
Each F tests the multivariate simple effects of Time within each level combination of the other effects shown. These tests are based on the linearly independent 
pairwise comparisons among the estimated marginal means. 
a. Exact statistic 
b. Computed using alpha = .05 
          
 
 
Within-Subjects Factors 
        
Measure: Power_Set2 
        
Time 
Dependent 
Variable         
1 Pre_Power_Set2 
        
2 Post_Power_Set2 
        
          
Between-Subjects Factors 
      
  Value Label N       
Supplement 1.00 MagnaPower 7 
      
2.00 Creatine 
Monohydrate 
8 
      
3.00 Placebo 8 
      
          
Descriptive Statistics 
     
Supplement Mean 
Std. 
Deviation N      
Pre_Power_Set2 MagnaPower 130.8714 35.48815 7 
     
Creatine 
Monohydrate 
121.3875 35.17830 8 
     
Placebo 132.7375 61.73755 8 
     
Total 128.2217 44.45920 23 
     
Post_Power_Set2 MagnaPower 145.6857 49.43957 7 
     
Creatine 
Monohydrate 
123.8500 27.76843 8 
     
Placebo 133.9625 54.54461 8 
     
Total 134.0130 44.03981 23 
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Box's Test of Equality of Covariance 
Matricesa 
        
Box's M 10.116 
        
F 1.440 
        
df1 6 
        
df2 8714.141 
        
Sig. .195 
        
Tests the null hypothesis that the 
observed covariance matrices of the 
dependent variables are equal across 
groups. 
        
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
        
          
Multivariate Testsa 
Effect Value F 
Hypothesis 
df Error df Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powerc 
Time Pillai's Trace .072 1.554b 1.000 20.000 .227 .072 1.554 .221 
Wilks' Lambda .928 1.554b 1.000 20.000 .227 .072 1.554 .221 
Hotelling's Trace .078 1.554b 1.000 20.000 .227 .072 1.554 .221 
Roy's Largest Root .078 1.554b 1.000 20.000 .227 .072 1.554 .221 
Time * 
Supplement 
Pillai's Trace .069 .736b 2.000 20.000 .492 .069 1.472 .157 
Wilks' Lambda .931 .736b 2.000 20.000 .492 .069 1.472 .157 
Hotelling's Trace .074 .736b 2.000 20.000 .492 .069 1.472 .157 
Roy's Largest Root .074 .736b 2.000 20.000 .492 .069 1.472 .157 
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
b. Exact statistic 
c. Computed using alpha = .05 
          
Mauchly's Test of Sphericitya 
  
Measure: Power_Set2 
  
Mauchly's W df Sig. Epsilonb   
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Within Subjects 
Effect 
Approx. Chi-
Square Greenhouse-
Geisser 
Huynh-
Feldt 
Lower-
bound   
Time 1.000 0.000 0   1.000 1.000 1.000 
  
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional to an 
identity matrix. 
  
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
  
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the Tests of 
Within-Subjects Effects table. 
  
          
Tests of Within-Subjects Effects 
Measure: Power_Set2 
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
Time Sphericity 
Assumed 
435.675 1 435.675 1.554 .227 .072 1.554 .221 
Greenhouse-
Geisser 
435.675 1.000 435.675 1.554 .227 .072 1.554 .221 
Huynh-Feldt 435.675 1.000 435.675 1.554 .227 .072 1.554 .221 
Lower-bound 435.675 1.000 435.675 1.554 .227 .072 1.554 .221 
Time * 
Supplement 
Sphericity 
Assumed 
412.678 2 206.339 .736 .492 .069 1.472 .157 
Greenhouse-
Geisser 
412.678 2.000 206.339 .736 .492 .069 1.472 .157 
Huynh-Feldt 412.678 2.000 206.339 .736 .492 .069 1.472 .157 
Lower-bound 412.678 2.000 206.339 .736 .492 .069 1.472 .157 
Error(Time) Sphericity 
Assumed 
5608.511 20 280.426           
Greenhouse-
Geisser 
5608.511 20.000 280.426           
Huynh-Feldt 5608.511 20.000 280.426           
Lower-bound 5608.511 20.000 280.426           
a. Computed using alpha = .05 
          
Tests of Within-Subjects Contrasts 
Measure: Power_Set2 
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera 
Time Linear 435.675 1 435.675 1.554 .227 .072 1.554 .221 
Time * 
Supplement 
Linear 412.678 2 206.339 .736 .492 .069 1.472 .157 
Error(Time) Linear 5608.511 20 280.426           
a. Computed using alpha = .05 
          
Levene's Test of Equality of Error Variancesa 
     
  F df1 df2 Sig.      
Pre_Power_Set2 2.080 2 20 .151 
     
Post_Power_Set2 .997 2 20 .387 
     
194 
 
Tests the null hypothesis that the error variance of the dependent variable is equal across 
groups. 
     
a. Design: Intercept + Supplement  
 Within Subjects Design: Time 
     
          
Tests of Between-Subjects Effects 
 
Measure: Power_Set2  
 Transformed Variable: Average 
 
Source 
Type III Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powera  
Intercept 791284.839 1 791284.839 202.426 .000 .910 202.426 1.000 
 
Supplement 1953.338 2 976.669 .250 .781 .024 .500 .084 
 
Error 78180.238 20 3909.012           
 
a. Computed using alpha = .05 
 
          
          
Estimated Marginal Means         
          
1. Grand Mean 
      
Measure: Power_Set2 
      
Mean Std. Error 
95% Confidence Interval       
Lower Bound 
Upper 
Bound       
131.416 9.237 112.148 150.683 
      
          
2. Supplement 
     
Measure: Power_Set2 
     
Supplement Mean Std. Error 
95% Confidence Interval      
Lower 
Bound 
Upper 
Bound      
MagnaPower 138.279 16.710 103.423 173.134 
     
Creatine 
Monohydrate 
122.619 15.631 90.014 155.223 
     
Placebo 133.350 15.631 100.745 165.955 
     
          
3. Time 
     
Measure: Power_Set2 
     
Time Mean Std. Error 
95% Confidence Interval      
Lower 
Bound 
Upper 
Bound      
1 128.332 9.676 108.148 148.517 
     
2 134.499 9.447 114.794 154.205 
     
          
          
4. Supplement * Time         
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Estimates 
    
Measure: Power_Set2 
    
Supplement Mean Std. Error 
95% Confidence Interval     
Lower 
Bound 
Upper 
Bound     
MagnaPower 1 130.871 17.505 94.357 167.386 
    
2 145.686 17.090 110.037 181.335 
    
Creatine 
Monohydrate 
1 121.388 16.374 87.231 155.544 
    
2 123.850 15.986 90.504 157.196 
    
Placebo 1 132.738 16.374 98.581 166.894 
    
2 133.963 15.986 100.616 167.309 
    
          
Pairwise Comparisons 
  
Measure: Power_Set2 
  
Supplement 
Mean 
Difference 
(I-J) Std. Error Sig.a 
95% Confidence 
Interval for 
Differencea   
Lower 
Bound 
Upper 
Bound   
MagnaPower 1 2 -14.814 8.951 .114 -33.486 3.857 
  
2 1 14.814 8.951 .114 -3.857 33.486 
  
Creatine 
Monohydrate 
1 2 -2.463 8.373 .772 -19.928 15.003 
  
2 1 2.463 8.373 .772 -15.003 19.928 
  
Placebo 1 2 -1.225 8.373 .885 -18.691 16.241 
  
2 1 1.225 8.373 .885 -16.241 18.691 
  
Based on estimated marginal means 
  
a. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
  
          
Multivariate Tests 
Supplement Value F 
Hypothesis 
df Error df Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Powerb 
MagnaPower Pillai's trace .120 2.739a 1.000 20.000 .114 .120 2.739 .351 
Wilks' lambda .880 2.739a 1.000 20.000 .114 .120 2.739 .351 
Hotelling's trace .137 2.739a 1.000 20.000 .114 .120 2.739 .351 
Roy's largest root .137 2.739a 1.000 20.000 .114 .120 2.739 .351 
Creatine 
Monohydrate 
Pillai's trace .004 .086a 1.000 20.000 .772 .004 .086 .059 
Wilks' lambda .996 .086a 1.000 20.000 .772 .004 .086 .059 
Hotelling's trace .004 .086a 1.000 20.000 .772 .004 .086 .059 
Roy's largest root .004 .086a 1.000 20.000 .772 .004 .086 .059 
Placebo Pillai's trace .001 .021a 1.000 20.000 .885 .001 .021 .052 
Wilks' lambda .999 .021a 1.000 20.000 .885 .001 .021 .052 
Hotelling's trace .001 .021a 1.000 20.000 .885 .001 .021 .052 
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Roy's largest root .001 .021a 1.000 20.000 .885 .001 .021 .052 
Each F tests the multivariate simple effects of Time within each level combination of the other effects shown. These tests are based on the linearly independent 
pairwise comparisons among the estimated marginal means. 
a. Exact statistic 
b. Computed using alpha = .05 
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